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Abstract
The work in this thesis sought to examine the effects of enhancing cardiac gap junction coupling
using the pharmacological agent Rotigaptide in clinically applicable models of acute myocardial
infarction (MI). Specifically, the studies in this thesis investigated the effect of Rotigaptide
on ventricular arrhythmogenesis and structural remodelling of the reperfused substrate, with
particular emphasis on the development, application and histological validation of diffusion
tensor magnetic resonance imagine (DTI) as a novel imaging modality to describe and quantify
structural remodelling post-infarction.
An ex vivo rat model of acute regional ischaemia-reperfusion was characterised and used to
study the effect of Rotigaptide on ventricular arrhythmogenesis during acute ischaemia and
reperfusion. Arrhythmias occurred during ischaemia in a monomodal distribution with a peak
incidence between 12-15 minutes after ischaemia. The incidence of reperfusion arrhythmias was
dependent on the preceding duration of ischaemia with a progressive reduction as ischaemic
time extended from 15 to 60 minutes. Rotigaptide pre-treatment afforded a significant reduction
in ischaemia-induced arrhythmias compared to administration at the onset of ischaemia or at
the time of reperfusion.
An in vivo rat model of infarction-reperfusion, mimicking clinical reperfusion in the setting of
acute MI was characterised and Rotigaptide administered prior to reperfusion and for a week
post-MI. At four-weeks post-MI animals were studied with 6-lead ECG, ambulatory telemetry,
programmed electrical simulation (PES), optical mapping, DTI and histology. Rotigaptide
reduced the susceptibility to arrhythmias induced by PES and partially restored DTI-derived
indices of tissue disruption in infarcted myocardium.
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Chapter 1
Introduction
1.1 Overview
The work described in this thesis concerns the effects of enhanced gap junction coupling on
the arrhythmia and structural phenotype of reperfused myocardium following infarction. In
addition, this thesis describes the development and application of cardiac diffusion weighted
MRI, a novel imaging modality which provides quantitative measures of structural changes
post-infarction.
This chapter provides an introduction to the electrophysiological and structural remodelling
that accompanies myocardial ischaemia, reperfusion and infarction with particular emphasis
on the mechanisms of arrhythmogenesis, and current clinical therapy and risk-stratification of
survivors of infarction. An overview of cardiac gap junction physiology will be followed by a
review of their function in normal myocardium and their role in ventricular arrhythmogenesis
in acute ischaemia-reperfusion and healed infarction. Modulation of gap junction coupling will
then be considered, paying particular attention to pharmacological agents that enhance coupling
and their potential application in reducing arrhythmic risk in ischaemia and infarction. Finally,
diffusion weighted magnetic resonance imaging will be introduced as a novel imaging modality,
able to provide quantitative measures that describe the cardiac microstructure. The principles,
physics and methods will be described before a review of current and potential future cardiac
applications of diffusion imaging.
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1.2 Myocardial Infarction & Ventricular Arrhythmias
Myocardial ischaemia is defined as the condition in which coronary blood flow is inadequate to
permit the maintenance of a steady state metabolism (Hearse 1990; Hearse 1994), myocardial
infarction (MI) occurs when the duration of ischaemia is sufficient to cause irreversible damage
to the myocardium (Ferrari 2001). Both ischaemia and infarction cause a series of structural
and electrophysiological changes that render the heart susceptible to ventricular arrhythmias
(Janse et al. 1981).
Ventricular tachycardia (VT), defined as ‘three or more consecutive complexes in duration em-
anating from the ventricles at a rate of greater than 100bpm’ (Zipes et al. 2006) and ventricular
fibrillation (VF), defined as ‘rapid, usually more than 300bpm, grossly irregular ventricular
rhythm with marked variability in QRS cycle length, morphology and amplitude’ (Zipes et al.
2006) are responsible for the majority of deaths in the early (in-hospital and within 30 days)
and late (weeks/months) phase of myocardial infarction, accounting for up to 100,000 deaths
per year in the UK (Morgan 2005) and 250,000 deaths per year in the US (Fishman et al. 2010)
1.2.1 Arrhythmia Incidence & Acute MI Mortality
Patients with acute MI are at increased risk from early ventricular arrhythmias (VT or VF) with
a reported incidence in large cohort studies of patients with ST-elevation MI of 10% (Gusto-1
Newby et al. 1998) and in patients undergoing primary percutaneous intervention (PPCI) of
5.7% (Mehta et al. 2009). These studies also reported the increased early (in-hospital) mortality
in patients with sustained ventricular arrhythmias, compared to those without, although the
longer term risk profile of these patients is unclear (Al-Khatib et al. 2002).
Healed infarction confers a similar risk from late ventricular arrhythmias (VT or VF), with an
incidence of sustained VT of 1% within 6 weeks (GISSI-3 Volpi et al. 2001) and a 2-3% annual
risk of sudden cardiac death (Sarter et al. 1996). Factors associated with increased incidence of
ventricular arrhythmias include age, hypertension, diabetes, reduced ejection fraction, increased
end-systolic volume (Volpi et al. 2001) and in the histological study of post-infarction human
hearts by Bolick et al. (Bolick et al. 1986), greater whole-heart mass, LV dilatation, infarct
area and infarct thickness.
Mortality from acute MI in the UK has fallen from 9.4 per 100 admissions (age-sex standardised
rate) in 2008 to 7.8 in 2011 (OECD 2013a), accompanying the 62% reduction in all-cause car-
diovascular mortality in the time period 1990-2011 (OECD 2013b). The reduction in mortality,
across all clinical spectra of acute myocardial infarction (i.e. ST-elevation MI, Non ST-elevation
MI), is attributed to the increasing use of reperfusion strategies and pharmacological therapies
proven to reduce mortality (e.g. aspirin, beta-blockade).
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1.2.2 Reperfusion Therapy
In ST-elevation MI (STEMI) the pathophysiology of an acute, complete occlusion of a coronary
artery owing to thrombus (DeWood et al. 1980), results in a wavefront of necrosis spreading from
myocytes in the subendocardial layer to the epicardial and mid-myocardial layers in a time-
dependent fashion (Reimer et al. 1979). Animal models of experimental coronary occlusion
have shown that within an hour of acute occlusion almost 50% of salvageable myocardium is
lost with 66% lost by three hours (Reimer et al. 1977), suggesting that timely restoration of
coronary artery flow (reperfusion) may limit the extent of myocardial damage.
Initial clinical reperfusion studies of thrombolysis with fibrinolytic agents (e.g. Streptokinase)
afforded an 18% reduction in early mortality, with the greatest reduction in patients who under-
went thrombolysis early (GISSI 1986). However, thrombolytic therapy has several limitations,
being contraindicated in patients with significant bleeding risk, being ineffective in up to 20%
of patients (GUSTO 1993) and having a small risk of haemorrhagic stroke. For these reasons,
invasive methods of restoring coronary flow were pioneered with cannulation of the occluded
artery, extraction of thrombus and stenting forming the basis of primary percutaneous coronary
intervention (PPCI). Compared to thrombolytic therapy, PPCI affords a significant improve-
ment in infarct artery patency and reduction in recurrent ischaemia, re-infarction, need for
further revascularisation and mortality, when delivered in a timely fashion (Keeley et al. 2003).
For these reasons, PPCI now forms the cornerstone of STEMI management, as reflected in UK
(NICE 2013) and international guidelines (O’Gara et al. 2013). Reperfusion arrhythmias oc-
curring in the context of thrombolysis or PPCI are most frequently accelerated idioventricular
rhythms or ventricular premature beats (Wehrens et al. 2000), but shown not to confer excess
mortality in large-scale clinical trials (ISIS-2 1988).
1.2.3 Mechanisms of Arrhythmogenesis
Mechanisms responsible for cardiac arrhythmias include triggered activity, enhanced automatic-
ity and re-entry, of which the later is the mechanism thought to be responsible for the majority
of clinically important arrhythmias. Mayer (Mayer 1906), following his observation of simple
ring-like re-entry in Jellyfish defined re-entry as ‘a continuous repetitive propagation of an ex-
citatory wave travelling in a circular path, returning to its site of origin to reactivate that site’
although it wasn’t until 1913 that the importance of re-entry was recognised as a mechanism
of arrhythmogenesis by Mines (Mines 1913).
In order for re-entry arrhythmias to initiate and sustain, adjacent tissue with differing electro-
physiological properties must be joined to form a circuit, through which an impulse can travel.
The ability of the circuit to conduct antegradely and retrogradely and the onset of unidirec-
tional conduction block and slow conduction occurring with critical timing enable an impulse
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to travel down one arm of the circuit whilst the other arm is blocked, and, provided that con-
duction is slow enough, back up the now recovered arm to form a complete circuit. Provided
that by the time the impulse has travelled up the second arm the initial arm has recovered, the
impulse can then travel back down the initial arm and the re-entrant circuit perpetuates.
Re-entry is typically divided into anatomical and functional re-entry. Anatomical re-entry oc-
curs when the circuit forms around an anatomic obstacle which acts as a fixed area of block,
around which propagation travels, and, provided the conditions for re-entry are met, may result
in re-entry arrhythmogenesis as seen clinically in typical atrial flutter, supraventricular tachy-
cardias associated with accessory pathways and ventricular tachycardia associated with scar
(Gough et al. 1985). Functional re-entry occurs owing to differences in the electrophysiological
properties of myocardium in the absence of an anatomical block. Examples of functional re-
entry include leading-circle re-entry where the impulse propagates in a circular fashion around a
refractory core (Allessie et al. 1977), anisotropic re-entry which relies on the anisotropic nature
of myocardium and preferential conduction in the longitudinal direction (Allessie et al. 1989),
figure-of-eight re-entry in which two circuits share a central common pathway of functional
block (El-Sherif et al. 1981a), and spiral waves in which circular waves rotate around a core of
potentially excitable cells that may meander across the myocardium (Davidenko et al. 1992).
1.2.3.1 Acute Ischaemia & Reperfusion
In acute myocardial infarction, changes in the electrophysiological properties of myocytes in
the ischaemic region render the myocardium susceptible to the development of re-entry and
non re-entrant arrhythmias. Accumulation of extracellular K+ and intracellular Ca2+ overload
cause a depolarisation in the resting membrane potential of myocytes within the ischaemic zone
and an intracellular acidosis with accumulation of intracellular lactate, hypoxia and a reduc-
tion in inward Na+ current result in reduced amplitude and upstroke velocity of the cardiac
action potential (AP) and shortening of the AP duration (APD) which occurs in a spatially
heterogeneous manner with adjacent regions of slow conduction, prolonged refractoriness and
spatial inhomogeneities in APD providing the conditions required for re-entry (Carmeliet 1999).
Early ventricular arrhythmias occur in a species-dependent pattern with a bimodal distribu-
tion demonstrated in experimental large-animal models of acute infarction (Harris 1950). The
immediate arrhythmias, termed ‘Phase 1a’, occur within the first 10 minutes post-infarction,
owing to the development of profound electrical inhomogeneities between the subepicardium
and mid-myocardial layers, providing the substrate required for re-entry (Kaplinsky et al. 1979).
Delayed arrhythmias, termed ‘Phase 1b’, occur within an hour post-infarction and are poorly
understood although increased catecholamine secretion, increasing extracellular and intracel-
lular resistance and Ca2+ overload are thought to enhance automaticity and triggered activity
(Penny 1984).
Arrhythmias often occur within seconds of reperfusion, attributed to the rapid development of
34
inhomogeneities in APD and AP amplitude of myocytes within and adjacent to the ischaemic
zone (Manning et al. 1984b). Arrhythmias also occur within minutes of restoration of coronary
flow as accumulated K+ and lactate is washed out and extracellular and intracellular resistance
restored (Wit et al. 2001). The timing of reperfusion arrhythmias is postulated to peak when
the difference between electrophysiological properties of myocytes in the ischaemic zone and
remote zone are maximal, prior to the development of irreversible injury, providing the greatest
inhomogeneity in APD and refractoriness, allowing for re-entry to initiate (Corr et al. 1983).
1.2.3.2 Healed Infarction
Arrhythmias occurring in the setting of healed infarction are predominantly re-entry in nature,
as demonstrated in experimental (El-Sherif et al. 1977; El-Sherif et al. 1981b) and human studies
(Bakker et al. 1988). Scar tissue acts as an anatomical block and slow, ’zig-zag’ conduction at
the infarct border zone as a result of collagen deposition between surviving bundles of myocytes
provides the necessary requirements for anatomical re-entry (Bakker et al. 1993). In addition,
myocytes undergo a time-sensitive sequence of ion channel remodelling (Ursell et al. 1985) with
gradual recovery of APD alongside restoration of Ca2+ and K+ currents in the epicardial border
zone (Dun et al. 2004) with localised abnormalities in Na+ and L-type Ca2+ currents responsible
for figure-of-eight re-entrant circuit stability in healed canine infarction (Baba 2005).
Cell-cell coupling, via cardiac gap junctions, is also disrupted during both acute ischaemia-
reperfusion and in the healed phase of infarction and plays a pivotal role in ventricular ar-
rhythmogenesis. A review of the physical properties and alterations in gap junction coupling
is presented in Section 1.3.
1.2.3.3 Determinants of Arrhythmogenesis in Healed Infarction
Factors which reflect arrhythmic risk and identify patients at risk of sudden cardiac death are
useful in risk stratifying and personalising therapy on a patient by patient basis. Infarct size
as a determinant of arrhythmogenesis was first noted in canine models in which animals with
large infarcts had spontaneous arrhythmias and were inducible for VT in comparison to those
with smaller infarcts in which no arrhythmias could be provoked (Kaplinsky et al. 1978). Early
human studies of the effect of infarct size showed that in early post-MI (within 10 hours),
infarct size estimated by serum creatinine kinase levels showed a positive correlation with the
total number of ventricular premature beats (Roberts et al. 1975). Human histological studies
of post-mortem specimens demonstrated that patients with a history of prior VT had larger,
more solid infarcts compared to those without (Bolick et al. 1986).
The advent of delayed enhanced MRI (deMRI) allowed for the assessment of both infarct size
and electrophysiological properties, in vivo, as in the study by Bello (Bello et al. 2005) which
demonstrated that patients with inducible VT had larger scars on deMRI, and that infarct size
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and surface area were better predictors of VT compared to left ventricular ejection fraction.
These findings were corroborated by Crawford in their combined invasive electrophysiology
study with electroanatomic mapping and deMRI (Crawford et al. 2010) which confirmed that
patients with inducible VT had larger infarct size, larger subendocardial infarct area and larger
peri-infarct size.
In addition to infarct size, the extent of the peri-infarct zone (also termed heterogeneous tissue
or grey zone) detected by deMRI is a strong predictor of VT inducibility (Schmidt et al.
2007) and predictive in identifying post-MI patients who receive appropriate ICD therapy
(Rayatzadeh et al. 2013). Modelling studies confirm that the peri-infarct zone is vital in the
initiation and maintenance of ventricular arrhythmias (Arevalo et al. 2013) with the presence of
all VT scroll-wave filaments confined to the peri-infarct zone. Similar conclusions were found in
the detailed histological study of Rutherford (Rutherford et al. 2012) which showed structural
remodelling alone in the infarct border zone of the rat infarct was sufficient to initiate and
sustain re-entrant arrhythmias. The clinical importance of the peri-infarct zone is supported
by the combined electroanatomic mapping and MRI studies of Perez-David (Perez-David et al.
2011) which showed that slow conduction channels, identified by electroanatomic mapping, act
as the isthmus of VT circuits and spatially correlate to anatomical channels identified on deMRI
in the peri-infarct zone.
1.2.4 Treatment of Late Ventricular Arrhythmias
The efficacy of current anti-arrhythmic therapy in reducing the incidence of ventricular ar-
rhythmias and sudden cardiac death in survivors of infarction is limited. In patients with
ventricular ectopy post-infarction, Class I agents (e.g. Flecanide) reduced the incidence of
ectopy but resulted in excess mortality leading to trials being halted early (CAST 1989). A
similar study design using Amiodarone (CAMIAT trial, Cairns et al. 1997), showed a neutral
effect on overall mortality but a reduction in the incidence of VF and arrhythmic death. Only
anti-arrhythmic therapy with beta-blockade has been shown to demonstrate a consistent in-
crease in survival post-MI with a reduction in sudden cardiac death and a 23% reduction in
odds of death compared to placebo (Freemantle et al. 1999).
Owing to the incomplete efficacy of anti-arrhythmic therapy, the implantable cardioverter-
defibrillator (ICD) has become the preferred therapeutic strategy for reducing the incidence of
sudden cardiac death in post-infarction survivors. MADIT-I (Moss et al. 1996), the first ran-
domised clinical trial to demonstrate the efficacy of ICD therapy, randomised post-infarction
patients with reduced LV ejection fraction (LVEF), documented asymptomatic VT and in-
ducible VT on electrophysiological testing to receive either an ICD or medical therapy. At
27 months follow-up, ICD therapy conferred a significant reduction in overall mortality and
arrhythmic death compared to medical therapy. MADIT-II (Moss et al. 2002), the follow-up to
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MADIT-I, randomised post-infarction patients with reduced LVEF but without the presence of
documented NSVT or an electrophysiological study to receive either an ICD or medical therapy.
Similar to MADIT-I, ICD therapy reduced overall mortality and sudden cardiac death after
20 months of follow-up. In comparing the efficacy of anti-arrhythmic therapy with ICD ther-
apy, SCD-HeFT (Bardy et al. 2005) randomised patients with reduced LVEF to either placebo,
amiodarone or ICD implantation. Amiodarone had no effect on mortality whereas ICD therapy
reduced overall mortality but only in patients with LVEF <30%.
Current UK guidelines recommend ICD therapy for patients who, without a treatable cause
have survived cardiac arrest due to VT or VF or have spontaneous sustained VT causing
syncope or haemodynamic compromise or have sustained VT without syncope or cardiac arrest
and have a LVEF of less than 35% with symptoms no worse than New York Heart Association
Class III (NICE 2014). In comparison, ACCF/HRS/AHA guidelines (Russo et al. 2013) state
that ICD implantation ‘may be appropriate’ in patients with a LVEF of less than 40%) and
NSVT on ambulatory monitoring and a negative VT inducibility study, depending on the extent
of revascularisation. Discrepancies in guidelines and difficulties in determining which patients
would benefit from ICD implantation are a reflection of the significant heterogeneity that exists
in the risk profile of survivors of MI. Attempts to risk stratify patients may improve cost-
effectiveness and prevent unnecessary ICD implants in low-risk populations but have proved
difficult to implement in clinical practice owing to the limited sensitivity and specificity of
individual risk metrics (e.g. reduced LVEF, signal averaged ECG, heart rate variability, (Bailey
et al. 2001)).
Despite the efficacy of ICD implantation in high-risk survivors post-MI, significant limitations
exist with their use. The cost-effectiveness, although deemed to be acceptable, is still high
at an estimate of $100,000 per quality-adjusted life year (Sanders et al. 2005). In addition,
ICD implantation is not without short-term (pneumothorax, bleeding, infection) and long-term
(erosion, lead displacement, inappropriate shock) complications and requires pulse generator
replacement every 5-10 years, determined by battery life.
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1.3 Cardiac Gap Junctions
1.3.1 Structure, Distribution & Regulation
Gap junction channels are formed between the cytoplasm of adjacent cardiomyocytes by the
interaction of stable protein complexes, termed connexons, within the plasma lipid membrane of
myocytes. Each connexon is comprised of six connexin protein subunits, with over 20 different
connexin subunits having been identified in humans (So¨hl et al. 2004), each uniquely identified
by their molecular weight in kiloDaltons (e.g. Connexin 43, (Cx43)). Connexin subunits are
comprised of four transmembrane and two extracellular loops which are preserved across the
family and an intracellular loop that connects the second and third transmembrane domain and
a carboxy terminus which differentiates each connexin subunit and determines the molecular
weight and functional properties of the channel (Kanno et al. 2001, Figure 1.1).
Figure 1.1: Topological model of Connexin molecule with four transmembrane domains (white),
the N-terminus and extracellular loops (grey) and the intracellular loop (A) connecting the
middle transmembrane domain and the carboxy tail (B, black). Reproduced with modification
from Kanno et al. 2001.
In mammalian cardiac tissue Connexin 43 (Cx43), Cx40 and Cx45 expression occurs with a
spatial distribution in a chamber-specific manner (Vozzi et al. 1999), with Cx43 the predomi-
nant connexin expressed in ventricular myocytes (Gros et al. 1996a). This variation in spatial
distribution is critical to successful cardiac conduction, owing to the differing conductance
properties of individual connexin channels resulting in modulation of impulse propagation in
the sino-atrial and atrio-ventricular nodes and resultant sequential conduction to atria and
ventricular chambers (Kreuzberg et al. 2006).
On a cellular level, Cx43 protein clusters at the step-like intercalated disk, alongside fascia
adherens junctions which transmit mechanical force and desmosomes, which act to reduce
shear and contractile stress by binding intermediate filaments (Severs et al. 2008, Figure 1.2).
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Figure 1.2: Distribution of Cx43-containing GJ channels from (A) Longitudinal section of rat
ventricular myocardium with GJ appearing in rows, corresponding to intercalated disks and
(inset) en-face view of single intercalated disk from human ventricular myocardium, and (B)
isolated rat myocyte showing presence of GJ channels present at multiple sites (corresponding
to multiple intercalated disks). Reproduced from Severs et al. 2008.
GJ channels exist in one of three functional states; open (maximal conductance), residual (10-
30% of maximal conductance) and closed, with variation in conductance determined by the
connnexin composition of the channel. The state of the GJ channel is regulated by several
factors, of which voltage-sensitivity and chemical gating are the most well described.
Homotypic channels (composed of only one connexin i.e. 12 Cx43 subunits) show a rapid non-
linear relationship between conductance and voltage, sensitive to the specific gating constants
(minimal and maximal channel conductances, voltage at which conductance is half-maximal) of
the individual connexin isoform (Moreno 2004). The likely mechanism, proposed by Moreno et
al. (Moreno et al. 2002), is that gating occurs due to the interaction between the GJ channel,
or nearby associated proteins, with the modified carboxyl tail of the connexin subunit in a
‘ball-and-chain’ fashion.
Chemical gating of GJ channels and alterations in channel state occur in response to a variety
of stimuli including changes in intracellular pH, phosphorylation and the presence of chem-
ical compounds in the intracellular space. Acidification leads to a reduction in GJ conduc-
tance, with a proposed mechanism whereby the carboxyl tail interacts with a separate region
of the connexin molecule to cause a ‘ball-and-chain’ effect, closing the channel (Morley et al.
1996). Cx43 contains 2 serine residues in the N-terminus and 21 serine residues on the carboxl
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tail, which undergo phosphorlyation by a range of protein kinases, including protein kinase
C, mitogen-activated protein kinase and pp60-SRC kinase, although the mechanism by which
phosphorlyation alters channel conductance remains unknown (Lampe et al. 2000; Lampe et
al. 2004; Solan et al. 2009). Chemical compounds that alter GJ conductance have also been
identified and include N-Alkyl alcohols (e.g. Heptanol, Johnston et al. 1980), Halothane (Burt
et al. 1989) and Quinine (Srinivas et al. 2001) although the magnitude and specificity of the
interaction on GJ channels directly is variable (Moreno 2004)
1.3.2 Role in Normal Myocardium
Propagation of the cardiac action potential (AP), generated as a result of the inward and
outward flow of Na+, K+ and Ca2+ ions, requires a means of spreading current from cell-to-
cell in a safe, efficient manner. This is achieved by coupling of cells by gap junctions which
act as low-resistance pathways, first proposed by Weidmann in 1966 (Weidmann 1966). Gap
junctions act as non-selective pores, allowing for conduction propagation to occur in a seemingly
continuous manner at macroscopic level (Rohr 2004; Bernstein et al. 2006), but actually in a
saltatory manner at single cardiomyocyte level with rapid intercellular propagation and slower
intracellular propagation (Rohr et al. 1992). In states of reduced GJ coupling (e.g. ischaemia),
conduction slows and becomes discontinuous owing to heterogenous uncoupling and activation
’jumping’ from severely uncoupled to moderately uncoupled regions (Rohr et al. 1998, Figure
1.3)
1.3.3 Role in Ventricular Arrhythmogenesis
The role of alterations in GJ coupling on ventricular arrhythmias occurring during acute is-
chaemia and reperfusion and in healed infarction have been extensively studied and reviewed
(Lerner et al. 2001; Severs et al. 2004; Wit et al. 2011)
1.3.3.1 Acute Ischaemia & Reperfusion
During the first 10-15 minutes of acute ischaemia (‘Phase 1a’) in large animal hearts, intercel-
lular resistance (attributed to cell-cell coupling via gap junctions) remains constant whereas
extracellular resistance (current across the extracellular space) steadily increases due to collapse
of the vascular bed (Carmeliet 1999). After 15 minutes of ischaemia, intercellular resistance
rises sharply (Kle´ber et al. 1987), which corresponds to the onset of ‘Phase 1b’ arrhythmias
(Groot et al. 2001) although causality has yet to be firmly established (Cascio et al. 2005). This
reduction in intercellular resistance, attributed to gap junction uncoupling occurs in a time-
dependent fashion with progressive dephosphorlyation of Cx43, and trafficking of Cx43 from
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Figure 1.3: (A) Phase-contrast image of cell strand, circles indicate photodetectors. Plot of
AP upstrokes recorded simultaneously during activation of the preparation from left with (B)
normal GJ coupling and (C) reduced GJ coupling. (D) Local activation map; the recording
sites producing the upstrokes shown in (C) are colour-coded and superimposed on a schematic
drawing of the preparation showing the cell borders. At the sites of white discs, no changes
in transmembrane voltage were recorded (electrically uncoupled cell with hatched outline).The
cross-hatched discs indicate the locations of signals for which it was not possible to assign
unambiguous activation times because of the presence of notched upstrokes. Reproduced with
modification from Rohr et al. 1998.
GJ to intracellular pools (Beardslee et al. 2000) in response to increased intracellular acido-
sis, increased intracellular Ca2+ and accumulation of waste products (fatty acids, amphiphiles)
(Carmeliet 1999).
Reperfusion arrhythmias, postulated to be predominantly re-entry in nature, occur due to
the rapid generation of inhomogeneities in the duration and amplitude of action potentials
within and adjacent to the ischaemic zone, exacerbated by the washout of K+ and lactate from
the extracellular space (Manning et al. 1984b; Wit et al. 2001). The extracellular resistance
recovers to normal levels as intravascular spaces expand, followed by a slower recovery (up
to 30 minutes) of intracellular resistance (Cascio et al. 2001) suggesting that GJ coupling
persists during the early, vulnerable reperfusion period and may play a role in arrhythmogenesis.
Pharmacological enhancement of GJ coupling, during ischaemia and susbsequent reperfusion,
has been demonstrated to reduce the incidence of reperfusion arrhythmias in large animal
models (Hennan et al. 2006) although the molecular mechanisms underpinning this benefit
remain unknown.
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1.3.3.2 Healed Infarction
In healed infarction, GJ remodelling plays a pivotal role in the generation of late ventricular
arrhythmias (Peters et al. 2000). Remodelling occurs in a time-dependent fashion with both a
reduction in total interconnected myocytes at the infarct border zone (Luke et al. 1991) and a
redistribution in Cx43 to the lateral side of myocytes (Smith et al. 1991). Lateralisation of Cx43
likely represents non-functional GJ channels and correlates with the location of of re-entrant
circuits in healed infarction (Peters et al. 1997; Cabo et al. 2006).
In addition, GJ may also play a role in determining the structural changes that occur post-
infarction. This was first postulated based on studies of healed porcine infarcts where reproduc-
tion of the infarct geometry using computer simulation required a cell-to-cell coupling variable
without which the geometry could not be reproduced (Garc´ıa-Dorado et al. 1989). On a cellu-
lar level, the observation that reperfusion induced hypercontracture spreads from cell to cell in
paired cell studies lends further support to this hypothesis although the molecular mechanism
underpinning these effects remain unclear. It has been hypothesised that that mediators of cell
death or promoters of cell survival may pass from cell to cell via open GJ channels (Decrock
et al. 2009) resulting in a ‘kiss-of-life’ or ‘kiss-of-death’ effect on adjoining myocytes (Wygoda
et al. 1997; Andrade-Rozental et al. 2000).
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1.4 Modulation of Gap Junctions
GJ coupling plays an important role in action potential propagation in normal myocardium
and alterations in GJ coupling result in electrophysiological remodelling that renders the post-
infarcted substrate pro-arrhythmic. In addition, the transfer of mediators of cell death or
survival via GJ may also determine the extent of infarct spread and morphology which in turn
contributes to the arrhythmogenicity of the healed substrate. Modulation of GJ prior to, or at
the time of ischaemic insult may ameliorate structural remodelling and reduce the risk of future
arrhythmic events. This is particularly appealing in the case of post-MI ventricular arrhythmias
where current anti-arrhythmic therapy has been shown to promote dispersion in refractoriness
and may conversely be pro-arrhythmic (Dhein et al. 1993). Large-scale clinical trials of current
pharmacological therapy have failed to demonstrate a significant mortality benefit, except for
beta-blockade, limiting therapeutic options to ICD implantation which appears only efficacious
in high-risk populations and possesses a significant cost and side-effect profile. Development
of pharmacological therapies that target other molecular mechanisms aside from conventional
cardiac ion channels are therefore appealing (Darbar et al. 2006), with cardiac gap junctions
viewed as a prime candidate for modulation (Wit et al. 2007).
1.4.1 Agents that Reduce GJ Coupling
During ischaemia, where GJ coupling is impaired, promoting further uncoupling may result in
complete conduction block and provide a mechanism to terminate re-entry arrhythmias. Early
studies with Heptanol which decreases GJ conductance demonstrated a preferential reduction
in transverse coupling, resulting in a reduction in transverse conduction velocity in isolated ven-
tricular canine myocardium (Balke et al. 1988) and the development of transverse conduction
block in isolated ovine myocardium (Delmar et al. 1987). In infarcted myocardium, Heptanol
induced conduction block at sites of previously slow conduction and reduced electrogram frac-
tionation at areas of slow conduction (Spear et al. 1990). Carbenoxolone, a glycyrrhetinic acid
derivative, reduces intercellular coupling without affecting ion channels (Groot et al. 2003),
and reduces conduction velocity in human atrial myocardium (Kojodjojo et al. 2006). The
molecular mechanisms of Heptanol and Carbenoxolone are not fully understood, with puta-
tive mechanisms including alterations in the fluidity and stiffness of the cholesterol-rich plasma
membrane resulting in alterations in open probability of GJ channels (Bastiaanse et al. 1993)
rather than a specific GJ uncoupling effect.
1.4.2 Agents that Enhance GJ Coupling
In 1980, Aonuma et al. (Aonuma et al. 1980) isolated a hexapeptide, termed anti-arrhythmic
peptide (AAP) from bovine and rat atria that was able to convert continuous fibrillation to nor-
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mal rhythm in cultured rat cardiomyocytes, without a direct effect on ionic currents (Argentieri
et al. 1989). Based on the molecular structure of AAP, the group of Dhein et al. (Dhein et al.
1994) synthesised a series of derivatives, of which AAP10 (Grover et al. 1998) and the later
more stable related molecules Rotigaptide (ZP123, Kjolbye 2003) and Danegaptide (GAP-134,
Butera et al. 2009) have formed the basis of most experimental studies (Dhein et al. 2009;
Vuyst et al. 2011).
1.4.2.1 Anti-Arrhythmic Peptides
The index compound, AAP, demonstrated anti-arrhythmic activity not only in the early work
of Aonuma, but also in the study of Kohama et al. (Kohama et al. 1988) with a reduction in
incidence of CaCl2 induced arrhythmias in mice pre-treated with AAP.
A similar anti-arrhythmic effect was seen using AAP10 in isolated perfused rabbit hearts with
a reduction in the dispersion of refractoriness, attenuation of the electrophysiological changes
of acute regional ischaemia without any alteration in APD, upstroke kinetics, AP amplitude
or resting membrane potential, suggesting the effects were not mediated by changes in ionic
currents (Dhein et al. 1994). This was confirmed by double-cell voltage-clamp studies of isolated
guinea-pig myocytes which demonstrated an increase in GJ conductance on treatment with
AAP10, without an effect on membrane conductance or resting potential (Mu¨ller et al. 1997;
Mu¨ller et al. 1997) with similar findings demonstrated in human atrial cardiomyocytes and
HeLa-Cx43 and HeLa-Cx45 cells (Hagen et al. 2009). In considering the molecular mechanism
of AAP10, Weng et al. (Weng et al. 2002) showed that AAP10 activates protein kinase C
(PKC), induces phosphorlyation of Cx43 and its affects can be totally inhibited by the use
of a PKCα inhibitor. The action of AAP10 appears confined to the ischaemia region, with
prevention of ischaemia-induced dephosphorlyation at Serine 368 and reduction in loss of Cx43
from the cell poles not present in non-ischaemic regions (Jozwiak et al. 2008).
1.4.2.2 Rotigaptide & Danegaptide
The clinical therapeutic potential of AAP10 is hindered by the lack of enzymatic stability and
rapid in vivo degradation with a half life of between three and four minutes. Rotigaptide (ini-
tially called ZP123), is a rotation-inversion isomer of AAP10, in which all L-amino acids have
been substituted for D-isomers, affording enhanced stability and protection against degradation
with an in vitro half life in humans of 14 days (Kjolbye 2003). In comparative studies, Rotigap-
tide was as effective as AAP10 in reducing dispersion and increasing conduction velocity in the
isolated perfused rabbit heart, and, as with AAP10, was found to be sensitive to selective PKCα
blockade (Dhein et al. 2003). Similar to the findings of Cx43 and Cx45 specificity for AAP10 by
Hagen et al. (Hagen et al. 2009), dye-transfer experiments using HL-1 and HeLa cells expressing
a range of connexin subunits showed Rotigaptide treatment was specific for Cx43 expressing
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cells (Clarke et al. 2006). Although specific to Cx43, the molecular mechanism of Rotigaptide
remains unclear. In an isolated guinea-pig model of global low-flow ischaemia Rotigaptide sup-
pressed discordant alternans, restored conduction velocity and prevented conduction slowing
with a significant reduction in dephosphorlyation of Cx43 without affecting total Cx43 levels
or Cx43 distribution (Kjølbye et al. 2008). This reduction in dephosphorlylation afforded by
Rotigaptide was localised to Serine 297 and 368 in an isolated rat model of global ischaemia
suggesting that these residues may be downstream molecular targets for Rotigatide (Axelsen
et al. 2006).
The potential anti-arrhythmic effects of Rotigaptide were further explored in the isolated
guinea-pig acidosis experiments of Eloff (Eloff et al. 2003). Rotigaptide inhibited acidosis-
induced conduction slowing without affecting Na+ current, confirming the GJ specific nature
of Rotigaptide, and, treatment in the absence of acidosis resulted in no alteration in CV, in
agreement with previous work (Haugan et al. 2005) suggesting that Rotigaptide preferentially
targets gap junctions undergoing acute metabolic stress.
In in vivo studies, Rotigaptide reduced the incidence of arrhythmias inducible during ischaemia
(Xing et al. 2003) and on reperfusion (Hennan et al. 2006) in canine ischaemia-reperfusion
models and reduced infarct size in the rat chronic MI model (Haugan et al. 2006) and the
canine ischaemia-reperfusion model (Hennan et al. 2006).
Danegaptide (initially called GAP-134), is a smaller, orally available molecule which mimics the
localisation of the functional groups of AAP10 and Rotigaptide (Butera et al. 2009). Initially
developed as a potential atrial fibrillation (AF) therapy, Danegaptide demonstrated an increase
in conduction velocity and reduction in inducibility of AF in a canine sterile pericarditis model
(Rossman et al. 2009), and a reduction in AF vulnerability in a canine pacing model (Laurent
et al. 2009). In large animal models of infarction, Danegaptide reduced infarct size (Skyschally
et al. 2013) and reperfusion arrhythmias (Hennan et al. 2009) and is currently in Phase II
clinical proof-of-concept trials (ClinicalTrials.gov identifier: NCT01977755).
1.4.3 Reducing Late Arrhythmic Risk
In the pro-arrhythmic healed MI substrate, changes in Cx43 distribution and functional state
are well defined (Peters et al. 2000) and do not appear amenable to modulation by agents to
enhance GJ coupling when treated during the healed phase (i.e. greater than five days post-
insult (Macia et al. 2011)). However, enhanced GJ coupling either prior to, or at the time of
insult, confers a reduction in immediate arrhythmic risk in a variety of in vivo (Xing et al. 2003;
Hennan et al. 2006) and in vitro (Jozwiak et al. 2008) models of ischaemia-reperfusion and is an
attractive strategy in reducing arrhythmic risk (Kjølbye et al. 2007) although the mechanisms
underlying such reductions are not fully understood. A reduction in infarct size measured at
early (up to four hours) and late (up to three weeks) time points has been a consistent finding
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in studies with Rotigaptide and Danegaptide although the relationship between a reduced early
area-at-risk and immediate arrhythmogenesis has not been fully resolved and in the single study
of healed infarction (Haugan et al. 2006) no measure of arrhythmogenicity was performed
Enhancing GJ coupling in the early phase of infarction-reperfusion may result in reduced in-
farct size or reduced infarct heterogeneity by altering the spread of mediators of cell death or
survival and altering the extent and pattern of infarction. Although the mechanism is yet to
be determined, maintaining open GJ channels may result in the passage of mediators of cell
survival from viable to at-risk myocytes or alternatively the passage of mediators of cell death
from at-risk to viable myocytes with a dilutional effect resulting in insufficient concentrations to
afford apoptosis. Whether the potential structural remodelling afforded by enhancing GJ cou-
pling at the time of insult confers a reduction in late arrhythmic risk remains to be determined
but offers potentially significant clinical benefit.
46
1.5 Cardiac Diffusion Magnetic Resonance Imaging
The three-dimensional laminar microstructure of the heart, first described histologically over
40 years ago in the canine studies of Streeter (Streeter et al. 1973a; Streeter et al. 1973b) is
pivotal in enabling the heart to pump with maximal efficiency. The development of a multitude
of imaging modalities including echocardiography, contrast-enhanced MRI and nuclear imaging
have enhanced the understanding of global changes in cardiac structure and function as a
result of a range of cardiac pathologies, although none have allowed for detailed examination of
changes on a microstructure level. Diffusion weighted MRI (DWI), developed by Basser (Basser
et al. 1994a; Basser et al. 1994b) in the early 1990s and first applied to cardiac MRI in the late
1990s (Scollan et al. 1998), offers an imaging modality able to provide quantitative indices to
describe the cardiac microstructure in normal and pathological states (Huang et al. 2010).
1.5.1 Principles of Diffusion MRI
Diffusion MRI provides a measure of the random movement of H+ ions, contained in H20, as
a result of agitation by thermal energy. This movement, termed ‘Brownian Motion’ after the
observations of the movement of pollen by Brown (Brown 1828), was mathematically described
by Einstein in his paper of 1926 (Einstein 1926). Einstein concluded that in an unrestricted
medium, molecules move according to a three-dimensional Gaussian distribution, dependent on
the diffusion coefficient and mass of the molecule and viscosity and temperature of the medium.
In an isotropic medium (such as H20), diffusion occurs equally in all directions, in contrast to
biological tissue, owing to the presence of cell walls and internal cell structures where diffusion
is restricted and no longer follows a Gaussian distribution profile (Hagmann et al. 2006, Figure
1.4).
A B
Figure 1.4: Diffusion within a single voxel. (A) Containing spherical cells with isotropic diffu-
sion and a spherical diffusion profile, compared to (B) Aligned cells with anisotropic diffusion
and a rod-shaped diffusion profile. Colorbar represents probability (red = low, blue = high).
Reproduced with modification from Hagmann et al. 2006.
By calculating the diffusion distribution profile from an individual voxel, quantitative indices
that describe the magnitude and anisotropy of diffusion can be derived, and, by considering
47
diffusion profiles of neighbouring voxels, probabilistic tractography calculated (Sosnovik et al.
2009c).
1.5.2 Physics of MRI & Diffusion Sensitisation
A detailed description of the components, physics and method of generating signal using mag-
netic resonance is provided in Chapter 5. Generating signal in MR images relies on the appli-
cation of radiofrequency pulse and/or field gradients to alter the local magnetic field and cause
H+ protons, contained within, to alter their frequency and phase of spin. Following removal of
the RF pulse and/or gradients, protons return to their equilibrium state and the rate at which
transverse and longitudinal magnetisation is restored (or decays) can be quantified (T1 and
T2/T2∗ relaxation) and forms the basis of discriminating between tissues owing to different
relaxation properties (Ridgway 2010).
Diffusion sensitisation describes the method of modifying a standard MRI pulse sequence by the
addition of extra gradients sensitive to the effects of diffusion (diffusion-sensitising gradients),
which enable the diffusion component of the MR signal to be measured. First successfully
applied in measuring the diffusivity of water in the 1950s by Carr and Purcell (Carr et al. 1954),
the technique was refined by Strejskal and Tanner in 1965 (Stejskal et al. 1965) and continues
to form the basis of modern-day diffusion pulse sequences. They inserted two time-dependent
diffusion-sensitising gradients, of equal polarity, either side of a 180o pulse of a T2-weighted
spin-echo sequence (Figure 1.5A). The first diffusion sensitising pulse induces a change in phase
of the spins, which, if there has been no translational motion in the time between application
of the second diffusion sensitising gradient, results in perfect rephasing and no signal loss when
readout. If, however, motion has occurred then rephasing is imperfect and a signal loss ensues,
described by the Stejskal-Tanner equation (Figure 1.5B).
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Figure 1.5: (A) Schematic representation of the Stejskal-Tanner pulse sequence with application
of two diffusion sensitising gradients (black boxes), of duration δ with time separation ∆, either
side of a 180o refocusing pulse in a spin-echo sequence (reproduced from Sosnovik et al. 2009c).
(B) Stejskal-Tanner equation describing diffusion signal where Si equals the diffusion weighted
signal, S0 equals the signal intensity without diffusion sensitisation, ADCi is the apparent
diffusion coefficient in the i direction and b represents the b-value.
By applying multiple diffusion sensitising gradients in multiple directions, the three-dimensional
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nature of diffusion can be sampled and fitted to descriptive models which describe the diffusion
profile in tissue. The most widespread model, which requires a minimum of six diffusion gradi-
ents (and a reference, non-diffusion image), is the diffusion tensor (DTI) model, first described
and formulated by Basser (Basser et al. 1994a; Basser et al. 1994b). This model generates a
diffusion ellipsoid which is mathematically defined by three orthogonal axes of varying mag-
nitude with the principal axes (the primary eigenvector or λ1) aligned with the longitudinal
direction of cardiac myofibre (Scollan et al. 1998). From this model several quantitative indices
can be generated including measures of the magnitude of diffusion (mean diffusivity (MD)) and
measures of the anisotropy of tissue (fractional anistropy (FA), axial or radial anisotropy)(Le
Bihan et al. 2001). In addition, descriptors of the three-dimensional fibre structure can also
be formulated, either by considering the geometry of the primary eigenvector with short and
long axis planes of the heart (helix and transverse angles) or by performing probabilistic fibre
tractography (Sosnovik et al. 2009c).
1.5.3 Cardiac Applications of Diffusion MRI
Initial applications of cardiac diffusion MRI provided validation of the technique against gold-
standard histology in a range of animal models and confirmed the relationship between the
principal direction of diffusion as detected by DTI and fibre orientation (Scollan et al. 1998;
Hsu et al. 1998; Holmes et al. 2000).
In post-infarction hearts, experimental data from both human and animal studies, with histo-
logical validation, has demonstrated that structural remodelling can be quantified using DTI
derived metrics that describe changes in myocardial architecture. Mean diffusivity, a measure
of the magnitude of diffusion has been shown to increase in infarcted regions, owing to disrup-
tion of normal cardiomyocyte cell membranes and increased extravascular space between loose
bundles of collagen (Wu et al. 2007a; Wu et al. 2009). Fractional anisotropy, a measure of
tissue anisotropy, has been shown to decrease, suggesting that the normal anisotropic structure
of bundles of cardiomyocytes is lost in infarcted regions (Chen et al. 2003; Wu et al. 2006b).
In probing the three-dimensional structure of ventricular myocardium, DTI has demonstrated
significant species differences in myocardial architecture (Healy et al. 2011), and, in infarcted
myocardium, has provided a description of the complex nature of changes in fibre orientation,
not feasible using other current imaging techniques (Chen et al. 2003). High resolution dif-
fusion imaging of post-infarcted rat hearts, in the form of diffusion spectral imaging (DSI),
demonstrated that fibre architecture at the infarct border zone was highly perturbed and irreg-
ular with surviving strands of myocytes extending from the border zone to the infarct region
(Sosnovik et al. 2009a, Figure 1.6).
Diffusion MRI is not limited to descriptive indices of infarcted myocardium; Sosnovik et al
(Sosnovik et al. 2014) used DTI to assess the efficacy of bone marrow cell integration in infarcted
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Figure 1.6: (A) Matrix form of the 3x3 diffusion tensor. (B) Diagonalisation of the tensor
results in three eigenvectors (λ1, λ2, λ3), the largest of which (λ1) corresponds to the direction
of diffusion along the long axis of the myocyte. (C) Primary eigenvectors can be linked to
form tractograms to represent the 3-D fibre architecture of the myocardium. Reproduced from
Sosnovik et al. 2009a.
regions, Mekkaoui et al (Mekkaoui et al. 2013) used DTI tractography to probe the embryonic
development of foetal human hearts and Pop et al (Pop et al. 2012) have applied fibre orientation
derived from DTI to computer models of action potential propagation.
DTI is able to provide descriptive indices (FA, MD) on a voxel-by-voxel level and a quantita-
tive expression of the three-dimensional structure of the myocardium (helix angle, transverse
angle), not possible with other imaging techniques, rendering it a powerful modality to describe
structural changes post-infarction. In addition, by considering the importance of the relation-
ship between changes in myocardial structure and ventricular arrhythmogenesis in the healed
infarct, it is conceivable that novel descriptors of changes in the microstructure, such as those
provided by diffusion imaging may allow for the identification and risk stratification of infarcts
susceptible to arrhythmogenesis.
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1.6 Hypothesis & Aims
The primary hypothesis addressed in this thesis is that enhanced gap junction coupling, in the
early reparative phase post-reperfused infarction renders the substrate less prone to arrhythmias
by reducing the complexity of structural remodelling.
The studies described in this thesis investigate this hypothesis by addressing two key aims; to
investigate the effects of pharmacologically enhancing gap junction coupling on electrophysio-
logical and structural properties of reperfused myocardium and to develop and apply diffusion
weighted imaging to the study of structural remodelling in reperfused myocardium.
In order to address the hypothesis and key aims the work in this thesis addressed a series of
specific aims
• Characterisation of a suitable arrhythmic model of acute ischaemia-reperfusion
• Assessment of the effects of enhancing GJ coupling on arrhythmogenesis during ischaemia
and reperfusion in the acute ischaemia-reperfusion setting
• Development and characterisation of a suitable in vivo model of infarction-reperfusion
including the electrophysiological and structural remodelling that occurs in the healed
phase post-MI
• Development, application and validation of diffusion weighted MR imaging as an imaging
modality to probe the structural remodelling of reperfused myocardium
• Assessment of the effects of enhancing GJ coupling in a clinically-applicable in vivo model
of healed infarction-reperfusion, specifically the effects on structural remodelling, assessed
with histology and diffusion imaging and late arrhythmogenesis, assessed with in vivo and
ex vivo electrophysiology modalities.
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Chapter 2
Materials & Methods
2.1 Overview
This chapter explains, in detail, the material and methods used in the studies encapsulated
within this thesis. It includes details of the materials used (animal species and pharmacological
gap junction modulator) as well as providing a detailed description of the protocols for in vivo
myocardial infarction-reperfusion surgery, in vivo assessment of arrhythmogenicity, the ex vivo
isolated heart perfusion protocols, optical mapping of voltage and calcium transients in the
whole heart, diffusion weighted magnetic resonance imaging and histological assessment of the
infarcted heart.
Further experimental detail, including results of validation studies, is provided in chapters in
which a specific methodology was used, in particular, Chapter 5 (Probing Structural Remod-
elling post-MI with Diffusion Weighted MRI)
2.2 Materials
2.2.1 Animal Studies
All studies were performed using Sprague-Dawley rats (male, 250-350g), obtained from Har-
lan Laboratories, UK, purchased and housed at Imperial College London Central Biomedical
Services (CBS) unit. All procedures were performed in accordance with the Animal (Scientific
Procedures) Act 1986 and all in vivo experimental work was carried out under Project Licence
(PPL 70/7419) and Personal Licence (PIL 70/24061) authority. Prior to commencement of any
in vivo work, PPL 70/7419 satisfied both local (Imperial College Ethical Review Board) and
national (Home Office) review processes to ensure the work proposed adhered to the highest
welfare and research standards as defined by the 3 ’R’s of animal research.
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2.2.2 Pharmacological Enhancement of Cardiac Gap Junctions
Studies in this thesis used the compound Rotigaptide (chemical formula C28H39N7O9), molec-
ular weight 618g/mol) to pharmacologically enhance cardiac gap junction coupling. Rotigap-
tide was obtained from an in-house stock, originally synthesised by the Imperial College Drug
Discovery programme and administered as described in Section 2.5.3 (ex vivo studies) and
Section 2.3.3.3 (in vivo studies).
2.3 In Vivo Model of Myocardial Infarction-Reperfusion
2.3.1 Background
The rat model of myocardial infarction described by Johns and Olsen (Johns et al. 1954) is a
popular model of experimental permanent artery occlusion, used extensively for over 50 years to
ligate the left anterior descending artery (LAD) and produce consistent infarction to allow the
study of ventricular remodelling (Pfeffer et al. 1979; Pfeffer et al. 1991) and arrhythmogenesis
post-infarction (Curtis et al. 1987). However, the advent and widespread availability of first
thrombolytic therapy, and more recently, primary percutaneous coronary intervention (PPCI)
in clinical practice, whereby flow in the acutely occluded artery is restored and myocardium
distal to the obstruction reperfused, has led to development of animal models to reflect this
paradigm shift.
Early experimental models of reperfused infarction in the dog were pivotal in demonstrating
the existence of ischaemic but viable myocardium (Reimer et al. 1977) which is salvageable by
early reperfusion resulting in reduced infarct size, and, in clinical practice, preserved ejection
fraction and reduced mortality (Hugenholtz 1987). The model of reperfused infarction in the
rat is well-described (Deloche et al. 1977) and provides the experimental model used in this
thesis. As in canine models and clinical practice, the duration of LAD occlusion is critical
to the extent of infarction and degree of remodelling in the rat heart, as examined in the
work of Hochman and Choo (Hochman et al. 1987a). They demonstrated that 30 minutes of
infarction prior to reperfusion resulted in reduced infarct size and transmural extent at two-
weeks post-reperfusion compared to either 120 minutes or permanent occlusion. These findings
were supported by Hale (Hale et al. 1988) who studied 30 minute and 90 minute durations
of occlusion at 6 weeks and demonstrated that the longer duration was indistinguishable from
the chronic MI model whereas the shorter duration reduced the extent of the LV scar and
prevented LV cavity dilatation and wall thinning. On the basis of these studies, the majority
of current in vivo rat infarction-reperfusion studies use durations of infarction between 30 and
60 minutes to provide separation between the pathophysiology of infarction-reperfusion and
chronic permanent infarction (Takemura et al. 2009).
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2.3.2 Pre-Operative Protocol
Upon arrival in the CBS unit, and in accordance with Home Office guidelines, animals were
allowed to acclimatise for a minimum period of seven days, prior to any surgical (recovery) pro-
cedures being performed. During this time animals were housed three to four per individually
ventilated cage and allowed free access to water and food.
Prior to surgery, animals were transferred to an anaesthetic box, under a fume hood, and
inducted with a 5% Isoflurane (Baxter Healthcare Corporation, USA), 95% Oxygen mix via
inhalation. Suitable depth of anaesthesia was checked by reduced toe pinch reflex and reduced
respiratory rate. Once suitably anaesthetised, animals were placed on a Bain co-axial inhalation
circuit to allow for shaving of the anterior chest wall and sterilisation with liberal application
of Povidone Iodine antiseptic solution (Videne, Ecolab, UK). Animals were then transferred to
the operating theatre and secured on a rigid board with strips of micropore tape (3M, US) to
facilitate intubation. Mechanical ventilation was essential to counteract lung collapse as a result
of the open thoracotomy required to visualise the anterior surface of the heart prior to coronary
artery ligation. Animals were intubated in a method similar to that described by Proctor et al.
1973); the upper incisors were retracted cephalicly with a small elastic band and the animal
placed in an upright position to allow the tongue to be retracted in an anterior and cephalic
direction. By transilluminating the pharynx, the vocal cords could be visualised and a modified,
blunt-tipped 16G cannula (Becton, Dickinson and Company, US) passed between them. On
removal of the metal stylet the remaining plastic endotracheal tube was swiftly connected to
a small animal ventilator (Harvard Apparatus Model 683 Small Animal Ventilator, Harvard
Appartus, UK) and the animal ventilated with a mixture of 2% Isoflurane, 98% Oxygen at a
rate of between 90-100 breaths per minute with a tidal volume of 2.0-2.5ml. Isoflurane was
chosen as anaesthetic agent due to its rapid induction and recovery properties and the ability
to titrate precisely to the designed level of anaesthesia. Furthermore, in comparison to other
inhalation anaesthetic agents (e.g. Halothane), Isoflurane has been shown to have a greater
safety margin (Kissin et al. 1983) and a reduction in depression of cardiac function (Skeehan
et al. 1995). Correct endotracheal tube position was verified by observation of equal, bilateral
chest wall movements and maintenance of a state of anaesthesia, assessed by lack of corneal
and toe-pinch reflex.
Once satisfied with ventilation and the depth of anaesthetic the animal was transferred to a
warmed heating pad and the operating field arranged with sterile drapes (Kimberley Clark,
UK). All surgical procedures were carried out under strict aseptic technique with thorough
pre-operative hand scrubbing with Chlorhexidine (Hydrex, Ecolab, UK), use of sterile gloves,
hat, gown and mask and autoclaving of all surgical instruments prior to use.
For pre-operative medication, animals were administered the analgesic Buprenorphine (Veter-
gesic, Alstoe Ltd, UK) at a dose of 0.05mg/kg and the antibiotic Enrofloxacin (Baytril, Bayer
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Corporation, USA) at a dose of 5mg/kg both subcutaneously using a 23G needle attached to
a 1.0ml syringe (Becton, Dickinson and Company, US)
2.3.3 Surgical Protocol
The animal was positioned supine and an incision made over the left lateral chest wall and
the subcutaneous tissue planes divided. Pectoralis minor and pectoralis major were carefully
dissected and retracted to expose the intercostal muscles. A transverse thoracotomy was per-
formed between the third and fourth intercostal space with particular care to avoid the left
internal mammary artery. The ribs and visible thymus were retracted to allow for visualisation
of the anterior surface of the left ventricle and identification of the left atrial appendage and
the origin of the LAD. A 6-0 prolene suture (Ethicon, UK) was passed approximately 1-2mm
distal to the tip of the left atrial appendage with sufficient depth through the myocardium to
ensure encircling of the intramyocardial LAD. Care was taken not to inadvertently occlude the
LAD so as to minimise any preconditioning effects. Once the ligature was in place a modified
slipknot was tied (see Figure 2.1 as described by Deloche et al. 1977) and artery occlusion
confirmed by the presence of blanching and regional hypokinesia of the anterior wall. If blanch-
ing and regional hypokinesia were not present, indicating unsuccessful ligature placement, the
suture was removed and a second or third attempt made to occlude the LAD. Prior to chest
closing, an 18G cannula (Becton, Dickinson and Company, US) without stylet was placed into
the thoracic cavity to act as a chest drain. The free end of the slipknot was carefully brought
through the chest wall, muscle and skin layers which were then closed with interrupted 4-0 silk
sutures (Ethicon, UK).
Figure 2.1: Diagrammatic representation of slipknot used to enable temporary occlusion of
coronary artery. (Reproduced from Deloche et al. 1977)
Once all layers were closed, free air was aspirated from the thoracic cavity through the chest
drain and a cycle of CPAP helped ensure full lung re-expansion. Anaesthesia was temporarily
reduced to 1% Isoflurane to allow for extubation and return of spontaneous ventilation at which
point the endotracheal tube and chest drain were removed and the animal maintained under
anaesthesia on a Bain co-axial circuit for the duration of the study.
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2.3.3.1 Studies of Variable Duration of In Vivo Infarction
There were two principle considerations in the choice of the duration of infarction for these
studies: 1) animal survival in the immediate post-reperfusion period and 2) ensuring sufficient,
consistent infarction and remodelling to allow for study of the potential effects of pharmaco-
logical therapy. The incidence of potentially fatal reperfusion arrhythmias was minimised by
considering the findings of the ex vivo studies described in Chapter 3 which showed that a
longer (greater than 30 minutes) duration of LAD occlusion significantly reduced the incidence
of reperfusion arrhythmias. The consideration of the extent of structural remodelling is outlined
in Section 2.3.1.
With these considerations, animals underwent either 30 or 60 minutes of occlusion, prior to
release of the slipknot (reperfusion) and weaning of anaesthesia. Another group of animals
underwent sham MI surgery to act as operated controls. This procedure was identical to that
described in 2.3.3 except the ligature was left slack, the chest, muscle and skin closed and the
animal maintained on the Bain Co-Axial circuit for 60 minutes prior to recovery.
2.3.3.2 Studies of Effects of GJ Modulation
Animals being studied to assess the effect of GJ modulation received an intraperitoneal (IP)
bolus of Rotigaptide (2.5nmol/kg) 15 minutes post-occlusion and release of the slipknot at 60
minutes post-occlusion followed by weaning and recovery. The choice of 60 minutes duration of
LAD occlusion prior to reperfusion was chosen on the basis of the findings discussed in Chapter
4.
2.3.3.3 Osmotic Minipump Implantation
Animals being studied to assess the effect of GJ modulation therapy on post-MI arrhythmo-
genesis and structural remodelling were subject to administration of either phosphate-buffered
saline (PBS) or Rotigaptide via osmotic minipump (Pump 2ML1, Azlet, UK). The control
group were administered PBS at a rate of 10 µl/hr for seven days (total 2ml). The treatment
group were administered Rotigaptide at a dose of 0.11nmol/kg/day dissolved in isotonic saline.
This dosing of Rotigaptide (bolus IP injection and minipump) has previously been shown to
demonstrate therapeutic steady state plasma concentrations and reduce infarct size (Haugan
et al. 2006).
Drug delivery via osmotic minipump allows for continuous drug administration in a convenient,
consistent manner, minimises the need to handle and stress animals following major surgery
and is a straightforward surgical procedure. In order to minimise repeat surgical procedures
and anaesthetics, animals underwent minipump implantation at the same time as reperfusion
MI surgery. The abdomen was shaved and cleaned with Povidone Iodine and a small (2cm)
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vertical skin incision made along the linea alba. The abdominal muscle layers were divided to
create a limited laparotomy and the minipump inserted into the IP cavity. The muscle and
skin layers were closed with 4-0 Silk and the study continued until reperfusion and recovery.
2.3.4 Post-Operative Protocol
All animals were recovered in a perspex hotbox with 100% oxygen supplementation (flow rate
4L/min) and only returned to a single animal individual ventilated cage once fully conscious
and mobile. Animals were checked for potential adverse effects (including wound dehiscence,
bleeding, signs of distress) twice daily for the first 72 hours following surgery then daily until
the end of the study protocol with specific attention paid to identification of humane end points
as defined in PPL 70/7419 and provision of further analgesia if necessary.
2.4 In Vivo Assessment of Arrhythmogenicity
To determine the arrhythmia phenotype of the in vivo model of infarction-reperfusion, and to
assess the extent, if any, of an anti-arrhythimc effect that Rotigaptide treatment may have, two
measures of in vivo arrhythmogenicity were used; ECG telemetry provided a measure of the
incidence of spontaneous arrhythmias post-infarction and 6-lead ECG provided a baseline set
of ECG parameters at four weeks post-infarction which could be compared between groups.
2.4.1 In Vivo ECG Telemetry
2.4.1.1 Background
ECG telemetry recordings were first used in studies of rat heart rate response during free and
learned behaviour in the 1970s (Bohus 1974). Early studies used tethered systems, whereby a
degree of restraint of animal movement was required in order to preserve electrical continuity
between electrodes (attached to the animal), recording wires and data acquisition systems (free
standing computers). The advent of wireless radio-telemetry transmitters and the refinement
of electrode positioning allowed for unhindered movement of the animal and an increase in both
quality and validity of recorded data (Kuwahara et al. 1994; Sgoifo et al. 1996).
Wireless ECG telemetry systems have been used widely as a tool for assessing in vivo arrhyth-
mias, ranging from studies of the time course of arrhythmogenesis post-MI (Opitz et al. 1995)
to studies of the response of ECG parameters to pharmacological and gene therapy (Baillard
et al. 2000).
The telemetry system consists of three main components; a transmitter unit, a receiver plate and
a data acquisition system. The transmitter unit (CA-F40, Data Sciences International, USA)
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is a small, lightweight (8gm, 4.7cc) hermetically sealed unit which is placed in the peritoneal
cavity, with two biopotential leads, tunnelled subcutaneously, across which a potential difference
is measured. Each transmitter unit transmits at a unique frequency and is manually paired to
a receiver plate (RPC-1 Receiver, DSI, USA) located directly beneath the animals cage. Each
telemetry receiver plate is connected to a data matrix (Data Sciences International, USA) via
an ethernet cable, which in turn, is connected to a free standing computer running Windows
XP and data acquisition software.
2.4.1.2 Surgical Protocol
Prior to surgery the animal was placed in an anaesthetic induction chamber with 5% Isoflurane,
95% Oxygen until a state of sufficient anaesthesia was reached. At this point the animal
was transferred to a Bain co-axial circuit, the abdomen was shaved, sterilised with Povidone
Iodine and the animal pre-medicated with analgesia (Buprenorphine 0.05mg/kg) and antibiotic
(Enrofloxacin 5mg/kg). The animal was then transferred to the operating theatre, secured onto
a flexible warmed heating map and maintained on a Bain co-axial circuit with a 2% Isoflurane,
98% Oxygen mix.
A 2cm vertical incision was made along the line of the linea alba and a 0.5cm incision made at
an oblique angle over the antero-lateral aspect of the right chest. The abdominal muscles were
divided and a laparotomy created, through which the wireless ECG transmitter was placed into
the abdominal cavity. The body of the transmitter was sutured to the anterior abdominal wall
using 4-0 silk and the two biopotential transmitter leads tunnelled through the subcutaneous
tissues to the right axilla and just below the cardiac apex respectively, creating a pseudo-lead II
ECG position. Once in place, the free ends of the leads were secured to underlying subcutaneous
tissue with a 4-0 silk suture and the transmitter turned on by placing a magnet nearby and
confirming transmission by tuning an AM radio to low frequency range (445MHz) and listening
for a constant audible signal. The abdominal and skin layers were closed with 4-0 silk, the
Isoflurane weaned and the animal recovered in a hotbox with 100% oxygen.
Once fully recovered, animals were returned to their singly-housed individual ventilated cage
with free access to water and food and placed on a custom-built housing rack (Techniplast, UK)
with metal inserts between cages on all four sides to prevent cross-talk between transmitters.
The unique ID of each transmitter was paired to the receiver plate beneath each cage to allow
for simultaneous display and recordings of ECG signals for up to four animals at any time.
Animals were checked for potential adverse effects (specifically wound dehiscence and bleeding)
twice daily for the first 72 hours following surgery then daily until the end of the study protocol.
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2.4.1.3 Data Collection and Analysis
Telemetry recordings were performed at between 25-30 days post infarction-reperfusion surgery
in order to assess the arrhythmia phenotype at this stage of healing which is at the end of the
reparative, collagen deposition phase but before the onset of LV dilatation and heart failure.
Recordings were performed for 72 hours, with specific attention paid to minimising disturbance
and stress to the animals during this time.
Data were recorded in 20MB segments (approximately 3 hours of data) using ART 3.1 soft-
ware (Data Sciences International, USA) before being exported and converted to IOX data files
using EMKA analysis software (ECG Auto v2.1.4.26, EMKA Technologies, France). For each
analysis, a 24hr window was extracted which matched the light-dark cycle of the animal facility
(7am-7pm light, 7pm-7am dark) so as to minimise any effect of diurnal variation. EMKA soft-
ware automatically analyses the entire ECG trace by comparing the ECG waveforms against
a library of abnormal waveforms which represent ventricular premature beats, ventricular ec-
topics, couplets and triplets. Although the analysis is automatic, there is a significant false
positive rate which varies depending on the initial QRS morphology which differs for each ani-
mal. Therefore, it was important to adjust the library of abnormal waveforms at the onset of
analysis and also manually check the detection and identification of each waveform to ensure
accuracy. Furthermore, the identification of consecutive ventricular ectopics to form runs of
ventricular tachycardia also depended on user scrutiny. Ventricular premature beats were iden-
tified provided they met two out of three criteria: 1) Atypical QRS and T-wave morphology , 2)
post-extrasystolic pause or 3) atrioventricular dissociation (Fernandes et al. 2006). Examples
of software detected arrhythmias are demonstrated in Figure 2.2.
Arrhythmias were defined in keeping with the Lambeth Conventions (Walker et al. 1988),
with ventricular tachycardia defined as a run of four or more consecutive ectopic beats and
ventricular fibrillation defined as a signal in which no individual QRS morphologies can be
distinguished from each other and no rate can be measured. For data analysis, the total
number of ventricular premature beats was reported in addition to calculation of a modified
arrhythmia score (Curtis et al. 1988, equation 2.1) which encapsulates complex (VT/VF) as
well as simple (VPB) arrhythmias.
Score = log[V PB] + 2× log[V T ] + 2× log[V F ] (2.1)
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Figure 2.2: Four (A-D) examples of wireless ECG telemetry traces demonstrating different ven-
tricular premature beat ectopic morphology (A, B), a triplet (C) and a short run of ventricular
tachycardia (D) Red dots indicate automatically detected abnormal beats
2.4.2 In Vivo 6-Lead ECG
2.4.2.1 Background
The 12-lead electrocardiogram (ECG), ubiquitous in modern clinical practice, has a rich history
of development over the last hundred years (Lewalter et al. 2003). Augustus Waller, working at
St Mary’s Hospital, Paddington, published the first human surface electrocardiogram in 1887
using a capillary electrometer which detected small changes in electrical current between two
electrodes resulting in the smallest of changes in the surface tension of a mercury filled capillary
tube (Waller 1887). However, it is William Einthoven who is credited with the development
of the first practical system of electrocardiography, after he made use of string galvanometers
to measure electrical current and assigned the letters P, Q, R, S and T to the deflections that
define the ECG of the present day (Einthoven 1903).
The role of the ECG is vital not only as a tool for the accurate and timely diagnosis of a range
of clinical cardiac diseases (e.g. myocardial infarction, atrial fibrillation) but also as a research
tool in basic science for the collection of baseline ECG data and the assessment of ECG changes
accompanying disease states. Electrocardiogaphy was first performed in the rat over 50 years
ago (Lombard 1952) and there exists a comprehensive collection of normal values across a range
of strains (White et al. 1960; Fraser et al. 1967) and disease states (Normann et al. 1961).
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2.4.2.2 Surgical Protocol
Owing to the limited size of the rat thorax only a 6-lead ECG was recorded. Animals were placed
in an anaesthetic induction chamber with 5% Isoflurane and 95% Oxygen until a sufficient state
of anaesthesia was reached. At this point the animal was transferred to the operating theatre
and placed on a Bain Co-Axial circuit with a flow rate of 2L Oxygen/minute and maintained
under anaesthesia with a 2% Isoflurane, 98% Oxygen mix.
Grass platinum sub-dermal needle electrodes (C-ISO-GNE3, iWorx Systems Inc, USA) were
attached to each limb with a reference electrode attached to the right leg. The needle electrodes
were then attached to an data acquisition unit (IX-228/S, iWorx Systems Inc, USA) via a 5-lead
ECG recording cable (C-AAMI-504, iWorx Systems Inc, USA). ECG Signals (leads I, II, III,
aVF, aVL and aVR) were acquired at a sampling frequency of 1KHz, bandpass filtered between
0.3-3.0Hz and displayed real-time using LabScribe 2 software (iWorx Systems Inc, USA). After
allowing for a five minute stabilisation time after placement of the needle electrodes and during
which no alterations were made to anaesthetic, a one minute recording was taken for oﬄine
analysis.
2.4.2.3 Data Collection and Analysis
Data were analysed oﬄine using LabScribe 2 software. A total of 10 consecutive beats were
averaged in the ECG lead with greatest QRS amplitude. Standard ECG parameters were
measured; the PR interval was defined from the first upward deflection of the P-wave to the
start of the R-wave; the QRS interval was defined from the start of the R-wave to the end of the
S-wave; the QT interval was measured from the start of the R-wave to the end of the T-wave
where the electrogram crossed the isoelectric line.
200ms
200mV
PR
QRS
QT
RR
Figure 2.3: Measurement of standard ECG parameters
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All measurements were reported in milliseconds (ms), the QT interval was reported as corrected
QT (QTc) defined as per Bazetts formula (Equation 2.2) which has been shown to report QTc
values within normal physiological range compared to either unadjusted or conventional (RR-
adjusted) corrections (Kmecova et al. 2010).
QTc =
QT√
RR
150
(2.2)
2.5 Ex Vivo Isolated Heart Perfusion
The studies in this thesis make use of the isolated rat heart preparation in two forms. First, as
a tool to study the time-course of arrhythmogenesis and the role of Rotigaptide in an ex vivo
model of infarction-reperfusion. Second, as a method to allow for the study of action potential
remodelling and Calcium handling in the post-infarcted heart by the use of fluorescence dyes
and the technique of optical mapping (a full description of which follows in Section 2.6)
2.5.1 Background
Oscar Langendorff, a German physician and physiologist is widely credited with developing the
first isolated mammalian heart preparation (Langendorff 1898), building on the isolated frog
heart pioneered by Cyon in 1866. The principles proposed by Langendorff over 100 years ago
are still widely in use today; the ascending aorta is cannulated and the heart perfused in a
retrograde manner with either serum or a physiological solution (e.g. Krebs-Henseleit buffer).
Retrograde perfusion against a closed trileaflet aortic valve results in the entire perfusate being
circulated in the coronary arteries via the ostia until the perfusate is drained into the right
atrium via the coronary sinus. The early preparations of Langendorff and his contemporaries
provided several fundamental advances in the field of heart biology. Discoveries included the
successful substitution of blood for a physiological (glucose-rich) medium, the ability to measure
myocardial oxygen consumption and the birth of studies in cardiac metabolism, the discovery
by Frank and Starling of the relationship between stroke volume and end diastolic volume
(Patterson et al. 1914) and the phenomenon of postextrasystolic potentiation where the force
of a cardiac extrasystole is magnified owing to a increase Ca2+ release from intracellular stores
(Taegtmeyer 1995).
The original, pressure-based method of coronary perfusion was refined in 1939 by Katz who
developed a constant-flow system which was purported to have two main advantages; it was
easier to continuously regulate coronary pressure and pharmacological studies could now be
performed with accurately known concentration of drugs.
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The isolated rat heart was first comprehensively described by Neely (Neely et al. 1967) who
made several important observations; he observed that the isolated rat heart preparation could
be stable for over three hours when perfused with physiological buffer, that heart size was a
key determinant of myocardial oxygen demand and that an increase in filling pressure (preload)
results in greater oxygen consumption. Building on the work of Neely, the isolated rat heart
preparation has become a well established tool in the field of heart biology and continues to
play a key role in physiological, pharmacological and metabolic studies (Bell et al. 2011).
The isolated rat heart preparation was chosen as an experimental tool for the studies in this
thesis owing to its reproducibility, ease of setup, cost, and ability to address specific hypotheses
compared to larger animal or clinical models which are either technically infeasible, unethical
or difficult to replicate.
2.5.2 Langendorff Perfusion Apparatus
Two sets of Langendorff perfusion apparatus were used during the course of the work in this
thesis. For the ex-vivo infarction-reperfusion experiments a constant pressure system was used,
whereas for the optical mapping experiments a constant flow system was used. A constant
flow system was necessary for the optical mapping experiments as the heart was mechanically
uncoupled (to reduce motion artefact) and hence lost the physiologically important dominant
diastolic suction wave, responsible for the majority of coronary flow (Davies et al. 2006).
Both perfusion systems used a circulating water heating system and a series of insulated tubes
to thermoregulate the perfusate which was maintained at between 36.5-37.5oC. Both perfusion
systems had flexible oxygen tubing routed in direct contact with the perfusate and a mixture
of 5% CO2, 95% O2 (Carbogen, BOC, UK) bubbled at a rate of 1.0-1.5L/min; this ensured
adequate oxygenation and provided sufficient CO2 to act as a buffer for the Krebs-Henseleit
perfusate. Both systems passed the warmed, oxygenated perfusate through a 5µm filter and
had a series of one-way valves and bubble traps mounted proximal to the aortic cannula which
allowed for the administration of drug boluses as needed and prevented air emboli from entering
the coronary circulation.
For the constant pressure apparatus the perfusate was placed into two tall side-by-side columns
which provided the hydrostatic force to generate a perfusion pressure of between 80-100 cm
H20 (equivalent to 80-100mmHg). The perfusate delivered to the heart could be alternated to
originate from either column A or column B by means of a series of insulated three-way taps
which allowed drug treatment to be administered as required. Eﬄuent was collected, measured
(see 2.5.3) and discarded.
For the constant flow apparatus the perfusate was placed into a water-jacketed 2L reservoir
(Radnoti, USA) where it was oxygenated, heated and then taken to the aortic cannula by a
series of insulated flexible Tygon tubes (Radnoti, USA) which ran through a peristaltic pump
64
(Radnoti, USA) enabling flow through the cannula to be controlled between 1.0-100ml/min
(typical flow rate 16-18ml/minute). The constant flow apparatus benefited from an in-line
pressure transducer, mounted proximal to the aortic cannula which allowed for precise titration
of flow to a pressure of between 90-100mmHg.
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Figure 2.4: Langendorff Perfusion Apparatus
2.5.3 Isolated Heart Protocol
For all ex vivo isolated heart preparations the following protocol was used, independent of the
mode of perfusion being pressure or flow driven.
Hearts were explanted from male Sprague-Dawley rats (250-350g) following cervical dislocation
under terminal anaesthesia (5% Isoflurane, 95% Oxygen mix) and the aorta, heart, lungs and
thymus placed into an ice-cold dish of heparinised, buffered Krebs-Henseleit solution (KHB).
The thymus, lungs and mediastinum were carefully dissected to identify the ascending aorta
taking care to minimise inadvertent air intake into the aorta. The ascending aorta was mounted
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onto a 1.2mm diameter metal cannula (Radnoti, USA) attached to the perfusion apparatus
and held in place with a small clip prior to securing with a 3-0 silk suture (Ethicon, UK). The
pulmonary trunk was identified and a small incision made to allow for free drainage of eﬄuent.
Buffered Krebs-Henseleit solution, (described by Krebs and Henseleit in 1932) was used as
perfusate for all studies owing to its ease of synthesis from stock chemicals, low cost and well-
established use. In mmol/L KHB contains Na+ 118, K+ 4.5, Mg2+ 2.4, Ca2+ 1.85, Glucose
11.1, CO2−3 25, PO
2−
3 1.38 resulting in a pH between 7.35-7.45 when bubbled with 5% CO2,
95% O2. Once the heart was secured onto the cannula and attached to the perfusion system
the pressure (or flow) was gradually increased until desired pressure (90-100mmHg) reached at
which point the heart was allowed to stabilise for 15 minutes. The mean time from explant to
start of stabilisation was under two minutes.
A fine silver electrode was lightly placed on the epicardial surface and a reference electrode on
the metal cannula to create a whole-heart unipolar electrode which was connected via a BioAm-
plifier (ADInstruments, USA) to a data acquisition system (Powerlab 8/35, AD Instruments,
USA) and displayed in realtime using LabChart 7 (ADInstruments, USA) at a sampling rate
of 1KHz and bandpass filtered between 0.3-30Hz.
Hearts were excluded from further study if at the end of the stabilisation period the heart rate
(HR) was less than 200 beats per minute (bpm) or greater than 400 bpm, the coronary flow
eﬄuent (for the constant pressure system) was less than 10mls/minute (suggestive of reduced
myocardial function) or greater than 20mls/minute (suggestive of proximal aortic leak), or there
had been runs of sustained arrhythmias during the last 10 minutes of stabilisation. Following
stabilisation, studies were continued as described in either Section 2.5.4 or Section 2.6.3.
2.5.4 Ischaemia-Reperfusion Protocol
Ex vivo ischaemia-reperfusion (I/R) studies were performed to explore the time-course of ar-
rhythmias occurring during acute LAD occlusion, those occurring during reperfusion, and the
effects, if any, of Rotigaptide on arrhythmogenesis. The ex vivo isolated heart preparation lends
itself to I/R studies owing in part to the reproducibility of the initial preparation and the ability
to control external variables (perfusion pressure, temperature, oxygenation) but also the abil-
ity to directly visualise the anterior LV surface to allow for precise placement, and subsequent
release, of the LAD ligature.
Shortly following aortic cannulation and before the period of stabilisation, hearts had a 7-0
Prolene suture (Ethicon, UK) placed 1-2mm distal to the tip of the left atrial appendage, of
sufficient depth to encircle the intramyocardial LAD. No further instrumentation of the heart
was performed and the suture remained slack for the following 15 minute stabilisation period.
Provided no exclusion criteria were met during stabilisation, the LAD was then occluded by
means of threading the loose ends of the suture through a perspex occluder tube and then
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pressing the tube firmly against the anterior LV surface, thereby ensnaring the LAD and causing
acute coronary occlusion. Sufficient ensnaring and occlusion of the LAD was demonstrated
by abrupt regional hypokinesia of the anterior LV wall, alteration in unipolar electrogram
morphology or axis and a greater than 30% reduction in coronary eﬄuent. All three criteria
needed to be satisfied for the study to continue as described in subsections 2.5.4.2 and 2.5.4.3.
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Figure 2.5: A Setup of isolated ex vivo rat heart during stabilisation (left) and LAD occlu-
sion (right). B-D demonstrate typical unipolar electrogram traces during stabilisation, LAD
occlusion and reperfusion. A run of reperfusion VT is indicated between the red stars.
At the end of the period of occlusion, the clamp holding the occluder tube was released and flow
restored. Reperfusion was confirmed by the presence of improved contractilty of the anterior LV
wall, normalisation of the unipolar electrogram and restoration of coronary flow effulent. Heart
rate was recorded immediately prior to a five minute period of reperfusion. This duration of
reperfusion was deemed sufficient as the majority (>90%) of reperfusion arrhythmias occurred
in the first 90 seconds following reperfusion with no difference in assessment of arrhythmia
incidence between 3 minutes post-reperfusion and 5 minutes post-reperfusion. Hearts in VF at
the planned time of reperfusion were excluded from further reperfusion analysis.
2.5.4.1 Arrhythmia Recording
The incidence and timing of ventricular premature beats, VT and VF were recorded during
the period of LAD occlusion and during the five minute reperfusion period. For each minute
of occlusion, the % of hearts experiencing VPB/VT/VF during that minute was expressed and
plotted as a function of time to obtain an arrhythmia distribution histogram. In addition,
for arrhythmias occuring during LAD occlusion, a validated, composite logarithmic arrhythmia
score was calculated (Curtis et al. 1988, equation 2.3) which encapsulates all forms of ventricular
arrhythmias including the duration of VF.
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Score = log[V PB] + 2× log[V T ] + 2× log[V F ] (2.3)
2.5.4.2 Studies of Variable Duration Coronary Occlusion
The time-course of arrhythmogenesis during coronary occlusion and the occurrence and timing
of reperfusion arrhythmias were studied as described in Chapter 3. These studies informed the
choice of duration of LAD occlusion for further ex vivo GJ modulation studies and for in vivo
studies of infarction-reperfusion.
The occluder tube remained in place for either 15, 30 or 60 minutes, during which, the incidence
and timing (on a minute-by-minute basis) of ventricular arrhythmias was recorded. At the end
of the period of occlusion, provided the heart remained in sinus rhythm, the heart was reperfused
as described in 2.5.4, removed from the aortic cannula and flash frozen in liquid nitrogen. A
group of hearts with the ligature left slack were perfused for 60 minutes without LAD occlusion
to act as controls.
2.5.4.3 Studies of the Effect of Rotigaptide on Arrhythmogenesis
For studies assessing the effect of Rotigaptide on arrhythmogenesis during LAD occlusion and
reperfusion, hearts were subject to 15 minutes of coronary occlusion followed by five minutes
of reperfusion. Fifteen minutes of LAD occlusion was chosen on the basis of this representing
the maximally pro-arrhythmic time point for reperfusion arrhythmogenesis as demonstrated in
Chapter 3.3.
Hearts were subject to perfusion with either a) KHB only (control) for the entire duration of
the study, b) KHB during stabilisation switched to Rotigaptide 50nM prior to occlusion, c)
KHB during stabilisation, switched to Rotigaptide (50nM) at the time of LAD occlusion and
continued reperfusion and d) KHB during stabilisation, occlusion and switched to Rotigaptide
(50nM) on reperfusion. Rotigaptide, at a concentration of 50nM has been shown to enhance
GJ coupling in isolated rat cardiac myocytes (Clarke et al. 2006) and maintain GJ coupling
and reduce discordant alternans in the isolated guinea pig heart (Kjolbye et al. 2007). Care
was taken to ensure that the temperature of the Rotigaptide perfusate was maintained at
36.5-37.5oC prior to switching perfusion to minimise the effects of transient hypothermia on
myocardial contractility and arrhythmogenesis.
At the end of the period of occlusion, provided the heart remained in sinus rhythm, the heart
was reperfused as described in 2.5.4, removed from the aortic cannula and flash frozen in liquid
nitrogen.
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2.5.5 Arrhythmia Provocation Studies
Arrhythmia provocation studies were performed in hearts having undergone in vivo infarction-
reperfusion (with or without GJ modulation) to provide a measure of the arrhythmia phenotype
and to assess for potential anti-arrhythmic benefits of GJ modulator therapy.
2.5.5.1 Background
Clinical pacing studies are widely used in modern electrophysiology as a means of inducing
tachyarrhythmias and may be used as a tool to stratify risk of fatal arrhythmias in patients post-
infarction. The use of pacing provocation studies in patients with prior myocardial infarction
and VT were first described by Wellens (Wellens et al. 1972) and the programmed electrical
stimulation (PES) protocol performed in his studies has changed remarkably little.
Typical extrastimulus pacing protocols consist of a drive train (usually 8 or more beats) paced at
a fixed cycle length (CL), termed S1, to allow for stabilisation of the refractory period, followed
by the introduction of one or more premature extrastimuli following the last S1 beat (termed S2,
S3 etc.). Introduction of the premature extra stimulus may cause premature depolarisation of
the myocardium resulting in either normal conduction or, if there is heterogenous repolarisation
and areas adjacent to one another with different refractory states, arrhythmogenesis; or may
not depolarise the myocardium, defining the refractory period of the tissue. PES extrastimulus
protocols have been widely used to define the arrhythmia phenotype in genetically engineered
models of cardiac disease (Berul 2003) and to probe the relative arrhythmia risk following
ventricular remodelling post-MI (Be´lichard et al. 1994).
2.5.5.2 Experimental Protocol
Hearts undergoing provocation studies were Langendorff perfused, stabilised and loaded with
fluorescent dye as described in Section 2.5.3 and 2.6.3.
The PES protocol was similar to that described by Lyon (Lyon et al. 2011). Hearts were subject
to a S1S2 extrastimuli provocation protocol with a drivetrain of 10 beats (S1) at a CL of 120ms
followed by introduction of a premature extra stimulus (S2) at a shorter CL. This shorter CL
started at 100ms and decremented by 2ms until the heart was refractory and failed to capture.
If the heart remained in sinus rhythm at the end of the S1S2 protocol, an S1S2S3 protocol was
performed with a drivetrain of 10 beats (S1) at a CL of 120ms, a fixed interval premature S2
stimuli at 100ms then a variable premature S3 stimuli starting at 80ms and decremented by
2ms until the heart was refractory. ECG and pacing data were recorded continuously for oﬄine
analysis.
69
2.5.5.3 Data Analysis
Arrhythmias were defined in keeping with the Lambeth Conventions (Walker et al. 1988),
with ventricular tachycardia defined as a run of four or more consecutive ectopic beats and
ventricular fibrillation defined as a signal in which no individual QRS morphologies can be
distinguished from each other and no rate can be measured. In order to reduce the false
positive rate of ventricular tachycardia and in appreciation that in clinical practice a short run
of ectopic beats post-pacing would not constitute a firm diagnosis of VT, VT was subdivided
into non-sustained VT (NSVT) for runs of VT between 4-15 beats and sustained VT (susVT)
for runs of VT greater than 15 beats. An arrhythmia score was then allocated, based on the
score proposed by Nguyen (Nguyen et al. 1998, as follows: no inducible = 0, NSVT on S1S2S3
= 1, SusVT on S1S2S3 = 2, NSVT = 3, SusVT = 4, On S1 pacing = 5, Post-stabilisation =
6.)
2.6 Optical Mapping of Intact Myocardium
2.6.1 Background
Optical mapping or optical imaging refers to the technique of using highly sensitive fluorescent
dyes to provide simultaneous non contact recording of optical signals from contiguous regions
of either the intact heart or multi-cellular tissue preparations. Commonly used fluorescent dyes
include those sensitive to changes in transmembrane voltage and intracellular Ca2+; allowing
for the measurement of the cardiac AP and Ca2+ transient respectively.
In the case of voltage sensitive dyes, the dye binds to the outer layer of the myocyte cell
membrane and alters its emission spectra in response to changes in transmembrane voltage.
The dye is excited by a light of wavelength within the dyes excitation spectra (in the case
of RH237, 535nm) and, in the process of returning to its original, pre-excited state, emits a
photon of light of longer wavelength (in the case of RH237, 660nm). The emitted photons are
passed and focused through an objective lens onto the sensor of the detector (e.g. Photodiode
array, CMOS camera), counted, and induce a change in charge on the surface of the detector
allowing a quantification of the total amount of fluorescence per unit time. The total number
of emitted photons is dependent on the initial emission spectra of the dye, so that changes in
transmembrane voltage can be detected as proportional alterations in the total photon count.
The exact mechanism by which voltage-sensitive dyes alter their emission spectra is not known,
however, the putative mechanism is that of electrochromism, whereby the charge within the
fluorescent dye molecule is altered due to myocyte depolarisation resulting in a spectral shift of
the dye. The principles of optical imaging with Ca2+ sensitive dyes is similar to that described,
except the dye crosses the cell membrane and binds to cytosolic Ca2+.
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The first application of cardiac optical imaging and the first optical recording of the cardiac
AP was the administration of the voltage-sensitive dye 540-Merocyanine by Salama and Morad
(Salama et al. 1976) to the epicardial surface of the isolated frog heart. With the advent of
potentiometric dyes with greater brightness, greater fractional fluorescence change and reduced
phototoxicity (e.g. di-4-ANEPPS, RH237) and the technological development of acquisition
systems with greater spatiotemporal range (Herron et al. 2012), studies with voltage-sensitive
dyes have greatly expanded our understanding of the mechanisms of arrhythmogenesis (Fedorov
et al. 2011) and electrophysiological remodelling in disease (Glukhov et al. 2012). Optical
mapping of hearts post-infarction has demonstrated a series of electrophysiological changes at
the infarct border zone (Mills 2005; Walker et al. 2007) and allowed for characterisation of re-
entrant epicardial VT ciruits (Takahashi et al. 2004; Ding et al. 2010) which demonstrate the
importance of the infarct border zone in providing a substrate for the development of functional
conduction block and areas of slow conduction to initiate and maintain re-entrant circuits.
Dual optical imaging of simultaneous AP and Ca2+ transients were first described by Choi
and Salama (Choi et al. 2000) in the isolated Guinea Pig heart to study the spatiotemporal
relationship between voltage and Ca2+ kinetics in discordant alternans. The technique has since
been refined (Laurita et al. 2001; Efimov et al. 2004) and applied to the study of spontaneous
Ca2+ oscillations in ischaemia-reperfusion (Lakireddy et al. 2006), voltage and Ca2+ dissociation
in VF (Omichi et al. 2004) and remodelling of the AP and intracellular Ca2+ dynamics post-MI
in the rabbit (Chou et al. 2007).
2.6.2 Hardware Setup
All optical mapping studies require a subject (the isolated rat heart), a fluorescent dye (see
Section 2.6.3.2), a means of exciting the fluorescent dye, and a series of optics and detectors
for collecting emitted photons and quantifying the fluorescent signal.
Optical mapping studies detailed in this thesis were performed using a custom made Dual-
CMOS (complementary metal-oxide semiconductor) camera optical mapping system (Cairn
Research Labs, UK) which allowed for high spatial (100µm pixel size) and high temporal
(sampling rate 1000 frames/second) resolution and greater quantum efficiency compared to
photodiode array (PDA) or charge-coupled device (CCD) camera systems. The combination of
high spatial and temporal resolution distinguishes optical mapping from other contemporary
basic electrophysiological methods (e.g. microelectrode arrays) and provides greater scope and
quality of data for studies at the whole heart level.
Excitation light was provided by an array of LEDs (Cairn Research Labs, UK) with removable
filters set to emit light at 535nm (green on visible light spectrum). Emitted light from the
epicardial surface of the heart passed through a x1 objective lens (Nikon, UK) and a macro-
scope (x0.63-x6.3 MVX10 Olympus, UK) to allow fine focusing before passing to two CMOS
71
camera heads via a set of dichroic mirrors. The two cameras were mounted perpendicular to
each other with the mirrors allowing emitted light to be split based on wavelength with light
between 575-590nm being passed to one CMOS camera (used for Ca2+ imaging) and light of
wavelength 660nm being passed to the other (used for voltage imaging). The CMOS cameras
(RedShirtImaging LLC, USA) provided a sensor size of 128x80 pixels, giving an effective pixel
size of 100µm and sampling rate of up to 5000 frames/second.
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Figure 2.6: Optical Mapping Hardware Setup
2.6.3 Optical Mapping Protocol
2.6.3.1 Experimental Setup
For all optical mapping studies, hearts were explanted and Langendorff perfused using a con-
stant flow system (rate 15-18ml/minute, to pressure 90-100mmHg) as described in Section
2.5.3.
Hearts were paced by positioning a platinum needle electrode on the epicardial surface of the
basal region of the right ventricular (RV) free wall, with a reference electrode attached to
the metal cannula. Pacing wires were connected to a reconditioned clinical pacing system
(Micropace, MicropaceEP Ltd, UK) and the heart paced with a standard rectangular pulse
of duration 1ms at twice diastolic threshold (diastolic threshold usually between 0.2-0.4mv).
Cardiac pacing was performed for all data acquisitions in order to provide a planar epicardial
wavefront front from which CV could be calculated as described in Section 2.6.5. Of note, there
were no differences in activation maps or CV between unipolar paced or bipolar paced hearts.
After placement of the pacing wire, hearts were allowed to stabilise for 15 minutes in a custom
built perspex chamber which served to keep the heart at physiological temperature (36.5-37.5oC)
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and facilitated optical imaging by providing a flat surface against which the surface of the heart
could be lightly placed prior to data acquisition. Care was taken on positioning of the heart so
as not to distort the shape or provoke arrhythmias as a result of manipulation and/or induction
of injury currents.
Following the stabilisation period, all hearts underwent dual optical mapping with imaging of
simultaneous calcium transients and cardiac APs .
2.6.3.2 Fluorescent Dye Loading
Optical calcium transients were imaged by loading the heart with the calcium sensitive dye
Rhod-2/AM (Invitrogen, UK). Rhod-2/AM is part of the Rhod family of long-wavelength
calcium indicators which exhibit large fluorescence intensity increases upon binding Ca2+ with
the excitation spectra of Rhod-2/AM between 530-550nm and emission spectra between 580-
590nm. The overlap in excitation spectra and the separation of emission spectra make Rhod-
2/AM particularly suitable for dual optical imaging alongside the voltage-sensitive dye RH237.
Each heart was loaded with between 150-200µg of Rhod-2/AM dissolved in 150µl of dimethyl
sulfoxide (DMSO, Invitrogen, UK) and 150µl of 20% (w/v) Pluronic-F127 (Invitrogen, UK).
Pluronic F-127 is a non-ionic detergent which helps solubilise Rhod-2/AM and facilitate dye-
loading. Rhod-2/AM was loaded over a period of five minutes via a side-port proximal to the
aortic cannula using a 22G needle attached to a 1ml syringe (Becton, Dickinson and Company,
US) with care taken to minimise inadvertent air emboli.
Optical cardiac action potentials were imaged by loading the heart with the voltage sensitive
dye RH237 (Life Technologies, USA). RH237 is a fast-response voltage-sensitive probe part
of the RH family of fluorescent dyes. RH237 binds to the myocyte membrane and undergoes
a change in electronic structure and fluorescence properties in response to alterations in the
membrane potential. These changes occur in a sufficiently fast manner to enable detection
of potential changes in the order of milliseconds making them particularly useful in studying
action potential propagation. The excitation spectra of RH237 is 535nm with an emission
spectra of >660nm.
Each heart was loaded with 30µl of RH237 solution, made from stock (5mg/ml RH237 in
DMSO) and dissolved in 0.5ml of warmed, oxygenated KHB to provide sufficient volume for
ease of handling. RH237 was loaded over a period of five minutes via a side-port proximal
to the aortic cannula using a 22G needle attached to a 1ml syringe (Becton, Dickinson and
Company, US) with care taken to minimise inadvertent air emboli. As RH237 does not need
to cross the myocyte cell membrane the time from loading until sufficient optical signal quality
is much reduced compared to Rhod-2/AM with excellent signal quality present within two
minutes post-loading.
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2.6.3.3 Excitation-Contraction Uncoupler Loading
In order to minimise movement artefact and preserve the quality of optical signals the excitation-
contraction uncoupler (ECU) Blebbistatin (Sigma-Aldrich, UK) was used. Blebbistatin is a
highly specific inhibitor of adenosine triphosphatases (ATPases) associated with Myosin II
isoforms (Allingham et al. 2005) which has been used extensively to reduce motion artefact in
a range of isolated heart preparations (Lee et al. 2012; Glukhov et al. 2012) prior to optical
imaging.
Blebbistatin has been shown to have no effect on electrical activity, including ECG parameters,
atrial and ventricular refractory periods or activation maps (Fedorov et al. 2007), and, in direct
comparison to older ECU (e.g. 2,3 butanedione monoxime), does not alter action potential
duration (APD) restitution properties or the incidence of sustained arrhythmias (Lou et al.
2012). Other ECU, such as cytochalasin-D and 2,3 butanedione monoxime have been shown
to have significant effects on Ca2+ and K+ currents, intracellular Ca2+ handling resulting in
reduced CV and alterations in APD restitution properties (Baker et al. 2004).
Despite the potential advantages of Blebbistatin over other ECU there still remain limitations
to its use. Blebbistatin is exquisitely sensitive to UV and blue visible light, with the resultant
photochemical reaction having a significant toxic effect on cells, resulting in eventual cell death
(Kolega 2004). Care must also be taken in the preparation of Blebbistatin so as to maximise
solubility and reduce formation of Blebbistatin precipitate. The study by Swift (Swift et al.
2012) demonstrated that vigorous mixing of Blebbistatin in a pre-warmed solution of DMSO
prevented precipitation when cooled to room temperature and that the emission and excitation
spectra of Blebbistatin prepared in this manner lie at 420/560nm respectively.
With these considerations in mind, Blebbistatin was prepared whilst minimising exposure to
visible light; 5mg Blebbistatin was dissolved in 1.72ml of DMSO to form a stock solution from
which 0.5ml was dissolved in 50ml of warmed, oxygenated KHB. Hearts were perfused with
Blebbistatin at an initial loading concentration of 30µM, reducing to a maintenance concen-
tration of 10µM, consistent with previous studies (Lou et al. 2011). These concentrations were
sufficient to mechanically uncouple the heart and reduce motion artefact without an appreciable
alteration in heart rate or perfusion pressure.
2.6.4 Optical Mapping Data Acquisition
After dye and ECU loading, data were acquired using Cardioplex Software (RedShirtImaging
LLC, USA) at a sampling rate of 1000/frames second with use of a built-in RAMdisk to
allow recording of longer data files as needed. Prior to each recording the illumination LEDs
were optimally positioned with sufficient current so as to provide maximal illumination to
the epicardial surface of the heart. This was checked by visualising the histogram for each
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camera channel to ensure sufficient light-dark contrast during illumination. Once satisfied with
sufficient illumination a still-frame image was taken to act as a reference frame for analysis.
For baseline recordings, hearts were paced at a cycle length of 150ms (above intrinsic rate)
and data sampled by means of gated LED illumination for between four to six seconds. For
recordings during arrhythmia provocation protocols hearts were paced as per protocol (see
Section 2.5.5.2) and data sampled in 30 second blocks until refractory or the presence of an
arrhythmia. If a sustained arrhythmia was present, ad hoc recordings of between four and ten
seconds were taken for oﬄine analysis.
2.6.5 Optical Mapping Data Analysis
All data were analysed oﬄine using a custom-written Matlab (Matlab v.2013b, Mathworks,
USA) GUI, kindly provided by the Efimov Group (Washington University, St Louis, Missouri,
USA, Laughner et al. 2012). Prior to analysis several modifications were made to the GUI; a
script was written to handle the native data format of the Cardioplex Software (*.DA) and the
capability of the GUI was extended to allow for simultaneous display and analysis of two data
channels (voltage and calcium) and the generation of user-defined regions of interest.
Pre-process 
Signals Toolbox
Load Data 
& Background
Fluorescence Display
(Left = Voltage; Right = Calcium)
Analysis Options
APD/dFdT/RT/CV
Optical Action Potential Display
(Left = AP; Right = Calcium)
Figure 2.7: Screenshot of modified GUI for analysis of dual voltage & Ca2+ optical signals
Prior to analysis a corresponding background image of the mapped epicardial surface was loaded
and regions of interest defined based on greyscale intensities with a colour image alongside for
comparison. Remote regions were defined as areas of hyperintense signal on greyscale image
which corresponded to normal myocardium on visual inspection. Infarct regions were defined as
areas of hypointense signal on greyscale image which corresponded to scar on visual inspection.
The infarct border zone was defined as the area in between remote and infarct regions with
75
a width of between 3-5 pixels (300-500 microns), previously demonstrated to encapsulate the
entire border zone in high resolution studies of infarcted rat myocardium (Rutherford et al.
2012). After definition of each region binary masks were generated and applied to the dataset so
as to extract only the specific region of interest for analysis. Optical signals were pre-processed
as described by Laughner (Laughner et al. 2012). To reduce high frequency noise a spatial filter
was applied by means of a 3x3 bin (each pixel being the average of itself and 8 neighbours)
and a 100th order finite impulse response (FIR) filter with a passband of 0-100Hz applied. To
construct activation maps and generate accurate measures of CV and action potential duration
(APD) baseline drift in optical signals was corrected by fitting and then subtracting a 4th
order polynomial before normalising the fluorescence intensity (0 = minimum to 1 = maximum
intensity)
-50% -75% -90%
APD50
APD75
APD90
dFdT Max *Rise Time
* Activation Time
Figure 2.8: Diagrammatic representation of optical AP and definition of action potential dura-
tion, rise time, activation time and dFdTmax
Analysis of the upstroke of the AP allowed activation time, maximum derivative of fluorescence
(dFdTmax) and rise time (RT) to be calculated. Activation time was defined as the time (in
ms) of the peak of the first derivative of the upstroke. dFdTmax was defined as the maximum
value achieved by the peak of the first derivative (expressed in units of fluorescence/ms) and
rise time (in ms) was defined as the time taken from the base to the peak of the upstroke.
dFdTmax and RT were calculated in a similar manner for Ca
2+ transients.
Activation maps were constructed by plotting each individual activation time using the built-
in ‘contourf’ function in Matlab with appropriate colorbar scaling to allow for comparison of
activation patterns between normal and infarcted myocardium.
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Global CV (cm/s) was calculated by choosing two epicardial points that lay on a line orthog-
onal to the wavefront direction. The global CV was defined as the distance between the two
epicardial points divided by the difference in their activation time.
Local CV (cm/s) was calculated as described by Bayly (Bayly et al. 1998). After calculation of
the activation time (from the maximal derivative) for a specific region of interest a 3rd order
polynomial surface was fitted to the activation time data. Then the surface derivative (i.e. the
gradient or rate of change of the surface) was calculated for each pixel and conduction velocity
calculated in orthogonal planes (x and y) from which the local conduction velocity can be easily
calculated using trigonometry. The standard deviation of local CV was reported as a measure
of CV heterogeneity.
Action potential duration (APD) was defined as the time (in ms) from the point of activation to
the time taken for the downstroke of the transient to reach 50%, 75% or 90% (APD50, APD75,
APD90) of the total fluorescence change during depolarisation. Ca
2+ transient duration (CaTD)
was defined in a similar manner. the standard deviation of APD (or CaTD) was reported as a
measure of APD/CaTD heterogeneity.
Data were analysed for 10 consecutive action potentials (or Ca2+ transients), averaged and
reported as mean values.
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2.7 Diffusion Tensor Imaging
2.7.1 Background
A major aim of this thesis was to develop and apply diffusion tensor magnetic resonance imag-
ing (DTI) to the study of structural remodelling post-infarction. Ex-vivo DTI offers non-
destructive, high resolution structural information and has been used to generate quantitative
metrics of cardiac myofiber architecture and disruption in normal and post-infarcted hearts in
a small number of animal (Chen et al. 2003; Strijkers et al. 2009) and human studies (Wu et al.
2006a).
A full description of the MRI physics underpinning diffusion weighted imaging, the merits
of using an echo-planar imaging or fast-spin echo sequence and the results of the pilot and
validation studies can be found in Chapter 5.
2.7.2 Pilot DTI Study
DTI was performed in collaboration with physicist Dr Josef Habib at the Biological Imaging
Centre, Hammersmith Hospital London. All data were acquired using a 9.4T MRI system
(Agilent, Palo Alto, CA, USA) equipped with a Direct Drive console and a 100 Gauss/cm
gradient set of inner diameter 60mm. A quadrature radiofrequency (RF) coil of inner diameter
33mm (Rapid Biomedical, Rimpar, Germany) was used in transmit/receive mode.
The aims of the pilot DTI study were several-fold. Primarily, it was designed to assess whether
DTI imaging was feasible using current hardware and expertise. Thereafter, it focused on opti-
mising the sequence (including pulse programming, all performed by Josef Habib), optimising
sample preparation and correlating DTI metrics with biological effects by co-registration with
histology. Following the pilot study, it was intended to apply our optimised protocol(s) to
use DTI to probe the effects of GJ modulation on infarct healing, however, in February 2013,
the Biological Imaging Centre at Imperial College was closed. In order to continue the work
described in this thesis a collaboration was established with the research group of Prof. Ajay
Shah at the BHF centre of Excellence at Kings College London.
2.7.2.1 Feasibility
The sequence developed by Dr Habib was a diffusion-weighted multi-shot echo planar imaging
(EPI) acquisition, a full description of which is provided in Chapter 5. The feasibility of
the sequence was tested by scanning a series of normal and post-MI hearts to assess whether
diffusion sensitisation could be applied and measured. Data was analysed both real-time on
the scanner console and oﬄine.
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2.7.2.2 Sample Preparation
Sample preparation ahead of ex vivo MR imaging involves fixing and embedding the tissue
to minimise degradation and reduce motion artefact prior to and during imaging. The use of
different fixatives (Shepherd et al. 2009a) and embedding protocols (Hales et al. 2010) have
been shown to affect the T1 and T2 relaxation times and the diffusion properties of tissues.
For this reason, a series of hearts were scanned (as described in Section 2.7.4) to probe the
effects of sample handling and preparation on the quality of diffusion weighted images and
the validity of DTI metrics, as assessed by the relative histograms of fractional anisotropy and
mean diffusivity values. Following this optimisation, the following sample preparation protocol
was used for all further studies.
After completion of ex vivo studies, hearts were removed from the Langendorff perfusion ap-
paratus and the aorta re-cannulated with a 1.2mm stainless steel cannula. Hearts were first
perfused with a heparinised, high K+ KHB solution (20mmol/L of K+) to arrest the heart in
end-diastole before being attached to a 50ml syringe pump (VWI International, UK), containing
10% neutral buffered formalin (NBF) . The heart was perfusion fixed with 10% NBF at a rate
of 10mls/minute for 10 minutes (total volume 100mls) prior to storage in a 20ml universal tube
(VWR International Ltd, UK) of 10% NBF to allow for immersion fixation. The atria were re-
moved using a razor blade to form a flat surface in the short-axis plane so as to ease planning of
DTI and subsequent histological co-registration. Fixation was commenced within 2 minutes of
cessation of perfusion so as to render the effective post-mortem interval time, and the potential
for alteration in the T1, T2 relaxation times and diffusion properties, minimal (Shepherd et al.
2009b). On the day of DTI scanning, a 4-0 silk suture was carefully placed through the septum
and the heart transferred to a container of phosphate-buffered saline (PBS). This container
was placed on a rocker for 20 minutes to enable washing in PBS to remove excess formalin and
allow the heart to rehydrate prior to scanning (Thelwall et al. 2006). After washing, the heart
was embedding in low-melting point 2% Agarose (Sigma-Aldrich, UK) to provide stability and
reduce motion artefact whilst scanning. A 20ml universal tube was filled with 2% Agarose and
cooled to just above gelling point (26-30oC) before the heart was suspended using the septal
suture, taking care to ensure that the epicardial surface of the heart was free from the inside
wall of the universal tube (Figure 2.9). Low melting point agarose was used to minimise any
potential deleterious effects of exposing the heart to the higher gelling temperatures of regular
agarose (>36oC).
The agar was then left to cool and solidify (30-45 minutes) before the 4-0 suture was carefully
removed and the heart placed in the RF coil for imaging. All hearts were scanned within 12
hours of embedding, then removed from agar and placed back in 10% NBF prior to histological
analysis.
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20 ml universal tube ﬁlled with 
2% low metling point agarose 
Heart suspended by means of 4-0 
silk suture passed through septum (green)
To Clamp
Figure 2.9: Embedding of sample in low-melting point 2% Agarose by means of suture placed
through septum
2.7.2.3 Histological Validation
Studies have demonstrated a quantitative agreement between diffusion anisotropy and myofibre
direction (Scollan et al. 1998; Garrido et al. 1994), specifically, the agreement between orien-
tation of the primary eigenvector of the diffusion tensor with orientation of local myocardial
fibres (Hsu et al. 1998). An important aspect of the pilot study was to validate this relationship
with diffusion tensor measurements and corroborative histology.
DTI data were acquired from a non-infarcted heart as described in Section 2.7.4, the primary
eigenvector map generated and co-registered to histology as described in Section 2.8.3. Eight
manually defined regions-of-interest with a median area of 25x25px were extracted from the 2D
co-registered data and saved as JPEG image files. Directionality analysis was performed using
the ’Directionality’ plug-in for ImageJ (Liu 1991). Image files were loaded and a 5x5 Sobel
filter applied to detect edges and compute the mean fibre direction for each ROI. The mean
fibre direction computed was compared between histology and primary eigenvector 2D images.
In addition to demonstrating the agreement between diffusion tensor and histological fibre
orientations, data from the pilot study, in conjunction with histology, were used to ascertain
the biological basis for changes seen in DTI metrics. A full description of the methods used
can be found in Section 2.8 and results in Chapter 5
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2.7.3 Diffusion Fast Spin Echo Sequence Validation
Following the closure of the Biological Imaging Centre at Hammersmith Hospital in February
2013, no further diffusion MRI studies could be performed at Imperial College. Further sequence
development, validation and data acquisition was performed in collaboration with physicist, Dr
Andrea Protti and the Pre-Clinical Imaging Unit at Kings College.
The Pre-Clinical Imaging unit at Kings College London has a 7.0Tesla Varian MR scanner,
running VNMRJ 3.2 software which allowed for the transfer of the optimised EPI sequence
and testing. Unfortunately, due to undetermined technical problems, the EPI diffusion module
gave rise to significant signal voids owing to a T2∗ effect in the infarct region, rendering data
interpretation impossible. As a result, an alternative sequence, less sensitive to T2∗ effects
(fast spin echo multi slice sequence (FSE)) was implemented. This sequence appeared to
null the EPI-signal void but required validation and testing before use. A full description of
the difficulties with using EPI and the improvement demonstrated with FSE can be found in
Chapter 5.
2.7.3.1 Validating FSE Diffusion Sensitisation Module
To test the FSE diffusion sensitisation module, a water phantom (20ml distilled H20 (Sigma-
Aldrich)) was scanned at room temperature (19oC).
The correct application of the diffusion sensitisation module was first tested by scanning the
phantom using the ‘trace’ diffusion scheme with all slice-geometry angles and offsets set to
zero. The trace diffusion scheme applies diffusion gradients along three orthogonal directions
([1,0,0], [0,1,0], [0,0,1]) where the z-axis is defined as that aligned with the bore of the scan-
ner. This was the simplest, and hence first test, without applying geometry offset or applying
directionality to the diffusion gradients ensuring that only a single gradient set was tested
for each individual gradient direction. Data were acquired with the following parameters; |G|
= 46.2 Gauss/cm (G/cm), ∆ = 6.7ms, δ = 2.5ms (to give calculated b-value = 600), data
matrix 128x128, field-of-view (FOV) 25.6x25.6mm, slice thickness 0.5mm, number of signal av-
erages (NSA) = 1. Data were exported, converted to NifTi format (Neuroimaging Informatics
Technology Initiative,see Section 2.7.5.1) and apparent diffusion coefficient (ADC) maps out-
put for each gradient direction (see Section 2.7.5.4). ADC values were extracted from n=15,
user-defined regions-of-interest (each ROI 40x40 voxels (from 128x128 data matrix), spatially
identical between ADC maps, total 24,000 voxels) and compared between gradient directions
(to ensure correct application of diffusion sensitisation) and against literature reported values
for ADC of H20 at room temperature. This experiment was repeated at b-value = 1000 (by
increasing |G| to 60).
The correct application of diffusion sensitisation gradients was then tested in multiple directions.
This was achieved by using the Jones6 gradient direction scheme with all angles and offsets
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set to zero. Data were acquired with the following parameters |G| = 60 G/cm, ∆ = 6.7ms,
δ = 2.5ms (to give calculated b-value = 600), data matrix 64x64, FOV 25.6x25.6mm, slice
thickness 0.5mm, NSA = 1. Data were exported, converted to NifTi format and ADC maps
output for each of the six diffusion directions. ADC values were extracted from n=15, user-
defined regions of interest (each ROI 20x20 voxels (from 64x64 data matrix), spatially identical
between ADC maps, total 6000 voxels) and compared between gradient directions and against
literature reported values for ADC of H20 at room temperature. This experiment was then
duplicated and repeated using random geometry (random offset, random rotation) and data
extracted and compared in an identical manner.
The final test of the application of diffusion sensitisation gradients was to ensure the correct
orientation independent application of diffusion sensitisation and hence the correct (internal)
calculation of the b-value by the diffusion module. This was achieved by using the Jones6
gradient direction scheme with randomly generated angles and offsets; with a constant b-value
the ADC of H20 should not change, independent of the diffusion parameters used. To test this
the b-value was kept constant at 600 and the following three sets of diffusion parameters used
1) |G| = 46.2 ∆ = 6.7ms, δ = 2.5ms, 2) |G| = 33.7 ∆ = 12.0ms, δ = 2.5ms and 3) |G| = 22.1
∆ = 8.1ms, δ = 5.0ms. For each set of parameters a data matrix of 64x64, FOV 25.6x25.6mm,
slice thickness 0.5mm and NSA = 1 was used. Data were exported, converted to NifTi format
and ADC maps output for for each gradient direction. ADC values were extracted from n=15,
user-defined regions-of-interest (each ROI 20x20 voxels (from 64x64 data matrix), spatially
identical between ADC maps, total 6000 voxels) and compared between parameter sets and
against literature reported values for ADC of H20 at room temperature.
2.7.3.2 Optimisation of FSE Sequence Parameters
For optimisation of the FSE sequence parameters, and to determine the minimum number of
signal averages (NSA), a normal, non-infarcted heart was scanned at room temperature.
To determine the sequence parameters for acquisition of data using the FSE sequence, five
separate sets of diffusion parameters were compared. Alterations in the strength of diffusion
gradients applied (|G|), the duration of the application of diffusion gradients (∆) and the
separation between gradients (δ) would be expected to result in small but potentially significant
changes in the magnitude of diffusion probed from the tissue and the resultant FA/MD metrics.
For each acquisition the Jones6 direction scheme was used with a data matrix of 128x128, FOV
25.6x25.6mm, slice thickness 0.5mm, NSA = 6 with a scan time of 110 minutes per scan. The
slice plan was orientated as previously described (Section 2.7.4.2). The five sets of diffusion
parameters used were as follows (b-value =1000 for all): 1) |G| = 43 G/cm ∆ = 12.0ms, δ =
2.5ms, 2) |G| = 54 G/cm ∆ = 8.0ms, δ = 2.5ms, 3) |G| = 22 G/cm ∆ = 12.0ms, δ = 5.0ms,
4) |G| = 37 G/cm ∆ = 16ms, δ = 2.5ms, 5) |G| = 28 G/cm ∆ = 8.0ms, δ = 5.0ms. Following
acquisition, data were exported, converted to NifTi and FA/MD maps generated (see Section
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2.7.5.2). The absolute values and the distribution (interquartile range, SD, SE) of FA and MD
maps were compared between the five parameter sets by extracting 1000 spatially identical
voxels from n=12 slices.
To determine the optimal number of signal averages (NSA) data were compared between one to
six NSA. Data were acquired as above and signal-to-noise ratio (SNR) calculated from b=0 im-
ages (images without diffusion sensitisation gradients applied) and plotted against NSA. SNR
was only calculated from b=0 images owing to signal attenuation in individual diffusion direc-
tion data and potential underestimation in FA/MD data owing to the mathematical transforms
of the data. SNR was defined as the ratio between average signal intensity in the tissue (S) to
the standard deviation of the noise (σ) (Equation 2.4, Reeder 2007). The noise in a complex
MR image has a zero-mean gaussian distribution which changes to a non-zero mean Rayleigh
distribution after Fourier transform to a magnitude image. As a result, measuring the standard
deviation of the noise in a magnitude image overestimates the SNR by approximately 53% and
as such, needs to have a correction factor of 0.655 applied (Henkelman 1985).
SNR = 0.655× S
σ
(2.4)
Signal intensity (mean and SD) was measured from n=10 slices, with 20 random ROI per slice
(10 in tissue, 10 in background). SNR increases with the square root of the NSA and the
predicted SNR was compared with the actual SNR from one to six averages.
2.7.4 DTI Data Acquisition
Owing to both MRI scanners running VNMRJ 3.2, the scanning protocol was almost identical
between Imperial College and Kings College, differing slightly due to the use of an EPI sequence
at Imperial and an FSE sequence at Kings College.
Samples, embedded in agar were placed in a 33mm quadrature RF coil and placed within the
bore of the magnet. The position of the sample was checked by running a scout sequence before
securing the coil in place. All scans were performed at room temperature (19oC) with minimal
variability demonstrated between the start and end temperature of the scan protocol (<0.2oC
change)
2.7.4.1 Scanner Calibration
In calibrating the scanner a series of standardised steps were taken for each sample. Firstly,
a pulse calibration using the in built ‘spuls’ sequence was performed to automatically set the
global frequency and perform a power calibration to determine the power (dB) required for
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a 90o pulse. Next, the RF coil was tuned and matched to fine-tune frequency and minimise
transmission losses to account for sample specific coil loading. This was performed manually by
running the in built ‘mtune’ macro and adjusting the tuning capacitor (changing the resonant
frequency of the RF coil) and the matching capacitor (matching the impedance of the RF coil
with sample to 50Ω). The presence of the sample within the scanner distorts the magnetic
field; shimming is the process of adjusting the magnetic field to produce a homogeneous field
throughout the entire sample. B0 shimming was performed by adjusting the current within
shim coils, aligned in multiple directions, to produce a free induction decay (FID) shape that
most closely resembled an exponential decay and maximised the area contained within the FID
envelope. Finally, the frequency and power calibrations were repeated to adjust for any changes
made during tuning or shimming.
2.7.4.2 Slice Plan & Geometry
Following calibration the geometry was planned. To do this, a low resolution ’scout’ sequence
was performed for five slices in two orthogonal planes (coronal and sagittal), and using these
images, the axial alignment was planned. In order to improve co-registration with histology,
the atria were removed following perfusion fixation to leave a flat, cut surface; this formed the
basis of the short-axis plane on which the axial alignment was planned. Slice thickness was
set to 0.5mm, with a data matrix of 128x128 and FOV of 25.6x25.6mm giving a voxel size of
200µm x 200µm x 500µm. The number of slices was increased to cover the entire volume of
the heart, typically resulting in between 31-35 slices.
2.7.4.3 Diffusion Sequence Parameters
The slice plan geometry was cloned and copied onto the diffusion MRI sequence (either diffusion-
EPI or diffusion-FSE).
For diffusion-EPI, the scan parameters were as follows: Jones 30 diffusion scheme (Jones et al.
1999), NSA = 6, TR = 2.5s, TE = 20ms, b-value = 1000, |G| = 27 G/cm ∆ = 9.0ms, δ =
5.0ms, for a total scan time = 70 minutes. As the diffusion EPI sequence was a multi-shot EPI
acquisition (K-space was filled with 4 shots, EPI factor 32), the delays in applying the gradients
were automatically optimised by using the gradient ‘autoset’ function prior to scanning.
For diffusion-FSE, the scan parameters were as follows: Jones 6 diffusion scheme (Jones et al.
1999), NSA = 6, TR = 2.5s, TE = 26ms, b-value 1000, |G| = 28 G/cm ∆ = 8.0ms, δ = 5.0ms,
for a total scan time = 110 minutes.
For either EPI or FSE scans, a b=0 image only (diffusion set to ‘off’) was run first in order to
confirm geometry and visually assess SNR. Following this, the diffusion sequence was started,
cloned and queued for the required number of repetitions.
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2.7.5 DTI Data Processing
Following acquisition, data were automatically converted from Varian FID format (binary data
containing transformed spectra) to Varian FDF (flexible data format) files before being exported
for oﬄine analysis. A series of sequential steps were applied to analyse the data; the data were
converted from FDF to NifTi format, the diffusion tensor was fitted to the data, and diffusion
MRI metrics calculated based on the properties of the fitted diffusion ellipsoid (e.g. fractional
anisotropy, mean diffusivity).
Unless stated, all DTI data processing was performed using custom-written Matlab scripts
(Matlab v.2013b, Mathworks, USA).
2.7.5.1 FDF to NifTi Conversion
Varian FDF (binary data) files were converted to NifTi data format and the b-values and b-
vectors of the diffusion gradients extracted from the text procpar file. The FDF header file was
read to extract the individual x, y, z component of the b-vector (from dro, dpe, dsl variables)
and the magnitude (from the b-value parameter). The number of slices, data matrix size and
end of the header file was then determined (from slices, floatmatrix, floatbits variables) and the
FDF data read in float-32, big-endian format. This process was looped over all FDF files in the
directory (one FDF file contained data for one slice in one diffusion direction) and the output
matrix reconstructed to generate a 4D NifTi file (sized: data matrix x data matrix x number
of slices x number of diffusion directions (including b=0), typically 128x128x33x7). A separate
text file containing the x, y, z vectors describing each diffusion direction and their magnitude
(b-value) was also exported.
b = γ2 × |G|2 × δ2(∆− δ
3
) (2.5)
The b-value (expressed in s/mm2) is calculated as described in Equation 2.5, where γ is the
gyromagnetic ratio (42.58MHz/T for H1 nuclei), |G| is the strength of the diffusion sensitising
gradients, δ is the duration of the gradients and ∆ is the interval between the two gradient
pulses.
2.7.5.2 Fitting of Diffusion Tensor & Calculation of FA & MD Maps
The diffusion tensor was fitted to each voxel using the freely available, previously validated
software, Diffusion Toolkit (DTK) (Wang et al. 2007). DTK uses a standard, linear least
squares fitting method to fit an ellipsoid to the diffusion data; representing the diffusion profile,
from which the program automatically outputs the vector and magnitude of each eigenvector
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(the 3 orthogonal vectors describing the ellipsoid, λ1>λ2>λ3) and outputs the following NifTi
images: b=0 (no diffusion sensitisation applied), DWI (total diffusion signal), mean diffusivity
(MD) and fractional anisotropy (FA).
Mean diffusivity (MD, equation 2.6) is a measure of the overall diffusivity of a voxel (ability of
water to move freely), independent of anisotropy and is affected by cellular size and integrity
(Basser et al. 1994a; Pierpaoli et al. 1996).
MD =
λ1 + λ2 + λ3
3
(2.6)
Fractional anisotropy (FA, equation 2.7) is a normalised, scalar measure of the degree of
anisotropy within a voxel. The theoretical range of FA values are from 0 (i.e. isotropic,
spherical motion) to 1 (i.e. anisotropic, unidirectional motion, Basser et al. 1996).
FA =
√
1
2
√
(λ1 − λ2)2 + (λ2 − λ3)2 + (λ3 − λ1)2√
λ21 + λ
2
2 + λ
2
3
(2.7)
2.7.5.3 Generation of Helix & Transverse Angle Maps
Prior to calculation of the helix and transverse angle, eigenvectors, which define the diffusion
ellipsoid profile for each voxel, were transformed from the global (magnet) co-ordinate system
to the anatomical co-ordinate system of the heart using the method described by Geerts (Geerts
et al. 2002). This method utilises the characteristics of the myofiber field as a starting point
for calculating the true LV axis. The first estimate of LV long axis was taken from the normal
to the imaging plane. Pixels with an out-of-plane component +/- 0.1 radians (6 degrees) (i.e.
those lying in the short-axis plane) were identified as an estimate of the mid-myocardium and
a circle fitted to these pixels with the centre of the circle providing a first estimate of the centre
of the LV. This was repeated for ten consecutive slices to generate a 3D stack of LV centroids,
through which a linear line was fitted. This linear line represented the true LV axis and allowed
for generation of a rotation matrix to transform the original eigenvectors from the global to the
(new) anatomic co-ordinate system.
To calculate the transverse and helix angle for each voxel, orthogonal planes were defined for
each slice (see Figure 2.10). The transverse plane was defined as being perpendicular to the
LV axis in the same plane as the LV short axis, on which lies the LV centre, and radial and
circumferential (orthogonal) vectors. The tangential plane was orthogonal to the transverse
plane on which lies the circumferential and z-axis (orthogonal) vectors.
Helix angle was defined as the angle subtended between a) the projection of the primary eigen-
vector onto the tangential plane and b) the transverse plane.
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Transverse angle was defined as the angle subtended between a) the projection of the primary
eigenvector onto the transverse plane and b) the tangential plane.
LV Centre
Epicardium
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Primary Eigenvector
Helix Angle
A B
Z
VCirc VCirc
VRadTransverse Plane
Primary Eigenvector
Transverse Angle
DC
Figure 2.10: Definition of (A) tangential plane and (B) transverse plane from LV geometry
and definition of (C) Helix angle and (D) Transverse angle from projection of primary eigen-
vector onto tangential and transverse planes respectively. Z = LV long axis direction, VCirc =
Circumferential Vector, VRad = Radial Vector.
2.7.5.4 Generation of ADC Maps
The apparent diffusion coefficient (ADC) for each voxel, for each gradient direction, was calcu-
lated as described in equation 2.8 (Burdette et al. 1998), where S0 is the voxel signal intensity
in the b=0 image, S is the voxel signal intensity after application of the diffusion gradient and
b is the b-value used for acquisition of the diffusion weighted image. The ADC represents
the combined magnitude of diffusion, incorporating free, hindered and restricted diffusion, as
occurs in biological tissues.
ADC =
(log S0
S
)
b
(2.8)
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As ADC calculations were performed for an individual gradient direction, the diffusion tensor
did not need to be fitted prior to analysis. The 4D NifTi file generated in Section 2.7.5.1 was
loaded into Matlab and a function to output ADC looped through each diffusion direction to
give the ADC for each voxel in each slice. The average ADC for each voxel was calculated as
the mean of the ADC in all gradient directions.
2.7.6 DTI Data Analysis
Following acquisition, processing and generation of DTI metrics (FA, MD, Helix and Transverse
angles), data were compared on a region-by-region and heart-by-heart basis to determine the
structural changes that were detected by DTI in post-infarction myocardium. For all hearts,
nine consecutive slices were analysed with the median slice representing the centre of the infarct
visible on b=0 image. Nine slices were chosen as this enabled full coverage of the infarct in all
cases without including non-infarcted slices either above the level of the LAD ligature or below
the level of apical extension.
2.7.6.1 Regional Segmentation
Diffusion MRI metrics of tissue complexity were validated against gold-standard histology as
described in Section 2.8.3 and Chapter 5. For in vivo studies of the effects of Rotigaptide treat-
ment on structural remodelling, hearts were segmented into three regions (remote, adjacent and
infarct) using the method described by Wu (Wu et al. 2011), in Figure 2.11. This segmentation
was achieved by defining the area of infarction based on the hyperintense signal of the infarct
on the b=0 image and from the change in wall-thickness as the infarct thins (Wu et al. 2009).
The wall thickness was measured in the centre of the infarct and in the lateral LV wall and the
infarct defined as the region bounded by two lines, each placed with origin at the LV centre and
crossing the myocardium where wall thickness equalled 50% of the value between infarct and
remote. The angle subtended by these two lines was termed θ and a remote region created of
similar size (to θ) on the posterior wall of the LV. The adjacent region was defined as a bilateral
region, either side of the infarct region which subtended an angle on either side, β equal to a
quarter of θ.
2.7.6.2 Analysis of DTI-derived Metrics
FA and MD metrics were calculated and extracted from each of the three regions for nine
consecutive slices and compared on a region-by-region and heart-by-heart basis using statistical
methods described in Section 2.9.
Helix and transverse angle data were analysed as described in the literature (Walker et al. 2005;
Schmitt et al. 2009). Data were compared across LV wall, from endocardium to epicardium by
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Figure 2.11: Single slice through infarcted heart showing segmentation of Myocardium into
Infarct, Adjacent and Remote regions. thinf = wall thickness in infarct, threm = wall thickness
in remote, θ = angle subtended by infarct and remote regions, β = 1
4
× θ= angle subtended
by adjacent regions. Green dot represents LV centre
dividing the LV wall into ten equally spaced regions (deciles) and extracting a mean value for
both helix and transverse angle (Figure 2.12, expressed in degrees). Owing to wall thinning in
the infarct region, data were only compared between adjacent and remote regions. The standard
deviation of transverse angle and helix angle was reported as a measure of the variability in
angular deviation (Chen et al. 2003).
For quantitative analysis of helix angle data, a comparison was made between fitting a linear
line through all data points, data points >30% from the endocardium and data points occupying
20% either side of the point of transition (i.e. helix angle = 0o) and reporting the slope and
y-intercept for each line. This was performed on non-drug treated hearts, in the remote region
so as to minimise potentially confounding effects of remodelling.
To determine whether a significant apex-base difference existed, linear lines of best-fit were
calculated and compared on a whole z-stack basis (all nine consecutive slices, data averaged)
versus on three region (basal, equatorial and apical (three slices per region)) basis. The slopes
and intercept were compared between the three regions to determine whether a significant
difference existed between basal, equatorial and apical segments of the infarct.
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Figure 2.12: Representative helix angle map from normal (non-infarcted myocardium) with
zoomed-in posterior LV wall region of interest (denoted ‘remote’) showing division of wall into
10 equally spaced regions. Green dot represents LV centre
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2.8 Histology
Masson’s trichrome histological staining was performed to calculate infarct size in studies char-
acterising the in vivo model of infarction-reperfusion, to compare and validate diffusion MRI
parameters in remote, infarct border zone and infarct regions and to assess the effects of en-
hancing GJ coupling on infarct size.
Histological sectioning, staining and image acquisition to characterise the in vivo model of
infarction-reperfusion (Chapter 4) was performed by Mr George Isitt, a 4th year MBBS stu-
dent constituting his Cardiovascular Sciences BSc Project (February - May 2013, Supervisors:
M.Debney and N.Peters). Histological sectioning and staining to assess the effects of GJ cou-
pling on infarct size (Chapter 6) was performed by Miss Lorraine Lawrence (Senior Histology
Technician, NHLI, Imperial College).
2.8.1 Masson’s Trichrome Staining
Masson’s Trichrome stain was chosen owing to the high contrast between normal (pink/purple)
myocardium, and infarcted (blue) myocardium allowing for ease of definition of remote, border
zone and infarct regions. Masson’s Trichrome staining consists of three dyes, used to selectively
stain the cell nuclei, cell cytoplasm and collagen. The exact mechanism of staining is unknown
but is thought to be as a consequence of the interaction between proteins found in individual
tissue types and the fixative agent used to preserve the tissue. The binding of proteins with
fixative molecules creates pores of variable size, depending on the tissue type (for example,
collagen forms a less dense network of pores compared to muscle) which alters the selective
permeability to molecules used in dye staining. The use of three sequential stains with dye
molecules progressively increasing in size allows larger dye molecules to penetrate and displace
smaller dye molecules from more porous areas whereas smaller dye molecules are retained in less
porous areas. Masson’s Trichrome results in cell nuclei appearing black, cytoplasm appearing
pink/purple and collagen appearing blue.
2.8.1.1 Tissue Handling
Following explantation, arrhythmia provocation studies and optical mapping, hearts were per-
fusion fixed with 100mls of 10% NBF before being immersion fixed in NBF prior to either
diffusion MRI scanning or histological analysis. To improve co-localisation between histology
and MRI images, and to allow for easier planning of MRI scans, a flat surface was created in
the short axis plane by placing the heart in a stainless steel rat heart coronal matrix (Zivic
Instruments, USA) and using a razor blade (VWR International) to remove the atria and basal
millimetre of the LV/RV. Care was taken to ensure that no distortion was made to the shape
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of the LV or RV, and the plane was made above the level where the LAD ligature had been
placed so as to ensure the entire infarct area was included.
Owing to the formalin-fixed nature of the tissue, hearts underwent paraffin infiltration and wax
embedding prior to staining. Hearts were placed in a tissue processing cassette (TissueTek,
Sakura Finetek Ltd, USA) and loaded into an automatic tissue processor (Tissue-Tek VIP 6,
Sakura Finetek Ltd, USA) which dehydrated the sample by passing through progressively con-
centrated ethanol (Sigma-Aldrich,UK), then cleared the sample in xylene (Sigma-Aldrich,UK)
before infiltrating with molten paraffin wax. Following this, to provide stability during section-
ing hearts were manually embedded in paraffin wax using a Tissue-Tek TEC 5 system (Sakura
Finetek Ltd, USA).
Hearts were sectioned at 6µm thickness with spacing of 1mm between sections, using an Accu-
Cut SRM 200 rotary microtome (Sakura Finetek Ltd, USA) and collected on poly-l-lysine
(Sigma-Aldrich, UK) coated slides (SuperFrost, VWR International, UK) and left to dry
overnight prior to staining. Sectioning at 1mm thickness resulted in a median of 14 slices
covering the heart from apex to base.
2.8.1.2 Tissue Staining Protocol
Immediately prior to staining, sections were dewaxed for 10 minutes in xylene and rehydrated
by passing through decreasing concentrations of ethanol (five minutes in each of: 100%, 70%,
30%, 0%).
Slides (up to 8, containing 16 sections) were placed in a glass slide rack (VWR International,
UK) for ease of handling, and immersed in Harris’ Haematoxylin solution (Sigma-Aldrich, UK)
for five minutes. Slides were then removed, washed, and briefly rinsed with distilled water
(Millipore Limited), UK) before being immersed in Biebrich Scarlet solution (Sigma-Aldrich,
UK) for ten minutes. Slides were then removed and washed thoroughly until water ran clear
and then immersed in a Phosphotungstic/Phosphomolybdic Acid solution (Sigma-Aldrich, UK)
for ten minutes. Slides were then removed, excess solution gently removed and immersed in
Anniline Blue solution for 30 seconds. Slides were then removed and thoroughly washed before
being immersed in 1% Acetic acid solution (Sigma-Aldrich, UK) for five minutes. Slides were
then removed, rinsed with distilled water and dehydrated by being passed through ascending
concentrations of ethanol (70%, 90%, 100%, 100%) for 30 seconds each before being cleared in
xylene for 15 minutes (three passes of five minutes each). Finally, excess xylene was carefully
removed and the slides mounted on a 22x50mm coverslip (VWR International, UK) using DPX
mountant medium (Sigma-Aldrich) before being left to dry overnight.
Slides were stored at room temperature and protected from sunlight and dust, prior to micro-
scope analysis
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2.8.1.3 Image Acquisition
For high resolution histology imaging prior to registration with MRI images sections were
imaged at x10 magnification using a bright field Zeiss Axio Observer inverted microscope, part of
the Facility for Imaging by Light Microscopy (FILM) at Imperial College. Image acquisition and
processing was controlled by Zen Software (Zen Black, Zeiss Limited, USA); sections were placed
on a motorised stage, focused and acquired in a tiled fashion (approximately 100 tiles/section)
which were automatically stitched and output as a Carl Zeiss Image (CZI) data file which was
exported as a TIF (tagged image format) file for infarct size calculation and diffusion MRI
analysis.
For infarct size quantification histology images were acquired using a HP Flatbed Scanner (HP
Scanjet G3110, Hewlett-Packard Ltd, USA) at a resolution of 1200dpi in TIF format.
2.8.2 Infarct Size Calculation
All infarct size calculations were performed manually using ImageJ software (v1.46, US National
Institutes of Health, Maryland, USA).
Two methods of quantifying infarct size were compared in the characterisation of the in vivo
model of infarction-reperfusion; an area-based approach which reports the relative ratio of
infarcted to remote myocardium and a length-based approach which reports the infarct size as
a function of the relative epicardial and endocardial length of the infarcted myocardium to the
entire LV epicardial and endocardial length (Takagawa et al. 2007)
The commonest method of reporting infarct size in the chronic MI model (permanent LAD
occlusion, studied at between two-four weeks post-MI) is the length-based method described
by Pfeffer (Pfeffer et al. 1979). This method is particularly suited to hearts with thin-walled
infarction as the surface area of the infarct is preserved in contrast to the volume of the infarct
which is reduced (Pfeffer et al. 1991).
An alternative methodology, the area-based approach, has been applied in studies of both
chronic and reperfused MI models studied between 1-28 days post-infarction (Michael et al.
1999; Virag et al. 2003). A significant limitation of this method, more apparent in chronic
MI models, is the potential under-estimation of infarct size owing to thinning and reduced
volume of infarcted myocardium in addition to compensatory hypertrophy of the remote LV
myocardium (Fishbein et al. 1978).
2.8.2.1 Length-based Method
For each slice the corresponding TIF file was loaded into ImageJ and four circumferences
traced manually; the infarct epicardial and endocardial circumferences and the LV epicardial
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Original Masson's Trichrome Image
Figure 2.13: Diagrammatic representation of (Left) Length-based approach to calculating in-
farct size and (Right) area-based approach
and endocardial circumferences. Two ratios were then calculated; the epicardial ratio defined
as dividing the sum of all infarct epicardial lengths from all slices by the sum of all LV epicardial
lengths from all slices and the endocardial ratio defined as the sum of all infarct endocardial
lengths from all slices by the sum of all LV endocardial lengths from all slices. The infarct size
(expressed as %) was calculated as the average of epicardial and endocardial ratio multiplied
by 100.
2.8.2.2 Area-based Method
For each slice the corresponding TIF file was loaded into ImageJ and the infarct size outline
and total LV outline were manually traced and the two areas measured automatically. Infarct
size (expressed as %) was calculated by dividing the sum of all infarct areas from all slices by
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the sum of all LV areas from all slices and multiplying by 100.
2.8.3 Histology and Diffusion MRI Analysis
Diffusion MRI was developed and applied to the study of post-infarction remodelling as de-
scribed in Section 2.7 and Chapter 5. As part of the validation of diffusion MRI, and to
understand the changes in diffusion MRI derived metrics that occur in the remote, infarct and
infarct border zone, it was important to have a robust, reliable means of defining and identifying
these three regions.
Analysis of histology and diffusion MRI images involved three steps; co-registration of histology
and MRI images, identifying the infarct, remote and border zone regions from the histology
image and extraction of diffusion MRI metrics from each region for comparison.
2.8.3.1 Image Co-registration
The first step to allow co-registration of histology and diffusion MRI images was to ensure that
they both occupied the same physical canvas size. This was achieved by manually creating
a binary mask image of the MRI data (from the DWI.nii file output from Diffusion Toolkit
reconstruction) using the image thresholding tool in ImageJ. This mask image was then up-
sampled to the canvas size of the histology TIF image using the ‘imresize’ function in Matlab
set to nearest neighbour interpolation; this resulted in typical up-sampling from 128x128 pixels
to 1920x1920 pixels.
Next, a rigid transformation of the histology image was performed using the ‘imtransform’
command. This necessitated the identification of control-point pairs which were defined using
the inbuilt tool ‘cpselect’ which displayed the histology image and MRI image side-by-side and
allowed manual selection of identical locations on both images. Common location of control-
point pairs were structures readily identifiable on both images, for example, contours within
the LV cavity, papillary muscles, insertion points of the RV and areas of wall thinning. Once a
suitable number of control-point pairs had been selected (median = 10/slice) they were passed
to the inbuilt Matlab function ‘cp2tform’, run with the option ‘affine’ and a 2D spatial trans-
formation matrix output. This transformation matrix was then applied to the histology image
using the ‘imtransform’ function and the output saved. By definition, the affine transformation
kept parallel lines parallel and straight lines straight; it allowed for scaling and shearing in
either the x or y direction (independently) or translation only.
Finally, a non-rigid transformation was applied to the affine-transformed histology image; this
allowed for fine tuning of the registration between histology and MRI image. This transforma-
tion was applied in Matlab using the Coherent Point Drift (CPD) algorithm (Myronenko et al.
2010). The CPD algorithm is a method of applying either rigid or non-rigid transformations to
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two point sets; one point set is treated as the data (MRI points), the other point set (histology
points) represents the centroids of a Gaussian Mixture Model (GMM) . The GMM centroids
are fit to the data using an expectation-maximisation algorithm and the posterior and corre-
spondence probabilities calculated. The CPD algorithm forces the GMM centroids to move
coherently, so as to preserve the topological structure of the data. The CPD algorithm has a
wide range of applications, including registration of end diastolic and end systolic cardiac CT
volumes (Pourmorteza et al. 2012) and in deformable shape modelling of the left atrium (Koch
et al. 2013).
The accuracy of the CPD algorithm was evaluated using the mean of the minimum Euclidean
distance between the MRI and histology images, evaluated at all point-sets.
2.8.3.2 Defining Regions of Interest
The co-registered histology image was used as the gold-standard to define the remote, infarct
and border zone region. Each histology image (representing one z-plane slice) was loaded into
Matlab and the three regions manually defined and the corresponding binary masks exported
(remote, infarct and infarct border zone). Infarcted myocardium was defined as voxels contain-
ing predominantly (>70% by area) blue staining, indicating the presence of collagen, remote
myocardium was defined as voxels containing predominantly (>70% by area) pink/purple stain-
ing and the interface between the two defined as infarct border zone with voxels containing a
mix of tissue staining. Binary mask images were then down-sampled from histology TIF image
resolution (1920x1920px) to MRI matrix resolution (128x128px).
2.8.3.3 Extraction of Diffusion MRI Metrics
In order to extract diffusion MRI metrics, each output (FA, MD, λ1, λ2, λ3) for each slice of
each heart analysed were loaded into Matlab as a NifTi file alongside the three binary masks
(also slice and heart specific) generated in Section 2.8.3.2. Each mask was applied to each
metric and the data output in column vector form for statistical analysis.
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2.9 Statistical Analysis
All statistical analysis was performed using GraphPad Prism (v5.0, GraphPad Software Inc,
CA, USA).
All data were analysed by a single operator, blinded to treatment group. Blinding was achieved
by renaming each dataset by assigning a computer generated random number identifier using
Microsoft Excel. Data analysis was then performed in ascending order based on the assigned
random number.
Prior to analysis, all data were tested for normality using D’Agostino-Pearson test for normality.
Data which were normally distributed were displayed as mean with standard error of the mean
(SEM) and analysed using two-tailed students t-test, or, for three groups or more, one-way
ANOVA with post-hoc Tukey test.
Data which were not normally distributed were displayed as median with interquartile range
(25%-75%) and analysed using Mann-Whitney test, or, for three groups or more, Kruskal-Wallis
test with post-hoc Dunns test.
For all statistical analyses, p<0.05 was considered statistically significant.
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Chapter 3
Ex Vivo Ischaemia-Reperfusion Studies
The studies described in this chapter concern the characterisation of an ex vivo model of
ischaemia-reperfusion developed to study acute arrhythmogenesis and the application of this
model to the study of the effects of pharmacological gap junction enhancement on arrhythmias
occurring during acute coronary occlusion and reperfusion.
3.1 Introduction
3.1.1 Ischaemia-Induced Arrhythmias
Acute regional myocardial ischaemia, as a result of sudden decreased coronary blood flow,
causes a series of electrophysiological changes which render the myocardium vulnerable to ar-
rhythmogenesis by a variety of mechanisms, including enhanced automaticity, triggered activity
and re-entry.
The resting membrane potential of myocytes within the ischaemic zone depolarises as a result
of accumulation of extracellular K+ and intracellular Ca2+ overload. The development of an
intracellular acidosis, accumulation of intracellular lactate, hypoxia and a reduction in inward
Na+ current result in a series of changes to the cardiac AP; the amplitude and upstroke ve-
locity decreases, the APD shortens and conduction slowing ensues. These effects occur in a
spatially heterogeneous manner so that the presence of areas of slow conduction and spatial in-
homogeneities in APD and the refractory period provide the conditions necessary for re-entrant
arrhythmias to sustain (Carmeliet 1999). The initiation of such arrhythmias is as a result of
several factors, including enhanced automaticity in ventricular myocytes, spontaneous depo-
larisation due to mechanical stretching, triggered activity due to DADs (as a result of Ca2+
overload) and flow of injury current from ischaemic to non-ischaemic myocytes (Janse et al.
1989).
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The arrhythmias associated with acute regional ischaemia occur within the first 30 minutes
and follow a species dependent pattern with either a bimodal (termed Phase 1a, Phase 1b)
or monomodal (termed Phase 1) distribution. Phase 1a arrhythmias are primarily re-entrant
in origin (Kaplinsky et al. 1979), with the site of origin on the border between ischaemic and
non-ischaemic tissue and the re-entry circuit initiated by either a non-reentrant mechanism
(e.g. triggered activity) or by re-entry itself. The mechanisms of Phase 1b arrhythmias are
poorly defined although associated with worsening Ca2+ overload, catecholamine secretion and
an increase in extracellular and intracellular resistance.
3.1.2 Reperfusion-Induced Arrhythmias
The electrophysiological basis of reperfusion arrhythmias has been the subject of extensive
study, although the precise cellular mechanisms remain undetermined (Manning et al. 1984b;
Wit et al. 2001). Unlike the distribution of arrhythmias occurring during acute ischaemia,
reperfusion arrhythmias often occur within seconds of restoration of coronary flow, attributed
to the swift development on reperfusion of inhomogeneities in the duration and amplitude of the
action potentials of myocytes within and adjacent to the ischaemic zone. Other factors, such
as the washout of accumulated K+ and lactate from the extracellular space and the restoration
of extracellular and intracellular resistance to pre-ischaemic levels may contribute to enhanced
automaticity of myocytes at the border zone between ischaemic and ‘normal’ myocardium. It
is postulated that the peak arrhythmia incidence occurs at a time at which myocytes within
the ischaemic zone become irreversibly injured and hence the difference in action potential
inhomogeneities is greatest between these irreversibly injured regions and adjacent, potentially
reversibly injured regions (Corr et al. 1983). These areas of maximal inhomogeneity in APD and
the accompanying conduction slowing provide the substrate required for re-entry arrhythmias
to initiate and be sustained. As time progresses and the ischaemic zone becomes increasingly
irreversibly injured, the degree of electrical heterogeneity within and adjacent to the ischaemic
zone reduces, resulting in reduced VT or VF on reperfusion.
3.1.3 Role of Gap Junction Coupling in Acute Arrhythmogenesis
In addition to the described ionic changes that occur during acute ischaemia and reperfu-
sion, cell-cell coupling plays an important role in arrhythmogenesis of Phase 1 and reperfusion
arrhythmias. During the early (‘Phase 1a’) stages of ischaemia, resistance through cell-cell
pathways (intracellular) is preserved whereas extracellular resistance increases due to collapse
of the microvascular and osmotic cell swelling (Kle´ber et al. 1987). As ischaemia time pro-
gresses beyond 15 minutes, intracellular resistance rises as a result of the uncoupling of GJ
channels which undergo progressive time-dependent dephosphorylation (Beardslee et al. 2000)
and redistribution to the sides of the myocyte (lateralisation) (Severs et al. 2008; Lampe et al.
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2006). Electrical uncoupling of myocytes and the resultant reduction in conduction velocity
occurs in an inhomogeneous distribution resulting in the substrate required for re-entry. The
distribution and degree of uncoupling between regions of excitable and inexcitable myocardium
has been shown to be a key determinant in the initiation of ischaemic mediated arrhythmias
(Groot et al. 2001).
On reperfusion, the extracellular resistance falls rapidly as the intravascular and interstitial
spaces expand. In comparison, the intracellular resistance falls more gradually, in parallel with
the restoration of the resting membrane potential, and slowing of conduction, and hence the
substrate required for arrhythmogenesis persists until cell-cell coupling is restored (Cascio et al.
2001).
The uncoupling of GJ channels and alterations in their spatial distribution and functional
state play a key role in arrhythmogenesis during ischaemia and reperfusion. Maintaining cell-
cell coupling during this time may be an effective anti-arrhythmic strategy (Wit et al. 2011).
Early work by Dhein (Dhein et al. 1994) using the peptide AAP-10 to enhance GJ coupling
in a rabbit model of ischaemia-reperfusion demonstrated an inhibition in the alteration of
activation patterns and reduced activation-recovery interval (ARI) dispersion with no effect
on ion channels. A similar study by Kjφlybe (Kjølbye et al. 2002) using the peptide HP-5
to enhance GJ coupling demonstrated a reduced dispersion of APD90 but no significant anti-
arrhythmic effect. In the study by Xing (Xing et al. 2003), pharmacological enhancement of
GJ coupling with the stable peptide Rotigaptide reduced the inducibility of VT within a one-
to four-hour time window after coronary artery occlusion in a canine model by preventing local
electrogram dissociation and unidirectional block. Hennan and colleagues (Hennan et al. 2006),
demonstrated a significant reduction in the incidence of reperfussion arrhythmias (VPB and
VT) in a four-hour canine model of ischaemia-reperfusion when administering Rotigaptide 10
minutes prior to reperfusion.
3.1.4 Hypothesis & Aims
The primary hypothesis addressed in this chapter was that pharmacological enhancement of
GJ coupling, using Rotigaptide, may confer an anti-arrhythmic effect and lead to a reduction
in acute ischaemia- and repefusion-induced arrhythmias.
The aims of this chapter were as follows
1. To study the time-course of acute ventricular arrhythmias following ex vivo ischaemia-
reperfusion and use these findings to define a pro-arrhythmic model of infartion-reperfusion
2. To use this model to study the effects of enhancing GJ coupling at different time points
of the ischaemia-reperfusion process; specifically pre-occlusion, at occlusion and at reper-
fusion
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3.2 Methods
The isolated rat heart preparation (Section 2.5) was used to study ex vivo arrhythmogenesis
with regional ischaemia-reperfusion induced as described in Section 2.5.3.
In all ex vivo studies, physiological factors that may affect arrhythmia susceptibility were
recorded and compared between groups. Heart rate (expressed in beats per minute (bpm))
was measured immediately prior to LAD occlusion and immediately prior to reperfusion (Ng
et al. 2013). Coronary flow rate (ml/min) was measured by collecting coronary eﬄuent pre-
and post- LAD occlusion and the difference expressed as a %. Hearts were excluded from study
if they met any of the exclusion criteria outlined in Section 2.5.3. The timing and occurrence of
ventricular premature beats and ventricular arrhythmias (VT or VF) were documented during
ischaemia and reperfusion and compared between groups. A composite logarithmic arrhythmia
score was calculated for arrhythmias occurring during ischaemia (Curtis et al. 1988, Section
2.5.4.1)
3.2.1 Protocol 1: Studying the Time Course of Arrhythmogenesis
The time-course of arrhythmias occurring during acute LAD occlusion and subsequent reper-
fusion were studied as a function of the duration of time of occlusion. A total of 24 hearts
were subjected to either 15, 30 or 60 minutes of LAD occlusion prior to 5 minutes reperfusion
(n=6/group) with a further group (n=6) subject to 60 minutes of perfusion only, to act as
non-infarcted controls (Figure 3.1)
Control 
15 minutes
60 minutes
30 minutes
Stabilisation
t = 0 (minutes) 15 30 45 75
Occlusion Group (n=6/group)
60
Perfusion Only; No Infarction
Variable Duration LAD Occlusion & Reperfusion
15 5
30 5
560
Figure 3.1: Experimental schematic for ex vivo studies of variable duration LAD occlusion.
n=6 per group
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3.2.2 Protocol 2: Effects of Rotigaptide on Arrhythmogenesis
The effects of Rotigaptide treatment on ex vivo arrhythmogenesis were studied using a pro-
arrhythmic model of regional ischaemia, determined after considering the results of Protocol 1
(15 minutes regional ischaemia). Rotigaptide was administered in three groups (n=9/group);
pre-LAD occlusion, at LAD occlusion and on reperfusion to determine the time point at which
Rotigaptide administration exerted an effect on arrhythmogenesis and compared against a non-
treated (control, n=9) group (Figure 3.2).
1. Control - KHB administered throughout loading, occlusion and reperfusion
2. Pre-Treated - Rotigaptide 50nM perfused from loading onwards
3. At Occlusion - Rotigaptide 50nM perfused from occlusion onwards
4. At Reperfusion - Rotigaptide 50nM perfused from reperfusion onwards
Group 1
Group 2
Group 4
Group 3
Stabilisation
All groups perfused 
with KHB
Drug Loading LAD Occlusion
t = 0 (minutes) 15 30 45
Reperfusion
KHB KHB KHB
ROT ROT ROT
KHB KHB ROT
KHB ROT ROT
50
Treatment Group (n=9/group)
Figure 3.2: Experimental schematic for Rotigaptide ex vivo studies. n=9 per group. KHB =
Krebs-Henseleit Buffer, ROT = Rotigaptide 50nM
A total of 36 hearts were used in these studies (n=27 in the 3 Rotigaptide treatment groups
and n=9 subject to regional ischaemia only, to act as no-drug controls.)
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3.3 Results
3.3.1 Variable Duration LAD Occlusion
3.3.1.1 Heart Rate & Coronary Flow Reduction
Baseline heart rate and coronary flow rate parameters are presented in Table 3.1. The mean
heart rate immediately prior to LAD occlusion from all preparations (n=24) was 311 ± 16
bpm with no difference between groups. A similar narrow heart rate range was demonstrated
immediately prior to reperfusion (284 ± 16 bpm, n=18), with no difference between groups. As
expected, there was a small reduction in heart rate on reperfusion compared to heart rate prior
to LAD occlusion of 29 ± 12 bpm. The mean reduction in coronary flow from all preparations
was 30 ± 3 mls/min, with no difference between groups.
Duration of HR (bpm) prior to HR (bpm) prior to CFR
LAD Occlusion (min) Occlusion Reperfusion Reduction (%)
0 307 ± 23 N/A N/A
15 295 ± 23 248 ± 36 35 ± 5
30 340 ± 25 308 ± 28 26 ± 5
60 300 ± 20 294 ± 15 29 ± 5
p value ns ns ns
Table 3.1: Heart Rate (HR) and Coronary flow rate (CFR) baseline parameters in ex vivo
studies of variable duration ischaemia-reperfusion. n=6/group
3.3.1.2 Ischaemia-Induced Arrhythmias
Hearts not subject to regional ischaemia (control, n=6) did not experience any ventricular
arrhythmias during the 60 minute perfusion period. Coronary flow rate in control hearts at the
end of stabilisation was 15 ± 2 mls/min compared to 14 ± 1 mls/min (p=ns) at the end of 60
minutes perfusion, suggesting that the preparation remained viable and stable throughout the
duration of the experiment.
All hearts subject to regional ischaemia, independent of duration, experienced VPB during
acute LAD occlusion. The incidence of VT was similiar in hearts subject to 15, 30 and 60
minutes of ischaemia (50% vs. 66% vs. 66%, p=ns), with only one heart (60 minute group)
experiencing transient VF at 16 minutes post-occlusion. The time distribution of ischaemia-
induced ventricular premature beats and ventricular tachycardia was explored by pooling data
from all hearts undergoing ischaemia-reperfusion (n=18) and plotting the histogram of VPB
and VT as a function of time. As shown in Figure 3.3, ischaemia-induced VPB and VT
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follow a monomodal distribution with the arrhythmia peak occurring between 12-15 minutes
following acute LAD occlusion. By 30 minutes post-occlusion, no further VT occurred and
VPB occurrence was sporadic. Separate histograms of each duration of ischaemia show similar
bell-shaped distributions, except the 15 minute occlusion group in which the downward (right-
sided) tail is truncated owing to experimental design, explaining the apparent reduced incidence
of VT in this group.
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Figure 3.3: Time course of (Top) ischaemia-induced VPB and (Bottom) ischaemia-induced
VT demonstrating a monomodal distribution with a peak between 12-15 minutes post acute
LAD occlusion
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3.3.1.3 Reperfusion-Induced Arrhythmias
All hearts experienced VPB within 30 seconds of reperfusion. Hearts subjected to shorter dura-
tion occlusion were significantly more pro-arrhythmic compared to longer duration of occlusion
(15 minutes vs. 60 minutes, incidence of VT 80% vs. 0%, p<0.05, incidence of VF 66% vs.
0%, p<0.05, Figure 3.4). Intermediate duration of occlusion (30 minutes) resulted in a similar
intermediate incidence of VT (50%) and VF (50%).
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Figure 3.4: Incidence of (Left) reperfusion-induced VT and (Right) reperfusion-induced VF.
* p<0.05 by χ2
Kaplan-Meier plots (Figure 3.5) of freedom from reperfusion VT demonstrated that for 15 and
30 minute groups, VT occurred within the first 60 seconds following reperfusion. Similar plots
for freedom from reperfusion VF showed that hearts in the 15 minute group had degenerated
into VF by 120 seconds post-reperfusion, compared to hearts subject to 30 minutes of occlusion
that took until 200 seconds post-reperfusion to degenerate to VF.
The results from this study informed the choice of LAD occlusion used in the ex vivo Roti-
gaptide studies; the aim of which was to determine whether pharmacological enhancement of
gap junction coupling, using Rotigaptide, had an anti-arrhythmic effect on either ischaemia or
reperfusion-induced arrhythmias. For this reason, a pro-arrhythmic model was desired, with
sufficient incidence of ischaemia and reperfusion-induced arrhythmias that would allow for any
potential beneficial anti-arrhythmic effect of Rotigaptide treatment to be revealed. The 15-
minute occlusion model demonstrated a high incidence of arrhythmias during both ischaemia
(100% VPB, 50% VT) and reperfusion (100% VPB, 83% VT, 66% VF) and was felt to rep-
resent a more pro-arrhythmic substrate, compared to the 30 and 60-minute models that had
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Figure 3.5: Kaplan-Meier plot of freedom from (Left) reperfusion-induced VT and (Right)
reperfusion-induced VF. 15’ = 15 minute LAD occlusion (n=6), 30’ = 30 minute LAD occlusion
(n=6), 60’ = 60 minute LAD occlusion (n=6). * p<0.05 vs. 60’
a marginally higher incidence of ischaemia-induced arrhythmias (66% VT vs. 50% VT) but
significantly fewer reperfusion-induced arrhythmias.
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3.3.2 Effect of Rotigaptide Treatment
3.3.2.1 Heart Rate & Coronary Flow Reduction
Baseline heart rate and coronary flow rate parameters are presented in Table 3.2. The mean
heart rate immediately prior to LAD occlusion from all preparations (n=36) was 337 ± 6
bpm with no difference between groups. A similar narrow heart rate range was demonstrated
immediately prior to reperfusion (312 ± 9 bpm, n=27), with no difference between groups. As
expected, there was a small reduction in heart rate on reperfusion compared to heart rate prior
to LAD occlusion of 6 ± 8 bpm. The mean reduction in coronary flow from all preparations
was 31 ± 2 mls/min, with no difference between groups.
Treatment HR (bpm) prior to HR (bpm) prior to CFR
Group Occlusion Reperfusion Reduction (%)
Control 343 ± 18 322 ± 23 29 ± 5
Pre-Treated 333 ± 10 312 ± 18 32 ± 4
At Occlusion 331 ± 10 346 ± 11 33 ± 3
At Reperfusion 339 ± 11 324 ± 22 31 ± 6
ANOVA (p value) ns ns ns
Table 3.2: Heart Rate (HR) and Coronary flow rate (CFR) baseline parameters in ex vivo
studies of the effects of Rotigaptide on arrhythmogenesis. n=9/group
3.3.2.2 Ischaemia-Induced Arrhythmias
During acute LAD-occlusion, all hearts, irrespective of Rotigaptide treatment group experi-
enced ischaemia-induced VPBs. The mean number of VPBs during 15 minutes of occlusion
was comparable in the control (KHB only) and Rotigaptide perfused at-reperfusion group (96
± 52 & 65 ± 26) and lower in the pre-treated and perfused at-occlusion groups (17 ± 8 & 21
± 6, p = 0.09, Figure 3.6).
The histogram distribution (Figure 3.7) of prevalence (% of hearts experiencing VPB/minute)
against time (per minute), for hearts pre-treated or perfused with Rotigaptide at LAD occlusion,
showed a loss of the arrhythmia peak demonstrated in control hearts and in earlier studies
(Figure 3.3).
Although the modest reduction in VPB with Rotigaptide pre-treatment failed to reach signif-
icance, the reduction in ischaemia mediated VT was more pronounced with only 11% (1/9)
of hearts experiencing VT compared to 66% (6/9) in control and reperfusion-treated groups
(p<0.05, Figure 3.8). When combined with the number of VPB in a composite, logarithmic
arrhythmia score (Section 2.5.4.1), the difference persisted (Figure 3.8) with a mean arrhythmia
score in the pre-treated group of 0.9 ± 0.2 compared to 2.3 ± 0.5 in control (p<0.05) and 2.2
± 0.5 in reperfusion-treated (p<0.05)
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Figure 3.6: Scatter Dot Plot of log(VPB) occurring during ischaemia. CON = Control, no
drug; PRE = Rotigaptide 50nM pre-treatment; OCC = Rotigaptide 50nM perfused at LAD
occlusion; REP = Rotigaptide 50nM perfused on reperfusion. n=9/group. p=ns by ANOVA.
Line and error bar displayed at mean and SEM.
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Figure 3.7: Time course of ischaemia-induced VPB (Left to Right) Control, Rotigaptide
50nM Pre-Treated & Rotigaptide 50nM at Occlusion demonstrating a loss of the monomodal
distribution of VPB with a flattening of the histogram and loss of the 12-15 minute arrhythmia
peak. n=9/group
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Figure 3.8: Reduced incidence of ischaemia-induced VT (Left) and arrhythmia score (Right)in
hearts pre-treated with Rotigaptide 50nM. CON = Control, no drug; PRE = Rotigaptide 50nM
pre-treatment; OCC = Rotigaptide 50nM perfused at LAD occlusion; REP = Rotigaptide 50nM
perfused on reperfusion. * p<0.05.
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3.3.2.3 Reperfusion-Induced Arrhythmias
The effect of Rotigaptide treatment on reperfusion-induced arrhythmias is summarised in Table
3.3.
Treatment Incidence of Incidence of Logarithmic
Group Reperfusion VT Reperfusion VF Arrhythmia Score
Control 100% (9/9) 66% (6/9) 3.7 ± 0.5
Pre-Treated 89% (8/9) 55% (5/9) 3.6 ± 0.5
At Occlusion 89% (8/9) 33% (3/9) 2.7 ± 0.5
At Reperfusion 89% (8/9) 66% (3/9) 3.6 ± 0.4
ANOVA (p value) ns ns ns
Table 3.3: Effect of Rotigaptide 50nM treatment (n=9/group) on incidence of reperfusion VT,
VF and composite logarithmic arrhythmia score
A modest reduction in VF incidence and reperfusion arrhythmia score was demonstrated in
the group perfused with Rotigaptide at LAD occlusion compared to control but failed to reach
significance (χ2 = 0.35, p=0.14 respectively).
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3.4 Discussion
3.4.1 Reproducibility & Validity of Results
Variations in heart rate both pre-LAD occlusion and pre-reperfusion are important determi-
nants of the occurrence of ischaemia-induced and reperfusion-induced arrhythmias during exper-
imental coronary occlusion (Ng et al. 2013). Chadda et al. (Chadda et al. 1974) demonstrated
a ’U’ shaped relationship between heart rate during ischaemia and frequency of ventricular ec-
topics in a canine model of LAD occlusion, supported by earlier experimental studies (Han 1969)
demonstrating an increased susceptibility to ventricular arrhythmias associated with bradycar-
dia due to increased dispersion of refractoriness (Han et al. 1966). In the isolated rat preparation
of regional ischaemia, Bernier (Bernier et al. 1989) demonstrated a rate-dependent increase in
the incidence of both ischaemia-induced VF and reperfusion-induced VF whilst pacing with a
particularly vulnerable rate-dependent window existing when reperfusion was initiated after 10
minutes of LAD occlusion (range 8-100%) compared to longer duration (40 minutes) of LAD
occlusion (range 33-50%). In the experimental model described in this thesis, the narrow range
of heart rates during occlusion and prior to reperfusion supports the conclusion that heart rate
was not a determinant of the incidence of either ischaemia- or reperfusion-induced arrhythmias
in our model.
Curtis and Hearse (Curtis et al. 1989b) demonstrated the sensitivity of ischaemia-induced and
reperfusion-induced arrhythmias to occluded zone size in their ex vivo rat model of regional
ischaemia. They showed a sigmoidal relationship between VT incidence (during ischaemia and
reperfusion) and occluded zone size with a significant correlation (r=0.82, p<0.001) between
the two. In the ex vivo isolated heart preparation two main methods exist for estimation of
occluded zone size during experimentation; the dye exclusion technique which requires injection
of a water-soluble dye (e.g. Evans Blue) and destructive measurement of areas of dye staining,
or, measurement of coronary flow pre- and post- LAD occlusion by collecting coronary eﬄu-
ent. The percentage reduction in coronary flow has been shown to linearly correlate (r=0.6,
p<0.001) with infarct size measured using the dye exclusion technique (Curtis et al. 1989a)
and was the method used during this thesis. The reduction in coronary flow rate across all
preparations (n=54) was 31±2 mls/min, indicating a sufficient sized occluded zone was repro-
ducibly generated, resulting in a substrate susceptible to arrhythmogenesis as evidenced by the
position of the coronary flow rate reduction on the sigmoidal curve described by Curtis (Curtis
et al. 1989b).
3.4.2 Temporal Nature of Arrhythmias in Ischaemia-Reperfusion
The description of the time course of arrhythmias occurring during acute LAD occlusion pro-
vided in this chapter is in agreement with the findings of Curtis and colleagues (Curtis 1998)
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who demonstrated a monomodal distribution with a peak of VF incidence occuring between 14-
16 minutes post-ligation. This monomodal distribution of early arrhythmias following coronary
ligation (termed Phase 1 arrhythmias) shows significant species variability, with early canine
work by Kaplinsky (Kaplinsky et al. 1979) demonstrating a bimodal distribution with an early
peak (5-6 minutes post ligation) and a delayed peak (12-30 minutes post ligation). Although
the monomodal distrubition of early arrhythmias in the rat heart is well established, the timing
of the arrhythmia peak and the incidence of VF are still subject to a degree of experimental
variability.
The peak of the monomodal distribution in studies presented in this chapter was 12-15 minutes
post-ligation, compared to 15-20 minutes in the ex vivo studies of Curtis (Curtis 1998) and 5-10
minutes in the in vivo studies of Opitz (Opitz et al. 1995). The earlier peak may be explained
by the higher mean heart rate of 320bpm, in keeping with the findings of Bernier (Bernier et al.
1989), that demonstrated a leftward (earlier) peak shift at higher heart rates.
The ex vivo model of ischaemia-reperfusion was sufficiently arrhythmogenic with an incidence
of ischaemia-induced VT of 61%, although the incidence of ischaemia-induced VF was only 5%.
The incidence of VF in regional ischaemia models varies considerably in the literature, owing to
variations in experimental setup. Ravingerova (Ravingerova et al. 1995) reported a 57% VF and
100% VT incidence by 30-minutes post-ligation although the mean heart rate pre-occlusion was
significantly lower at 260bpm and fell to 210bpm during ischaemia. In addition to heart rate,
alterations in perfusion composition, specificially K+ concentration, as described in the studies
by Curtis (Curtis et al. 1989a) is also a determinant of VF incidence. VF incidence in their
15- and 30- minute model (with K+ = 4mmol/L) of occlusion was 33% and 42% respectively
(with 100% incidence of VT), which reduced in a step-wise fashion to 0% as K+ concentration
increased. The experimental setup (K+, Ca2+ concentration, occluded zone size, temperature)
used in the studies in this chapter does not differ from that in studies with either a high or low
incidence of VF (Carbonin et al. 1991), and the observed variability in arrhythmia incidence,
across a range of published literature, remains unexplained.
After the early Phase 1 arrhythmias, there follows a quiescent period during which the heart
is free from ventricular arrhythmias. This was demonstrated by the right-sided tail of the
histogram distribution plot of VPB and VT which, by 60 minutes post-ligation had reached
zero. In vivo experimental artery occlusion suggests a second phase of arrhythmias (Phase 2)
occurs in the rat at 90 minutes post-ligation (Opitz et al. 1995), although this distribution has
not been demonstrated ex vivo and was beyond the time scope of these studies.
Reperfusion arrhythmias, as confirmed in this chapter, occur rapidly (within 60-90 seconds) on
restoration of coronary flow following release of the LAD ligature. Early reperfusion (after 15
minutes of occlusion) resulted in a significantly pro-arrhythmic substrate in comparison to late
reperfusion (after 60 minutes of occlusion), not explained by changes in heart rate, or occluded
zone size. The increased incidence at 15 minutes of ischaemia may be explained by considering
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the timing of the arrhythmic trigger (reperfusion) within a vulnerable time window in which
ischaemic myocardium demonstrates maximal heterogeneity of AP duration and refractoriness,
rendering the substrate exquisitely vulnerable to re-entry and triggered arrhythmias. As time
progresses (30 and 60 minutes of ischaemia), the myocardium transitions towards a permanently
injured state (infarction) and the discordant electrophysiological changes necessary to initiate
and sustain arrhythmias (APD dispersion, refractoriness) are reduced. These observations
are consistent with other ex vivo and in vivo studies of rat ischaemia-reperfusion that have
demonstrated a bell shaped curve of arrhythmia incidence with a steep decline in reperfusion
arrhythmias occurring after 15-20 minutes in the ex vivo model (Ravingerova et al. 1995) and
earlier, at 5-10 minutes in the in vivo model (Manning et al. 1984a).
3.4.3 Effects of Rotigaptide on Ischaemia and Reperfusion-induced
Arrhythmias
Pre-treatment with Rotigaptide was protective against ischaemia-induced but not reperfusion-
induced arrhythmias with a significant reduction in the incidence of VT during ischaemia
compared to control. Treatment with Rotigaptide after LAD occlusion, but before reperfusion,
afforded a modest reduction in the incidence of reperfusion VF but no alteration in the incidence
of ischaemia-induced arrhythmias.
Several explanations exist to account for the difference in results seen with variations in the
temporal administration of Rotigaptide. Due to the experimental setup, Rotigaptide perfu-
sion at the time of LAD occlusion occurred after ligation was complete (<5 seconds) and
as such, the area of ischaemia and area-at-risk remained Rotigaptide naive until reperfusion.
Enhancing GJ coupling of remote myocardium and myocytes adjacent to the occluded zone
(i.e. the at-occlusion group) is insufficient to prevent ischaemic-induced arrhythmias, however,
global enhancement of GJ coupling (i.e. the pre-treatment group) does reduce the incidence
of ischaemic-VT. These observations suggest that it is the effect of Rotigaptide on myocytes
within the ischaemic region which modulates the arrhythmic substrate or reduces arrhythmic
triggers.
Arrhythmic triggers, in the form of Ca2+ induced DADs, or spontaneous depolarisations due
to stretch, arise from myocytes adjacent to ischaemic and non-ischaemic myocardium. Xing et
al. (Xing et al. 2005) demonstrated no effect of Rotigaptide treatment on induction of DADs,
triggered activity or inducibility of focal VT from within the ischaemic zone in a canine model of
MI, using an experimental protocol identical to the at-occlusion treatment group in this chapter.
Alternatively, Rotigaptide may modulate the substrate by reducing cell-cell uncoupling that
occurs in the ischaemic zone. This may occur either due to myocytes existing in a hyper-coupled
state prior to ischaemia or by the presence of Rotigaptide within the ischaemic zone during
occlusion attenuating uncoupling as it occurs. Whether the concept of hyper-coupling exists was
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explored in the study by Dhein et al (Dhein et al. 2003). They demonstrated that in isolated-
perfused rabbit hearts, not subject to ischaemia, Rotigaptide or AAP-10 treatment resulted
in reduced epicardial dispersion of the activation recovery interval and increased conduction
velocity of a magnitude between 25-50%. Although not performed, superimposed ischaemia
would be expected to increase dispersion of the ARI and reduce CV back to baseline levels,
but, provided that sufficient cell-cell coupling could be maintained, may not be of sufficient
magnitude to result in arrhythmogenesis.
Although it appears that myocytes within the ischaemic zone exist in a state of sufficient
coupling to reduce the occurrence of ischaemia-induced VT (in the pre-treated group), the
incidence of reperfusion VT was similar between control and all Rotigaptide groups. The lack of
a protective effect of Rotigaptide on reperfusion-VT/VF is in contrast to the findings of Hennan
(Hennan et al. 2006) who showed between a 2- and 5-fold reduction in VT on reperfusion.
However, comparing the results in this chapter and those from the Hennan study is difficult
owing to significant differences in model and experimental design. They used an in vivo canine
model designed to specifically study the effects of pharmacological therapy on subacute (up to
60 minutes) reperfusion arrhythmias with a very low incidence of early reperfusion VT (<5%)
and a monomodal peak occurring at 30 minutes following reperfusion in contrast to the model
used in this thesis with a high incidence of early reperfusion VT (>90%) and VF (>60%).
In the case of the at-reperfusion group, the lack of effect was likely due to insufficient time
for Rotigaptide to exert any increase in cell-cell coupling due to the rapid onset (with 30-60
seconds) of reperfusion VT or VF. For the remaining groups, consideration needs to be given
to the intrinsic arrhythmogenicity of the model. At 15 minutes of ischaemia the incidence of
ischaemia-induced arrhythmias (VPB/VT) is maximal and reperfusion at this time results in the
greatest incidence of reperfusion-induced arrhythmias. The high incidence of both ischaemia-
and reperfusion-induced arrhythmias may represent a broader pro-arrhythmic substrate and
arrhythmias attributed to ‘reperfusion’ may in actual fact occur regardless of restoration of
coronary flow owing to ongoing ischaemia and electrical instability. Despite an increase in
cell-cell coupling of myocytes in the remote and adjacent zones (in the at-occlusion group) and
either an enhancement or maintenance of cell-cell coupling in the ischaemic zone (in the pre-
treated group), the degree of cell-cell coupling is not sufficient to overcome the flow of injury
current and widespread spatial inhomogeneities in APD and conduction velocity afforded by
reperfusion, resulting in arrhythmogenesis.
3.4.4 Limitations
The ex vivo isolated rat preparation used in ischaemia-reperfusion studies is a stable, repro-
ducible model, appropriate to the study of acute arrhythmogenesis. However, the high ar-
rhythmia incidence of the 15-minute model means that separating ischaemia-induced from
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reperfusion-induced arrhythmias occurring at this time point to be difficult. The fact that
reperfusion arrhythmias occurred with almost equal distribution in all Rotigaptide treatment
groups, despite differences existing in the incidence of ischaemia arrhythmias, suggests that
restoration of flow had a causal role in arrhythmogenesis at this time point. However, use of
a model with greater separation between the temporal distributions of ischaemia and reperfu-
sion arrhythmias, i.e. a 30-minute occlusion model, may allow for more definite conclusions to
be drawn as to responsible mechanisms and the effect, if any, of pharmacological therapy. A
disadvantage however of using a longer duration model is the overall reduced susceptibility to
reperfusion arrhythmias as the ischaemic zone stabilises.
With respect to the molecular mechanisms underpinning ischaemia- and reperfusion- arrhyth-
mias, these have been extensively described (Carmeliet 1999) and were felt not to warrant
further characterisation in this model. The molecular mechanisms of Rotigaptide however,
remain elusive, and were not studied specifically here. The probable mechanism, that of ac-
tivation of protein kinase C (Weng et al. 2002) and prevention of the dephosphorylation of
Cx43 (specifically at the Ser297 and Ser368 residues of the carboxyl tail) has been identified
in whole-heart low-flow ischaemia studies (Axelsen et al. 2006). Similar findings were demon-
strated in a rabbit model of regional ischaemia using the peptide AAP-10 (a precursor to
Rotigaptide), which prevented ischaemia-induced Cx43 phosphorylation and redistribution in
myocytes within the ischaemic zone (Jozwiak et al. 2008). This selective AAP-10 activity on
myocytes in the ischaemic zone is in agreement with our findings of an anti-arrhythmic effect
in the pre-treatment group only. Further work to unravel the molecular mechanism of Rotigap-
tide by either studying the distribution of Cx43 (fluorescent immunolabelling) or the functional
state (western blotting) would need to be interpreted with caution, as the effects of ischaemia,
reperfusion and Rotigaptide therapy will be intertwined and inseparable.
3.4.5 Summary
The studies in this chapter described the development of an ex vivo model of ischaemia-
reperfusion, defined the time course of acute ischaemia-induced arrhythmias, examined the
effect of varying the duration of ischaemia on the incidence of reperfusion arrhythmias and
assessed the effect of enhancing GJ coupling on acute arrhythmogenesis.
Ischaemia-induced VPB and VT followed a monomodal distribution with a peak between
12-15 minutes post-ligation, and, in this model, ischaemia-induced VF was relatively rare.
Reperfusion-induced VT and VF were present in the majority of hearts perfused at 15-minutes
post-ligation, but not present in hearts perfused at 60-minutes post-ligation, findings supported
by previous studies. Rotigaptide treatment pre-occlusion afforded the greatest reduction in the
incidence of ischaemia-induced VT although Rotigaptide treatment did not have a significant
effect on the incidence of reperfusion arrhythmias.
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These studies suggest that in the clinically relevant setting of reperfusion occurring at the time
of PPCI, Rotigaptide treatment, although not pro-arrhythmic, lacks efficacy in reducing the
acute arrhythmias of ischaemia or reperfusion. However, enhancing gap junction coupling in the
sub-acute phase and early healing phase of infarction may represent an alternative treatment
strategy and will be explored further in an in vivo model of reperfused infarction (Chapter 4
and Chapter 6).
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Chapter 4
Developing an In Vivo Model of
Infarction-Reperfusion
The studies in this chapter describe the development of an in vivo rat model of infarction-
reperfusion and the characterisation of the electrophysiological and structural remodelling that
occurs in the healed phase post-MI. These studies allowed for application of the model to the
study of the effects of enhancing GJ coupling, with Rotigpatide, described in Chapter 6
4.1 Introduction
4.1.1 Role of Reperfusion in Myocardial Infarction
Following acute coronary occlusion, myocytes in the subendocardial layer begin to undergo
rapid, irreversible necrosis which spreads in a wavefront manner owing to the presence of a
gradient distribution of collateral supply, to involve the epicardial and mid-myocardial layers as
occlusion time increases (Reimer et al. 1979). Reperfusion of the occluded coronary artery limits
this wavefront of necrosis and timely restoration of flow has been consistently demonstrated
to confer a significant mortality benefit. Mechanistically, reperfusion appears to afford its
benefits by a combination of reduced infarct size owing to myocardial salvage, reduced infarct
expansion, dilatation and thinning, and preservation of LV function (Simoons et al. 1986;
Braunwald 1989). Early clinical studies of reperfusion of acute MI focused on using fibrinolytic
agents (e.g. Streptokinase, Tissue Plasminogen Activator) and demonstrated a time-dependent
reduction in mortality with greatest benefit conferred when flow was restored early (GISSI
1986; ISIS-2 1988; Simoons et al. 1993). However, significant limitations exist with fibrinolytic
therapy; some patients are ineligible for thrombolysis, immediate revascularisation fails in up
to 15% (GUSTO 1993) and risk of re-infarction increases owing to lack of long-term vessel
patency (Gibson et al. 2003). For these reasons, primary percutaneous intervention (PPCI)
119
with cannulation of the occluded artery, extraction of thrombus, balloon angioplasty and stent
deployment has become the preferred method of reperfusion with superior short and long-term
survival, reduced non-fatal re-infarction and reduced complications of bleeding (Andersen et
al. 2003; Nielsen et al. 2010; Steg et al. 2012). Although acute reperfusion (pharmacological
or mechanical) strategies are currently indicated only in patients with evidence of significant
myocardial injury (ST segment elevation), spontaneous reperfusion also occurs in a subset of
patients (9-28%) and appears to afford the same benefits of increased myocardial salvage and
reduced infarct size (Christian et al. 1998).
4.1.2 Structural Remodelling in Healed Infarction
Owing to limited histological analyses of reperfused human myocardium, non-invasive imaging
modalities, specifically delayed-enhanced contrast MRI (deMRI) has proved pivotal in increas-
ing the understanding of the effects of reperfusion on structural remodelling in the form of
infarct size and transmural extension. Contrast agents (e.g. Gadolinium-DTPA), are primarily
extracellular molecules and exist in higher concentrations in areas where the extracellular or
interstitial space is expanded (acute or chronic infarction, Kim et al. 1999; Rehwald 2001).
The higher concentration of contrast agent results in a reduction in T1 relaxation time and the
appearance of regions of hyperenhancement on MRI.
In assessing the acute effects of reperfusion, the deMRI study of O’Regan (O’Regan et al.
2009) imaged 15 patients within 7 days post-PPCI to assess the effect of reperfusion on the
extent of myocardial salvage. As expected, all infarcts involved the sub-endocardium but the
degree of transmural extension was variable, occurring in only 60% (9/15), with a mean depth
from the epicardial surface of 2mm in patients with partial-thickness infarction. The extent of
myocardial salvage post-reperfusion was higher in the transmural direction, compared to the
lateral direction, in keeping with the detailed histological findings of Lee et al. (Lee et al. 1981).
In a post-mortem series of hearts between 3-16 days post-MI, infarct size, as a percentage of
the vascular bed at risk (i.e. that supplied by a lone coronary artery) ranged between 50-88%
with this variability confined to the extent of transmural, not lateral infarct extension. This
variability in transmural extension has been demonstrated in established (>100 days) infarction
(Chan et al. 2008) with an increase in transmural extension found to be inversely correlated
with time-dependent improvement in contractile function (Choi et al. 2001).
4.1.3 Arrhythmogenesis in Healed Infarction
Post-infarction, the increased incidence of ventricular arrhythmias, in the form of VT or VF are
recognised to increase both short and long-term mortality and are responsible for the majority
of sudden adult cardiac deaths in post-infarction survivors (Newby et al. 1998; Henkel et al.
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2006). The work of El-Sherif (El-Sherif et al. 1977; El-Sherif et al. 1981b), in the canine
model of infarction, demonstrated the re-entry nature of ventricular arrhythmias arising from
the epicardial border zone with development of functional conduction block, a prerequisite
in arrhythmia initiation and maintenance. This re-entry mechanism was corroborated in the
human studies of De Bakker (Bakker et al. 1988), who demonstrated that slow conduction, a
pre-requisite for re-entry, was present at the infarct border zone as a result of collagen deposition
between bundles of surviving myocytes (Bakker et al. 1993).
Changes to the properties of myocytes in the infarct and infarct border zone have been the
focus of extensive experimental studies to delineate the cellular mechanisms responsible for
arrhythmogenesis (Pinto et al. 1999). The largest body of work has made use of the recently
healed (3-7 day) canine infarct, which demonstrates a complex, time dependent sequence of ion
channel remodelling, calcium handling and altered gap junction coupling (Ursell et al. 1985).
Evidence suggests that myocytes overlying the area of infarction have similar resting potential
to remote myocytes and there is conflicting, species-dependent evidence for changes in resting
potential of cells at the infarct border zone, with neither rat (Santos et al. 1995) nor canine
models (Ursell et al. 1985) demonstrating significant change. In the feline model of infarction
studied by Wong et al. (Wong et al. 1982), myocytes in the healed infarct region were shown to
have a prolonged APD, compared to a shortened APD in border zone myocytes. This shortening
of the APD in the epicardial border zone was also demonstrated in a canine model of infarction
but was found to be time dependent with restoration to a normal APD at two months post-
infarction, attributed to dynamic remodelling and recovery of the L-type Ca2+ channel current
and transient outward K+ current (Ito)(Dun et al. 2004). Ion channel remodelling has also been
shown to play a causative role in arrhythmogenesis with differences in whole cell Na+ current
and L-type Ca2+ current between the central common pathway and the outer pathway of the
VT circuit resulting in greater re-entry circuit stability (Baba 2005).
In addition to ion current remodelling, gap junction remodelling has a pivotal role in arrhyth-
mogenesis with redistribution of Cx43 to the lateral border of myocytes found to correlate
with the location of the central common pathway of re-entrant arrhythmias and preservation
of transverse conduction (Peters et al. 1997). Furthermore, the conductance and distribution
of GJ channels is heterogeneous within different regions of the re-entrant pathway, giving rise
to discordant coupling and conductance, supporting the ability of the substrate to sustain
arrhythmias (Cabo et al. 2006).
4.1.4 Experimental Models of Infarction-Reperfusion
Owing to the increasing use of PPCI and the difficulties in examining the effects of infarction
and reperfusion when evaluating the role of novel pharmacological agents in modulating the
healing process in clinical practice, several animal models of infarction-reperfusion have been
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developed (Verdouw et al. 1998).
Large animal models of infarction (e.g. canine, porcine) were some of the first developed
(Beck et al. 1941) and were extensively used in studies of infarct border zone conduction
remodelling (Ursell et al. 1985) although have reduced in use owing to cost, maintenance, and
social considerations. In addition, the use of the canine model is limited by the presence of a
well collateralised coronary circulation which may explain the variability in experimental infarct
size (Lowe et al. 1978). The extent of collateral circulation is a species-dependent phenomenon,
for example, the rat coronary circulation has very few collaterals compared with the wholly
collateralised guinea-pig circulation. For the induction and study of regional infarction, the ideal
experimental preparation would mimic the human physiology (sparse collaterals) as closely as
possible but be offset against requiring a sufficient lack of collaterals to create a defined region
of infarction. For this reason, in addition to cost and ease of handling considerations, small
animal (rat, mouse) models of infarction have been developed and are well-established in the
literature (Curtis et al. 1987).
Early models of infarction in the laboratory rat made use of the technique of permanent LAD
ligation described by Johns and Olsen (Johns et al. 1954). This method produces consistent
infarction in over 80% of experiments, resulting in a consistent generation of early arrhythmias
in the acute ischaemic phase and a typical pattern of infarction with a large, dense, homogeneous
scar at the end of the healed phase (Curtis et al. 1987). Although highly applicable to the study
of acute ischaemia-induced arrhythmias and the effects of structural remodelling due to chronic
vessel occlusion, this model of permanent ligation differs substantially from the pathophysiology
and histology of reperfused infarction where the infarct scar is often more patchy, heterogeneous
and not transmural. Studies of infarction-reperfusion in the rat demonstrate that beyond 90
minutes of infarction, the resulting infarct size and degree of transmural extension of scar is
identical to that seen in permanent occlusion models (Hochman et al. 1987b; Hale et al. 1988),
although the expansion index (a measure reflecting the extent of thinning and dilatation of
the infarct region) is reduced with reperfusion times of up to 6 hours (Morita et al. 1993).
Studies of shorter duration infarction (30-minute), demonstrated significantly smaller infarct
size, reduced expansion index and limitation of infarct location to the mid-myocardial wall
without transmural extension. In the experimental rat model of MI, the natural history of the
healing process from the acute inflammatory response through to necrosis, chronic inflammation
and scar formation is usually complete by 21 days post-infarction (Fishbein et al. 1978) and
occurs at twice the rate compared to human infarction (Hochman et al. 1982). This has been
corroborated with cine MRI studies in a reperfusion-infarction model which demonstrated left
ventricular end-diastolic and end-systolic volumes increased up to four weeks post-infarction
but then plateaued, suggesting that remodelling was complete (Jones et al. 2002).
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4.1.5 Hypothesis & Aims
The aim of this chapter was to develop and characterise a small animal (rat) model of in
vivo infarction-reperfusion, to be used in future studies to assess the pharmacological effects of
enhancing GJ coupling in vivo. Specifically, the aim was to study the effects of two different
durations of infarction on electrophysiological and structural remodelling characterised at the
healed phase of infarction (four weeks); specifically the effects on:
1. The in vivo and ex vivo arrhythmia phenotype in the form of spontaneous ventricular
arrhythmias, ECG parameters, arrhythmia vulnerability and remodelling of the cardiac
AP and Ca2+ transient
2. The degree and extent of structural remodelling in the form of infarct size and transmural
extension
The choice to characterise the model at two time points (30- and 60- minute duration of
infarction) prior to reperfusion was made with the intention of generating a model with a de-
fined arrhythmia phenotype (to enable the study of potential pharmacological anti-arrhythmic
effects) which was also structurally separate from the chronic (permanent) occlusion model,
in an attempt to best mimic the clinical phenotype seen post-PPCI. The choice of the 30-
minute time point was informed by the results discussed in the ex vivo studies of Chapter
3 which demonstrated that 30-minutes of ischaemia ex vivo was after the peak incidence of
both ischaemia-induced and reperfusion-induced arrhythmias and should result in increased
operative survival and adequate study numbers. The choice of the 60-minute time point was
informed by the studies of structural remodelling (Hochman et al. 1987b; Hale et al. 1988) with
the intention to maximise the extent of structural remodelling (infarct size and transmural
extension) but ensure sufficient separation from the chronic infarction phenotype.
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4.2 Methods
4.2.1 Surgical Model of Infarction-Reperfusion
Male Sprague-Dawley rats (250-350g) underwent myocardial infarction surgery, with reperfu-
sion, as described in Section 2.3.3. To determine the effects of infarction time on the degree
of electrophysiological and structural remodelling, animals underwent infarction-reperfusion
surgery in three distinct groups. A sham-operated group acted as controls and had the 6-0
suture passed through the myocardium, under the LAD but left slack so as not to induce in-
farction, the chest closed and the animal weaned from the ventilator and recovered. The two
remaining groups underwent infarction-reperfusion with one group having the LAD ligature re-
leased after 30 minutes of occlusion, the other after 60 minutes of occlusion. Following recovery
from surgery animals were singly housed until four weeks post-infarction
4.2.2 In Vivo Electrophysiological Studies
A measure of the spontaneous incidence of ventricular arrhythmias following infarction-reperfusion
was made by performing in vivo telemetry recordings at four weeks post-infarction, when the
healing process was complete, before the onset of heart failure by implanting wireless ECG
telemetry transmitter as described in Section 2.4.1, between 7-10 days post-MI surgery. At
four-weeks post-infarction a 72 hour recording was taken from which a 24 hour block of data
was analysed and the total number of VPB, VT and VF episodes quantified and a composite
arrhythmia score calculated (Curtis et al. 1988, Equation 2.1).
A recording of the rat 6-lead ECG was performed to assess for changes in basic ECG parameters
(RR interval, PR interval, QRS duration, QTc interval)as described in Section 2.4.2, between
days 26-30 post-MI surgery. Data were collected for five minutes following anaesthetic stabil-
isation and analysed oﬄine using LabScribe v2.0 with the average ECG intervals (PR, QRS,
RR, QTc) reported for 10 consecutive beats.
4.2.3 Ex Vivo Electrophysiological Studies
The electrophysiological remodelling of the action potential and calcium transient following
infarction-reperfusion was characterised by performing dual optical mapping as described in
Section 2.6 at four-weeks post-infarction.
Following optical mapping the susceptibility to re-entry arrhythmias induced by programmed
stimulation was tested using an extrastimulus pacing protocol as described in Section 2.5.5 with
calculation of an arrhythmia score for each heart (Section 2.5.5.3).
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Following optical mapping and PES studies, hearts were removed from the Langendorff appa-
ratus and perfusion-fixed with 100mls of 10% NBF for 10 minutes prior to storage in 10% NBF
before either diffusion weighted MR imaging and/or histological analysis.
4.2.4 Optical Mapping Optimisation
Prior to performing dual optical mapping studies the experimental protocol was optimised
by ensuring correct dual CMOS camera alignment, determining the optimal time of Ca2+
dye loading and testing for cross-talk between voltage (RH237) and Ca2+ (Rhod-2/AM) dyes.
Cameras were aligned by using a fluorescence grid and the built-in ‘dual-head align mode’ in
RedShirt Software and the path of emitted light finely manipulated through the dichroic mirrors
using two adjustable thumb-screws until images from both cameras overlapped.
4.2.4.1 Calcium Dye Loading & Signal Quality
The time required for Rhod-2/AM to de-esterify, enter myocytes and produce Ca2+ transients
in response to changes in intracellular Ca2+ was assessed by taking a series of recordings at
five minute intervals post-loading. Optical signal quality increased dramatically as a function
of time up to 25/30 minutes post-loading, after which, signals remained constant. Based on
these observations, a 30 minute loading period was observed after Rhod-2/AM administration
before voltage sensitive dye and excitation-contraction uncoupler loading and data acquisition.
4.2.4.2 RH237 & Rhod-2/AM Dye Crosstalk
To address any potential interactions between Rhod-2/AM and RH237 or defects in the detec-
tion of one or both sets of signals, a series of recordings were taken for separate hearts loaded
with either a) RH237 first, followed by Rhod-2/AM or b) Rhod-2/AM first, followed by RH237.
Data were acquired prior to loading of the second dye with both optical mapping cameras to
ascertain the extent (if any) of bleed through of voltage signal onto the Ca2+ channel or vice
versa. This demonstrated no appreciable optical signal in either voltage or Ca2+ channel when
either just Ca2+ or Voltage were loaded respectively. Data were recorded post loading of the
second dye with both optical mapping cameras to demonstrate the presence of signal in the
second channel and the lack of effect on the magnitude of signal in the first channel suggest-
ing that any potential cross-talk between RH237 and Rhod-2/AM using this optical mapping
system is negligible.
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4.2.5 Infarct Size Quantification
Histological analysis was performed on formalin-fixed, wax embedded sections as described in
Section 2.8.
A total of 15 hearts underwent infarct size quantification using the area-based method; 3 sham-
operated, 6 30-minute occlusion and 6 60-minute occlusion. In addition to the area-based
method, an alternative method of quantifying infarct size, the length-based method, was used
when appropriate and compared to the area-based method as described in Section 2.8.2.
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4.3 Results
4.3.1 Study Numbers & Operative Mortality
A total of 31 animals underwent in vivo surgery; 5 sham-operated controls, 16 underwent 30
minutes of infarction prior to reperfusion and 10 underwent 60 minutes of infarction prior to
reperfusion. Mortality in the three groups was 0%, 37% and 30% respectively, resulting 5,
10 and 7 survivors for studies at four-weeks post-MI. Animal weight pre-surgery, weight at
four-weeks post-surgery and weight gain were similar between groups (Table 4.1).
Sham 30’ 60’ p value
Number Operated 5 16 10 -
Survival Rate 100% 63% 70% -
Pre-Op Weight (g) 314 ± 15 306 ± 11 293 ± 10 ns
4 Week Weight (g) 499 ± 16 465 ± 16 440 ± 11 ns
Weight Gain (g) 185 ± 21 159 ± 18 147 ± 10 ns
Table 4.1: Total number of animals studied, survival rate and pre-operative and four-week
weight (g) for in vivo infarction-reperfusion characterisation. Sham = sham-operated, 30’ = 30
minute occlusion, 60’ = 60 minute occlusion
Overall mortality was 29% (n=9 animals) in these studies with four occurring within minutes of
LAD ligation due to intractable VF, two occurring during intubation and ventilation prior to the
start of surgical procedure, two occurring intra-operatively due to either uncontrollable bleeding
or haemodynamic collapse as the result of acute cardiogenic shock and one occurring between
12-24 hours post-operatively due to presumed early VF. Of note, no deaths were attributed
to acute reperfusion arrhythmias. Prior to this study, excess mortality had been identified in
animals undergoing prolonged open-chested ventilation (beyond 30 minutes) with bradycardia
and circulatory collapse despite adequate oxygenation, anaesthesia and temperature control.
Due to this, the closed-chest approach to infarction-reperfusion surgery, with limited ventilator-
dependent time and externalisation of the free-end of the LAD ligature (described fully in
Section 2.3.3) was developed.
4.3.2 6-Lead ECG Parameters
ECG data were recorded from all surviving animals (n=22, 5/10/7 in each group) at four
weeks post-infarction reperfusion, summarised in Table 4.2. Animals undergoing 60 minutes
of infarction prior to reperfusion had a significantly wider QRS duration compared to either
sham-operated or 30-minute occlusion animals. There were no significant difference in either
PR, QTc or RR intervals between groups.
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ECG Interval (ms) Sham 30’ 60’ p value
PR 47 ± 3 46 ± 1 51 ± 2 ns
QRS 26 ± 1 26 ± 1 32 ± 1 ∗ ∗<0.05
QTc 74 ± 5 76 ± 2 73 ± 3 ns
RR 168 ± 5 173 ± 5 172 ± 9 ns
Table 4.2: Surface 6-lead ECG intervals at 4 weeks post-infarction reperfusion surgery. Sham
= sham-operated n=5, 30’ = 30 minute occlusion n=10, 60’ = 60 minute occlusion n=7. ∗ vs.
Sham-operated and 30-minute occlusion group.
4.3.3 Incidence of Spontaneous Arrhythmias
Telemetry data were recorded from all surviving animals (n=22, 5/10/7 in each group) at
four-weeks post-infarction reperfusion and is summarised in Figure 4.1.
Sham 30' I/R 60' I/R
1
10
100
1000
10000
*
*
Operative Group
N
um
be
r 
of
 V
PB
s/
24
hr
Sham 30' I/R 60' I/R
0
1
2
3
4
5
Operative Group
A
rr
hy
th
m
ia
 S
co
re *
*
Figure 4.1: (Left) Scatter dot plot of incidence of VPB (log-transformed) and (Right) Scatter
dot plot of composite arrhythmia score for a 24 hour period. Dots represent data from indi-
viduals animals during a 24 hour period recorded 4 weeks post-infarction reperfusion, line at
median ± IQR. Sham = sham-operated n=5, 30’ I/R = 30 minute occlusion n=10, 60’ I/R =
60 minute occlusion n=7. I/R = Infarction-Reperfusion. ∗ p<0.05 vs. Sham-operated
Sham-operated animals were not free from VPBs but had a significantly reduced incidence (4
± 1/day) compared to 30-minute occlusion (43 ± 11, p<0.05) and 60-minute occlusion (71 ±
34, p<0.05) groups. The incidence of VPBs were similar between 30- and 60-minute occlusion
groups. A logarithmic composite arrhythmia score, incorporating episodes of VT (12%, 2/17)
and VF (0%) during the 24 hour period, also demonstrated significant differences between
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sham-operated animals (0.6 ± 0.1) compared to 30-minute occlusion (1.5 ± 0.2, p<0.05) and
60-minute occlusion (1.7 ± 0.2, p<0.05) groups.
4.3.4 Optical Mapping Optimisation
The time taken for Rhod-2/AM to de-esterify, cross the cell membrane and bind to intracellular
free Ca2+ was assessed by comparing the signal at baseline to serial time-points post-loading
(Figure 4.2). As time progressed, the amplitude of the Ca2+ transient became more evident as
signal strength increased, so as to provide clear separation between background optical noise
and true signal. By 30-minutes post-loading the SNR had plateaued at a temporary maxima
and signals were of sufficient quality for acquisition and analysis.
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Figure 4.2: Time-dependent increase in quality of Calcium signal (single pixel) post-loading
with optimal signals present 30 minutes post-loading
There was no appreciable crosstalk between RH237 and Rhod-2/AM dyes using the optical
mapping setup described, as shown in Figure 4.3. On single dye loading, signal was present
only in the voxels for the camera with filters appropriate to the wavelength of emitted light with
only background fluorescence (noise) detectable in voxels for the second camera. On loading of
the 2nd fluorescent dye, separate, appropriate signal was then visible in voxels for both cameras.
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Figure 4.3: (A) Single pixel signal from both cameras during single (left) followed by dual (right)
dye loading with A Rhod-2/AM loading first and B RH237 loading first. Note background
noise only in signal from camera of non-loaded dye.
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4.3.5 Action Potential & Calcium Transient Remodelling
The ex vivo preparation failed in two hearts from the 60-minute occlusion group with lack of
spontaneous rhythm on Langendorff perfusion. As a result, the dual optical mapping protocol
was performed in 20 animals (5/10/5 in each group). Only hearts in the 60-minute occlusion
group had visual evidence of an epicardial, transmural infarct, therefore, data were analysed for
the remote region of the sham-operated group (n=5) and the 30-minute occlusion group (n=10)
and for the remote, infarct border zone and infarct region in the 60-minute group (n=5, 4 with
epicardial border zone). Representative optical action potential and calcium transient traces
from sham and 60-minute occlusion hearts are shown in Figure 4.4 and Figure 4.5 respectively.
A B C
100ms
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Figure 4.4: Optical mapping data from sham-operated heart. (A) Grey-scale CMOS image
showing homogeneous signal intensity across visible LV epicardial optical mapping field, (B)
Representative action potential traces derived from RH237 fluorescent dye, (C) Representative
calcium transient traces derived from Rhod-2/AM fluorescent dye.
Local conduction velocity was significantly slowed at the infarct border zone (IBZ) compared
with remote (27.6± 12.1 vs. 67.7± 3.6 cm/s, p<0.05) with crowding of isochrones on activation
map on visual inspection (Figure 4.6). The conduction velocity for the remote regions in sham,
30-minute occlusion and 60-minute occlusion groups were similar (69.7 ± 7.1 vs. 75.5 ± 3.0 vs
67.7 ± 3.6 cm/s, p=ns).
The upstroke of the action potential was significantly remodelled within the IBZ and infarct
region with significant prolongation of the rise time compared to remote (remote 6.6 ± 1.6 vs.
IBZ 14.3 ± 4.7 vs. Infarct 21.5 ± 4.5 ms, p< 0.05 by ANOVA) and reduced dFdTmax in the
infarct region compared to remote (0.103 ± 0.014 vs. 0.172 ± 0.005 AU/ms p< 0.05 Figure
4.7). Rise time in the remote regions of sham, 30-minute occlusion and 60-minute occlusion
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Figure 4.5: Optical mapping data from 60-minute occlusion heart.(A) Grey-scale CMOS im-
age showing heterogeneous signal intensity and visible epicardial border zone (dashed white
line) with reduced signal intensity in infarcted area, (B) Representative action potential traces
derived from RH237 fluorescent dye, (C) Representative calcium transient traces derived from
Rhod-2/AM fluorescent dye.
groups were similar (5.2 ± 0.1 vs 5.8 ± 0.6 vs 6.6 ± 1.6 ms, p=ns), as were dFdTmax (0.170 ±
0.006 vs. 0.165 ± 0.003 vs. 0.172 ± 0.005 AU/ms, p=ns).
As expected the upstroke of the Ca2+ transient took longer (prolonged rise time) and was
shallower (reduced dFdTmax) compared to the optical action potential (data from sham hearts
remote region only (n=5), AP rise time 5.2 ± 0.1 ms vs. Ca2+ rise time 16.8 ± 1.6 ms, p<0.05,
AP dFdTmax 0.170± 0.006 AU/ms vs Ca2+ dFdTmax 0.107± 0.008 AU/ms, p<0.05). In hearts
undergoing 60-minutes of occlusion, the rate of upstroke (dFdTmax) of the Ca
2+ transient was
reduced in the infarct region compared to remote (0.072 ± 0.007 vs. 0.110 ± 0.005 AU/ms,
p<0.05) with values in the remote regions of sham, 30-minute occlusion and 60-minute occlusion
groups all found to be similar (0.107 ± 0.008, 0.107 ± 0.004, 0.110 ± 0.005, p=ns). There were
no differences in the rise time of the Ca2+ transient between remote regions in sham, 30-minute
and 60-minute groups (16.8 ± 1.6 vs. 22.4 ± 2.0 vs. 16.1 ± 3.2 ms, p=ns) or between remote
and infarct regions in the 60-minute occlusion group (16.1 ± 3.2 vs. 23.5 ± 3.4 ms, p=ns).
Remodelling of the action potential duration (Table 4.3) was only demonstrable in the infarct
region at the shortest duration (APD50) when compared to remote (infarct 61± 4 ms vs. remote
35 ± 8 ms, p<0.05) with longer APD (APD75 and APD90) showing similar durations across all
regions. Comparing all AP durations in the remote regions of sham, 30-minute occlusion and
60-minute occlusion group demonstrated similar results with no difference between groups.
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Figure 4.6: (A) Local conduction velocity in remote region of sham-operated (Sham, n=5),
30-minute occlusion (30’ I/R, n=10) and remote and border zone (IBZ) regions of 60-minute
occlusion (60’ I/R, n=5) groups with significant slowing at IBZ compared to remote. ∗ p<0.05
vs. 60’ I/R remote region. (B) Representative activation map from sham-operated group, with
highlighted area demonstrating uniform activation across entire epicardium and (C) Represen-
tative activation map (left) and grey-scale CMOS image (right) and highlighted area demon-
strating crowding of isochrones and conduction slowing at infarct border zone.
APD dispersion, calculated as the standard deviation of APD values, showed a significant
increase in infarct and border zone regions compared to remote at APD50 (Table 4.3), although
this difference was not present at APD75 or APD90.
Operative Group
APD Duration (ms) APD Dispersion (ms)
APD50 APD75 APD90 APD50 APD75 APD90
Sham - Remote 26 ± 2 53 ± 4 72 ± 6 2 ± 1 3 ± 1 4 ± 1
30’ - Remote 34 ± 3 65 ± 5 85 ± 4 3 ± 1 3 ± 1 3 ± 1
60’ - Remote 35 ± 8 66 ± 8 85 ± 8 3 ± 1 3 ± 1 4 ± 1
60’ - IBZ 54 ± 7 76 ± 6 90 ± 6 7 ± 1∗ 5 ± 2 5 ± 2
60’ - Infarct 61 ± 4∗,# 78 ± 3 91 ± 3 5 ± 1∗ 5 ± 1 5 ± 1
ANOVA (p value) ∗,#<0.05 ns ns ∗<0.05 ns ns
Table 4.3: APD Dispersion in hearts undergoing infarction-reperfusion studies. ∗p<0.05 vs.
60’ remote region, #p<0.05 vs. 60’ border zone (IBZ) region.
Calcium transient duration (CaTD) showed no remodelling in infarct region compared to re-
mote, or across remote regions in the different operative groups (Table 4.4). Likewise, CaTD
dispersion was similar across all groups.
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Figure 4.7: (A) Prolongation of Rise Time (ms) at infarct border zone and infarct region
compared to remote with (right) representative colour maps of rise time distribution in sham-
operated and 60-minute occlusion groups. (B) Reduction in rate of rise of optical AP (dFdTmax,
F/ms) in infarct region compared to remote and infarct border zone with (right) representative
colour maps of dFdTmax distribution in sham-operated and 60-minute occlusion groups.
Operative Group
CaTD Duration (ms) CaTD Dispersion (ms)
CaTD50 CaTD75 CaTD90 CaTD50 CaTD75 CaTD90
Sham - Remote 53 ± 6 73 ± 7 87 ± 7 4 ± 1 4 ± 1 5 ± 1
30’ - Remote 61 ± 3 84 ± 3 98 ± 3 4 ± 1 4 ± 1 4 ± 1
60’ - Remote 61 ± 5 82 ± 6 103 ± 5 4 ± 1 4 ± 1 6 ± 1
60’ - IBZ 64 ± 3 80 ± 1 95 ± 1 5 ± 1 5 ± 1 5 ± 1
60’ - Infarct 61 ± 2 75 ± 2 95 ± 3 5 ± 1 5 ± 1 7 ± 1
ANOVA (p value) ns ns ns ns ns ns
Table 4.4: CaTD Dispersion in hearts undergoing infarction-reperfusion studies.
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4.3.6 Susceptibility to Inducible Arrhythmias
The ex vivo preparation failed in two hearts from the 60-minute occlusion group with lack of
spontaneous rhythm on Langendorff perfusion. As a result, the PES protocol was performed in
20 animals (5/10/5 in each group) . No arrhythmias were inducible in the sham-operated group
(incidence of SusVT and NSVT 0%) compared to the 30-minute occlusion group (incidence
60%, χ2<0.05) and the 60-minute occlusion group (incidence 60%, χ2<0.05, Figure 4.8). The
incidence of sustained VT was lower than that of NSVT in the 30-minute (30%) and 60-minute
(25%) groups but still higher than sham-operated (0%). The arrhythmia score, which takes into
account the pacing protocol used to induce either NSVT or SusVT, was significantly higher in
30-minute (2.1 ± 0.6) and 60-minute (2.0 ± 0.8) compared to sham-operated (0 ± 0, p<0.05,
Figure 4.8).
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Figure 4.8: Results of ex vivo PES at four weeks post-infarction reperfusion surgery; (A) Scatter
dot plot of arrhythmia score & (B) Susceptibility to non-sustained VT and sustained VT. ∗
p<0.05 vs. sham-operated
4.3.7 Infarct Size Quantification
Infarct size in the 30-minute occlusion group was small (4.2 ± 2.3 %), with confinement of
all scar to the mid-myocardial region with no transmural extension with several hearts (n=3)
demonstrating no visible infarct. In comparison, hearts in the 60-minute occlusion group showed
transmural extension in half (3/6) with the remainder (3/6) displaying patchy, transmural in-
farction, representative serial histology sections from each group are shown in Figure 4.9. Infarct
size, measured by the area-based approach, was significantly increased in hearts undergoing 60-
minutes of occlusion (10.2 ± 2.1 % of total LV area) compared to sham-operated controls (0.2
± 0.1 %, p<0.05, Figure 4.10A).
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Comparison of the area-based and length-based methods for quantifying infarct size in the
three hearts with obvious transmural extension and wall thinning revealed that the area-based
method reported significantly smaller infarct size (area-based 12.4 ± 1.4% vs. length-based
26.0 ± 5.3%, p<0.05), with consistent differences in all slices from apex to base (Figure 4.10B,
4.10C)
4.3.8 Effect of Infarct Size on Arrhythmogenesis
The relationship between infarct size and PES susceptibility was explored by categorising data
into two equal size groups, PES+ve or PES-ve, based on the position in the distribution of PES
arrhythmia score values. All PES-ve hearts had an arrhythmia score of 0, all PES+ve hearts
had an arrhythmia score of >2, demonstrating sufficient separation between groups. Infarct
size was significantly larger in the PES+ve group, compared to PES -ve (n=6 in both groups,
7.8 ± 3.0 vs. 0.7 ± 0.3 %, p<0.05, Figure 4.11). Performing a non-parametric correlation of
the dataset revealed a positive correlation between PES derived arrhythmia score and infarct
size (Spearman R coefficient=0.72, p<0.05)
A similar categorisation of data into Tele+ve or Tele-ve, based on the position in the distribution
of telemetry derived arrhythmia score also revealed a significant difference in infarct size between
the two groups, with Tele+ve hearts having significantly larger infarct size compared to Tele-ve
hearts (n=6 in both groups, 8.8 ± 2.5 vs. 1.1 ± 0.7 %, p<0.05, Figure 4.11).
No correlation existed between either the number of VPBs or arrhythmia score from telemetry
and the arrhythmia score on ex vivo PES (Spearman R coefficient=0.37, p=0.12), suggesting
the two modalities reflect different characteristics of the arrhythmia phenotype.
No correlation existed between QRS duration and infarct size, the number of VPBs or arrhyth-
mia score from telemetry or the arrhythmia score on ex vivo PES.
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Figure 4.9: Representative Massons Trichrome histological sections from (top) apex to (bottom)
base at 2mm intervals for (A) Sham-operated, (B) 30-minute occlusion and (C) 60-minute
occlusion groups. Red asterisks highlight areas of blue (collagen) staining representative of
scarred myocardium post-infarction.
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Figure 4.10: (A) Increase in infarct size (area-based method) for hearts undergoing 60 minutes
of infarction-reperfusion compared to sham operated. (B) Increased infarct size on calculation
using length-based method over area based method for n=3 hearts with thin, transmural in-
farction and (C) Slice-by-Slice increase in infarct size for each heart. Sham = sham-operated
n=3, 30’ = 30 minute occlusion n=6, 60’ = 60 minute occlusion n=6. ∗ p<0.05
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Figure 4.11: Relationship between Infarct Size (%) and Arrhythmia Phenotype; (Left) Ex vivo
PES Arrhythmia Score and (Right) In vivo Telemetry Arrhythmia Score
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4.4 Discussion
A series of in vivo and ex vivo methodologies were used to characterise the arrhythmia and
structural phenotype of the reperfused infarct and describe the electrophysiological modelling
and inform the duration of infarction, prior to reperfusion, in studies of pharmacological gap
junction enhancement (Chapter 6).
4.4.1 Reperfused Myocardium as an Arrhythmic Substrate
ECG parameters were similar between all groups, with the exception of a longer QRS interval in
the 60-minute occlusion group, which did not correlate with either infarct size, susceptibility to
programmed arrhythmias or incidence of spontaneous arrhythmias on ECG telemetry. Reports
of ECG parameters in healed infarcts are conflicting, attributed to the variation in experimental
technique and animal strain and sex used. The prolonged QRS interval in longer duration
infarction is in agreement with the vectorcardiography study of Tseng et al. (Tseng et al.
1995), but not with the study of Santos et al. (Santos et al. 1991) or Miranda et al. (Miranda
et al. 2007), all of which used a permanent occlusion model of infarction. The RR, PR and QTc
intervals measured are in agreement with published values using the same strain, sex and weight
of the study by Fernandes (Fernandes et al. 2006), that also demonstrated no alterations in
ECG parameters between sham-operated and infarcted animals. The prolonged QRS duration
is of uncertain significance, and may be as a result of infarct or ECG-lead position, with no
predictive value in describing the arrhythmia phenotype or the degree of structural remodelling.
There were clear differences in susceptibility to programmed arrhythmias between sham-operated
hearts and those undergoing infarction-reperfusion, independent of infarction duration. In both
reperfusion groups, the incidence of sustained VT induced by a triple extrastimulus protocol was
comparable to the 29% reported by Mills et al.(Mills 2005) in a permanent occlusion model and
the 35% reported by Ding et al.(Ding et al. 2010) in a 25-minute occlusion model. Interpreting
the results and significance of induced arrhythmias from PES protocols requires appreciation
of the sensitivity and specificity of different pacing protocols and experimental preparations.
In murine electrophysiological studies, Maguire et al. (Maguire et al. 2003) demonstrated that
VT was inducible in 30% of wild-type mice with significant differences due to age and strain-
differences. In addition, the use of an aggressive pacing protocol with burst pacing and very
short extrastimuli cycle-lengths resulted in higher inducibility of VT (11% inducible on triple
extrastimulus pacing vs. 27% inducible on burst pacing). These limitations have also been ap-
preciated in clinical electrophysiological studies with an increase in the number of extrastimuli
from one to three resulting in an increased sensitivity (lower false negative rate) but reduced
specificity (higher false positive rate) in determining whether a substrate is arrhythmogenic
and susceptible to spontaneous arrhythmias and/or sudden arrhythmic death (Buxton et al.
1984). Re-entry is the primary mechanism of PES induced arrhythmias (Wellens 1978), and,
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coupled with the positive association between infarct size and PES, suggests that the reperfused
substrate provides the conditions necessary (fixed or functional unidirectional block, conduc-
tion slowing), for re-entry arrhythmias to sustain. The positive correlation between infarct size
and arrhythmia susceptibility is in agreement with the MRI study of Bello et al. (Bello et al.
2005), that showed a significant correlation between infarct surface area and mass determined
by deMRI and inducibility of monomorphic VT in patients post-MI.
At the end of the healed phase of infarction, the incidence of spontaneous arrhythmias was
shown to be significantly higher in hearts subject to infarction-reperfusion surgery, compared
to sham, although the total number of ventricular premature beats was substantially lower
when compared to permanent occlusion models studied at a similar time point or infarction-
based heart failure models studied at 16-weeks (Lyon et al. 2011). Possible explanations for
this reduced incidence likely reflect the extent and severity of remodelling that occurs in per-
manent occlusion models which have increased infarct size and, as time progresses, devel-
opment of the heart failure phenotype and abnormal Ca2+ handling with increased delayed
after-depolarisations and triggered activity.
4.4.2 Electrophysiological Remodelling of Reperfused Myocardium
Neither the sham-operated or 30-minute occlusion group demonstrated an epicardial bor-
der zone on visual inspection prior to optical mapping or on subsequent histology. As two
groups they were identical with regards to epicardial local conduction velocity, APD, CaTD,
AP and Ca2+ upstroke kinetics, however, they differed with respect to the presence of mid-
myocardial, non-transmural infarction and susceptibility to programmed arrhythmias in the
30-minute group only. These phenotypic differences can not be explained by the observed op-
tical AP and optical Ca2+ data. It is possible that due to lack of dye penetration or photon
scattering of emitted light, the 3D volume of tissue imaged may contain only healthy, viable
myocardium, not underlying infarcted myocardium, resulting in the appearance of apparent
‘normal’ epicardial conduction and transient characteristics. Acquiring data during atrial pac-
ing or intrinsic rhythm may help reveal conduction abnormalities owing to the presence of
patchy mid-myocardial infarction resulting in slowed conduction which may reveal itself as
patchy epicardial breakthrough.
In the 60-minute group, all hearts with a visible epicardial border zone demonstrated conduc-
tion slowing at the infarct border zone, but none demonstrated fixed conduction block during
baseline pacing. The local CV of 72cm/s in the remote region for all hearts is similar to the CV
of 70cm/s reported in the 25-minute model of infarction-reperfusion by Ding et al. (Ding et al.
2010), and, the reduction in CV of 59% at the IBZ is in-keeping with their 53% reduction and
the 40% reduction demonstrated by Mills et al. (Mills 2005). The slowing of conduction velocity
is likely due to a reduction in GJ coupling and the 40% reduction in dFdTmax, at the IBZ and
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infarct, presumably owing to reduced influx of the fast sodium current (INa) (Shaw et al. 1997)
although alterations in upstroke kinetics detected by optical imaging are susceptible to partial
volume effects. Despite this reduction in dFdTmax and ensuing conduction slowing, no hearts
with visible epicardial border zone demonstrated fixed conduction block during baseline pacing.
Significant changes in APD or CaTD were not seen at the IBZ but a prolonged APD50, without
alterations to the Ca2+ transient did occur in the infarct region. The prolongation of APD50
only was also demonstrated by Ding et al.(Ding et al. 2010), although their measurements were
performed only at the infarct border zone, not in the infarct owing to poor signal quality and re-
duced SNR. The presence of good quality optical signals in the infarct region suggests that dye
uptake in this area was satisfactory, owing to the presence of an open coronary artery, lending
support to the validation of this as a model of reperfusion. Absolute APD duration is pacing
dependent, with values similar to those reported by Ding et al. (Ding et al. 2010), although
shorter than those reported by Mills et al. (Mills 2005). Possible reasons include the use of a
different excitation-contraction uncoupler, 2,3-butanedione monoxime, which has been shown
in small animal optical mapping studies to artificially lengthen the APD (Baker et al. 2000),
and a prolonged period of cardioplegic arrest (20 minutes) for dye-loading prior to Langendorff
perfusion. The pattern of APD distribution with preservation in the IBZ and prolongation
in the infarct is in-keeping with reported patterns in the healing canine infarct (Ursell et al.
1985), although it is prudent to acknowledge that ion channel remodelling appears to occur in a
dynamic, species-dependent fashion and comparing and extrapolating results should be treated
with caution.
In addition to changes in static electrophysiological parameters (conduction velocity and APD
at fixed cycle length pacing), an additional mechanism that may contribute to arrhythmogenesis
concerns the properties of the APD restitution curve. The restitution curve describes the
relationship between APD and preceding diastolic interval and is measured by decremental
pacing until the effective refractory period of the tissue is reached. By plotting APD against
diastolic interval a tangent can be fit to the curve, with a steepness of >1 indicating an increased
predisposition to arrhythmogenesis owing to increased wavebreak promotion (Cao et al. 1999
Weiss et al. 2002). Reducing the steepness of the restitution curve (i.e. flattening) has been
hypothesised to reduce wavebreak and thus reduce the onset of VF (Garfinkel et al. 2000).
Alterations in the restitution curve are of particular interest at the infarct border zone where
both ionic and structural remodelling occurs. Modelling studies of myocytes at the infarct
border zone with remodelled INa and ICa currents, based on validated post-MI canine exper-
imental work, demonstrates abnormal APD restitution properties with prolonged refractory
period and increased APD dispersion resulting in conduction block at the border zone (Decker
et al. 2010). Similar results have been demonstrated using a human infarct border zone model.
APD dispersion is well recognised as a key mechanism for promoting arrhythmogenesis in both
experimental (Kuo et al. 1983) and cellular models of infarction (Krogh-Madsen et al. 2007).
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Although not specifically examined in the studies described in this thesis, the experimental
protocol employed could be readily adapted to allow for examination of the APD restitution
curve. Pacing at a cycle length above the intrinsic rate of the myocardium and then decremental
pacing by 20ms (for two minutes at each cycle length) until the refractory period is reached
would allow for measurement of APD 50, APD75 and APD90 at each cycle length on a region-
by-region basis allowing restitution curves to be plotted. From each curve the steepness of the
tangent to the curve could be calculated which could then be compared against the results from
both programmed and spontaneous measures of arrhythmogenicity.
4.4.3 Structural Remodelling of Reperfused Myocardium
Structural remodelling, in the form of collagen deposition as a result of infarction-reperfusion
was greater in the 60-minute occlusion group, compared to 30-minute and sham-operated.
Infarct size was significantly greater in this group with a larger proportion of infarcts demon-
strating transmural extension, wall thinning and infarct dilatation.
Infarct size was dependent on the method used to calculate infarct size with the length-based
method producing values up to 50% higher than the area-based method. In the mouse perma-
nent occlusion study of Takagawa (Takagawa et al. 2007), systematic calculation of infarct size
revealed a mean area-based measurement of 12.1% compared to a length-based measurement
of 30.1% with compression of the range of values 0.4-fold, similar to the 0.3-fold compression
presented in this chapter. The variation between length-based and area-based methods of cal-
culating infarct size has been attributed to the combination of loss of myocyte volume and
thinning that occurs in the infarct region as collagen replaces infarcted myocardium and the
increase in the volume of remote myocardium due to compensatory hypertrophy as remodelling
progresses. Although the magnitude of difference in the effect between the two methods is
greatest in permanent occlusion models, owing to reproducible thinning and dilatation of the
infarct region, the difference still exists in the reperfusion model, although to a lesser extent. In-
farct size in 30- and 60-minute groups calculated using the area-based method was comparable
with reported values (Ieishi et al. 2007; Ding et al. 2010), and, as expected, lower than reported
values in longer duration (90-minutes) or permanent occlusion models (Hochman et al. 1987b).
The description of the infarct morphology with patchy, non-transmural extension occurring in
both 30- and 60-minute groups and reduced wall thinning and dilatation of the infarct zone is
also supported by previous infarction-reperfusion studies (Hale et al. 1988).
4.4.4 Summary
The studies described in this chapter defined the arrhythmia and structural phenotype of an
in vivo model of infarction-reperfusion. Both durations of infarction (30 and 60 minutes)
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resulted in a model with a significant incidence of spontaneous arrhythmias, and susceptibility
to programmed arrhythmias, when studied at the end of the healing phase. A longer duration of
infarction prior to reperfusion resulted in a larger infarct size, with greater transmural extension,
in keeping with both previous experimental studies and more akin to the pathophysiology and
remodelling seen in clinical studies of reperfused infarction. The presence of an epicardial
border zone enabled the remodelling of the AP and Ca2+ transient to be studied in more detail,
revealing slowed conduction at the IBZ with abnormal upstroke kinetics (reduced dFdTmax and
prolonged rise time) and prolongation of APD50 and increased APD50 dispersion in the infarct
region. Hearts with sub-epicardial (non-transmural) infarction, did not demonstrate significant
AP or Ca2+ transient remodelling with preservation of epicardial conduction velocity but did
share the arrhythmia phenotype of hearts with transmural extension. A positive correlation was
demonstrated between susceptibility to programmed arrhythmias and infarct size, suggesting
that a sufficient mass of infarcted tissue is necessary to sustain re-entry arrhythmias.
The principle aim of the studies described in this chapter was to characterise a small-animal
model of infarction-reperfusion, which mimics, where possible, the pathophysiology and histol-
ogy that occurs in clinical practice. In addition, testing the potential efficacy of a pharmaco-
logical agent that may either reduce the incidence of arrhythmias or reduce infarct size requires
the initial model to have a sufficient incidence of arrhythmias and substantial infarct size so
as to be able to detect significant differences. For these reasons, the 60-minute duration model
was chosen as the most appropriate model for studies of the effects of enhancing GJ coupling
(Chapter 6).
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Chapter 5
Probing Structural Remodelling
post-MI with Diffusion MRI
5.1 Overview
This chapter details the background, methods and results of studies performed in developing
and applying diffusion tensor MR imaging (DTI) to the study of structural remodelling in
reperfused myocardium.
The principles of magnetic resonance imaging, specifically diffusion MR imaging will be ex-
plored, with particular emphasis given to the pulse sequences used to apply diffusion sensitisa-
tion. Then follows a review of current cardiac applications of DTI and the rationale, methods
and results of the initial pilot study. Finally the limitations encountered after the pilot study
and the subsequent methods and results of the fast spin echo sequence validation will be de-
tailed.
The initial DTI pilot and validation was performed in collaboration with physicist Dr. Josef
Habib, at the Biological Imaging Centre, Hammersmith Hospital, Imperial College London
between April 2012 and February 2013. Following closure of the Biological Imaging Centre
in February 2013, further imaging studies (Section 5.7 and Chapter 6) were performed in
collaboration with Prof. A. Shah and physicist Dr. Andrea Protti at the Preclinical Imaging
Unit, Kings College London.
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5.2 Principles of Magnetic Resonance Imaging
5.2.1 MRI Components
The basic electromagnetic components required for a MRI system are a set of main magnetic
coils, three gradient coils and an radiofrequency transmitter and receiver coil. The flow of
electrons through the coils acts to produce a magnetic field in each.
The main magnetic field is generated by current flow through the main magnetic coil and is
orientated along the z-axis of the scanner, termed b0, with units in Tesla (T). Clinical MR
scanners commonly use a field strength ranging from 0.5-3T, compared to the pre-clinical
scanners used in this thesis which possessed a field strength of 7T and 9T.
The gradient coils act on top of the b0 field in the x, y and z direction to modulate the strength
of the b0 field in the direction specified by any combination of the three coils.
The final coil; the radiofrequency coil, sits closest to the patient or sample and is of smaller
amplitude compared with the main and gradient coils but oscillates at a frequency in the
megahertz range and transmits energy for a short period of time, termed an RF pulse. In order
for this RF pulse to efficiently transfer energy to the protons, the frequency must match that
of the precessional frequency of the protons.
5.2.2 Magnetic Resonance
Signal in most MR images is generated from probing the magnetic resonance properties of the
H+ proton which is found in abundant quantities in water and fat. Each individual H+ proton
has it’s own intrinsic nuclear spin that generates a small magnetic field. Placing a H+ rich
sample inside the bore of a MRI scanner causes a change in the random orientation of nuclear
spins so that protons are either aligned towards or away from the main magnetic field. For
reasons of energy conservation, there is a preference of spins to be aligned in the direction of
the b0 field and this generates a net magnetisation (termed M0).
Precession is the term used to describe the spinning of protons about their axis. The Larmor
equation governs the relationship between the frequency of precession (f, how many times the
protons spin), the main magnetic field strength (B0) and a constant termed the gyromagnetic
ratio (γ, for H+ ions = 42.6 MHz/T)
f = γ ×B0 (5.1)
To generate an MR image the first step is to apply a RF pulse (at Larmor Frequency of the
H+ proton) which causes the net magnetisation (M0) to move away from the z axis and begin
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precessing at the Larmor frequency. This rotation can be split into a longitudinal (Mz) and
transverse (Mxy) component, both of which are examined in turn.
5.2.3 Relaxation Effects
If a RF pulse is applied and flips the magnetisation through 90o the longitudinal component of
magnetisation is transiently zero and the transverse component is maximal. After the RF pulse
is turned off, protons begin to return to their equilibrium state (aligned with b0). Conceptually
this can be split into two relaxation processes; that occurring along the longitudinal axis and
that occurring in the transverse plane.
5.2.3.1 T1 Relaxation
Longitudinal relaxation, also termed T1 relaxation, describes the exponential recovery of mag-
netisation in the z-axis direction, which, in the case of a 90o pulse, had been reduced to zero.
The time taken for longitudinal magnetisation to recover to 63% of equilibrium is termed the
T1 time constant or T1 relaxation time. This time is determined by the rate of energy exchange
between protons and surrounding tissues (‘spin-lattice‘ relaxation), which in turn is determined
by molecular size and motion.
5.2.3.2 T2 Relaxation
Tranverse relaxation, also termed T2 relaxation, describes the decay in magnetisation that
occurs in the x-y axis, usually at a much faster rate than T1 relaxation. Immediately after the
application of a 90o RF pulse, the transverse magnetisation is maximal and spins are said to
be in phase (they precess in the same direction). However, as soon as the RF pulse is removed,
spins begin to dephase owing to the random interaction between the small magnetic fields of
neighbouring protons which causes random fluctuations in the Larmor frequency and subsequent
loss of phase. This spin-spin relaxation and loss of magnetism occurs in a random exponential
manner with the time taken to decrease to 37% of maximal magnetisation termed the T2 time
constant (T2 relaxation time). As the determinant of T2 relaxation is spin-spin interaction
only, water, in which molecules are widely spaced, has less frequent spin-spin interaction and
a longer T2 relaxation time compared to other tissues e.g. muscle which has tightly packed
molecules with frequent spin-spin interaction and hence a shorter T2 relaxation time.
5.2.3.3 T2* Relaxation
In addition to spin-spin interaction, spins also dephase owing to magnetic field inhomogenities,
chemical shift effects and susceptibility effects. These effects are static over time and follow a
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spatial distribution so that the Larmor frequency, and hence the rate of precession, will vary at
different locations within the magnetic field. The time taken for the transverse magnetism to
decrease to 37% of maximal magnetisation owing to the combined effect of spin-spin relaxation
and all other forms of dephasing is termed the T2* time constant (T2* relaxation time) and is
always shorter than the T2 relaxation time.
The oscillating decay of transverse magnetism owing to T2* effects is termed the free induction
decay (FID), which, although measurable, decays rapidly and experiences further dephasing
as a result of spatial encoding. The more commonly measured MR signal takes the forms of
echoes, generated by using a specific pulse sequence of which spin-echo and gradient-echo are
the most common.
5.2.4 Pulse Sequences
Different tissues, owing to differences in H+ density, size and interaction with the molecular
structure of the tissue possess different T1, T2 and T2* relaxation times. By altering the pulse
sequence (the timing and order of the application of RF pulses and gradient pulses) and altering
the echo time (TE) and/or repetition time (TR) the sensitivity or weighting of an acquisition to
a specific relaxation time can be probed. For example, using a long TE and a long TR results
in a T2 weighted image as the long TE maximises the amount of signal from T2 relaxation and
the long TR minimises the amount of signal from T1 relaxation.
5.2.4.1 Spin Echo
Spin echo sequences, originally described by Hahn (Hahn 1950), generate an echo using an
additional 180o refocusing RF pulse (Figure 5.1). This 180o pulse, applied at half the time to
echo (TE), reverses the polarity of dephased spins. As the effects of spin-spin interaction are
random, the refocusing pulse has no effect on dephasing due to T2 relaxation, but, as static
field inhomogeneities (T2* effects) remain fixed, spins experience the same dephasing but this
time in the opposite direction, i.e. they become rephased. This rephasing is maximal at TE
(provided the refocusing pulse was applied at TE/2) and the echo generated represents T2
relaxation only.
5.2.4.2 Gradient Echo
Unlike spin echo sequences, gradient echo (also called gradient-recalled echo) do not use a
refocusing pulse to generate an echo. Instead, magnetic field gradients are applied along a
specific direction, resulting in a change in Larmor frequency and dephasing of spins along the
direction of the applied gradient with rapid FID decay. Shortly after, application of a second
gradient in the same direction but opposite polarity, reverse the dephasing and leads to recovery
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Figure 5.1: Spin echo pulse sequence diagram showing timing of RF and gradient pulses. RF
= Radiofrequency excitation pulse, ADC = Analog-to-digital converter. G = Gradient. TR =
Repetition time, TE = Echo time. Reproduced from Pooley (Pooley 2005)
of the FID and generation of an echo (Figure 5.2). Unlike spin echo, the transverse decay of
the signal is determined by T2*.
Figure 5.2: Gradient echo pulse sequence diagram showing timing of RF and gradient pulses.
RF = Radiofrequency excitation pulse, ADC = Analog-to-digital converter. G = Gradient.
Reproduced from Pooley (Pooley 2005)
5.2.5 Image Reconstruction
5.2.5.1 Spatial Encoding
To localise the MR signal in three dimensions a series of gradient pulses are applied in sequence,
termed spatial encoding. The first gradient pulse, the slice select gradient is applied at the same
time as the RF excitation pulse and ensures that only protons within a defined bandwidth (range
of frequencies) are excited. The second gradient pulse, the phase encoding gradient is usually
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applied along the y-axis resulting in a change in magnetic field strength which causes precession
to either increase or decrease in frequency relative to the position along the gradient. The final
gradient pulse, the frequency encoding gradient, also termed the readout gradient, is applied
at right angles to the phase encoding gradient and again causes a change in precession relative
to proton position along the gradient.
5.2.5.2 Signal Readout & k-Space
The MR signal is readout during application of the frequency encoding gradient in a composite
form representing all frequencies of the signal. Spatial encoding is then repeated with an
increase in the strength of the phase encoding direction and another echo measured. The time
between repetitions is termed repetition time (TR).
MR signals are digitised and stored in a two-dimensional Fourier space termed k-space with x
and y axis units in spatial frequencies (Mezrich 1995). Different spatial frequencies represent
different contribution to reconstructed image quality. Low spatial frequencies (near the centre
of k-space) contribute signal content and contrast whereas high spatial frequencies (near the
edge of k-space) contribute fine detail of the image. The entirety of k-space needs to be filled
before undergoing a 2D Fourier Transform (Fourier et al. 1878) to reconstruct the final image.
Typically k-space is filled by multiple repetitions in the phase-encoding direction, with each
repetition filling a line of k-space.
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5.3 Principles of Diffusion MRI
5.3.1 Concept of Molecular Diffusion
Molecular diffusion refers to the random movement of molecules as a result of thermal en-
ergy, termed ‘Brownian Motion’, first described by Einstein (Einstein 1926). He demonstrated
that in an unrestricted medium, movement of molecules followed a three-dimensional Gaussian
distribution, with the distance travelled by a molecule per unit of time determined by a diffu-
sion coefficient, dependent on the mass of the molecule, and viscosity and temperature of the
medium.
Water, owing to the abundance of H+ ions and the widespread distribution in biological tis-
sue is an attractive molecule to study with diffusion MRI. However, in biological tissue, water
molecule displacement rarely follows the described Brownian path and Gaussian probability
distribution, owing to the presence of cell walls, internal cell structures and other molecules, all
of which restrict free diffusion (Le Bihan 2003). Such alterations result in changes to the three-
dimensional diffusion distribution profile, of varying complexity, reflecting the underlying tissue
architecture. A well described change in the diffusion distribution profile from spherical (unre-
stricted Gaussian diffusion) to cigar shaped, occurs in neuronal and cardiac tissue due to the
fibrillar nature resulting in preferential diffusion parallel and hindered diffusion perpendicular
to the orientation of the fibrils (Hagmann et al. 2006).
5.3.2 Diffusion Sensitisation
Although the effects of diffusion on precession of H+ protons were noted in the 1950s (Carr et al.
1954) it wasn’t until the seminal work of Stejskal and Tanner in 1965 (Stejskal et al. 1965) that
laid the foundations of the MR techniques still use in today. Building on the concept of spin-
echoes outlined by Hahn (Hahn 1950), they inserted two time-dependent diffusion-sensitising
gradients, acting in the same direction, either side of the 180o refocusing pulse of a T2-weighted
spin-echo sequence. The first of these gradient pulses induces a change in phase of the spins,
which, if there has been no translational motion (diffusion) results in perfect rephasing when
the second gradient pulse is applied. However, if there has been motion between the first and
second gradient pulses, then the resultant imperfect phasing results in signal loss. This diffusion
encoding is represented by the Stejskal-Tanner equation:
Si = S0 × e(−b×ADCi) (5.2)
Where for a single voxel Si equals the diffusion weighted signal, S0 equals the signal inten-
sity without diffusion sensitisation (T2 weighted signal) and ADCi is the apparent diffusion
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coefficient in the i direction. The b factor, also termed b-value is a scalar value representing
the properties of the gradient applied and can be written in terms of |G|, the strength of the
gradients, ∆ the separation time between the onset of the first and second gradient pulse, δ the
duration of the gradient pulse and γ, the gyromagnetic ratio of H+.
b = γ2 × |G|2 × δ2(∆− δ
3
) (5.3)
Application of a single diffusion gradient acts only to measure diffusion along the direction of
the gradient, hence diffusion-sensitisation is commonly applied along a combination of the x,y
or z directions so as to sample the three-dimensional distribution of diffusion that occurs in
biological tissues (Mukherjee et al. 2008).
5.3.3 Diffusion MR Pulse Sequences
Any MR pulse sequence can be sensitised for diffusion by application of two magnetic field
gradient pulses with the correct polarity and timing. In the studies described in this thesis
two sequences were used; both sensitised diffusion by means of using a spin echo sequence but
differed in the readout of MR signal. The sequence used at Imperial College was a spin-echo
sequence with multi-shot echo planar imaging (EPI) readout, whereas the sequence used at
Kings College was a fast-spin echo sequence.
5.3.3.1 Fast Spin Echo
Conventional spin echo sequences acquire only one phase-encoding step, fill only one line of
k-space per repetition time, and suffer from long acquisition times (equal to number of phase-
encoding steps multiplied by TR). Fast spin echo (FSE) , developed in the 1980s (Hennig et
al. 1986), uses multiple 180o refocusing pulses after the initial 90o pulse to generate multiple
echoes (termed echo trains). By applying a different phase encoding to each echo, another line
of k-space can be filled during one TR period and total acquisition time is reduced. A typical
fast spin echo pulse sequence is shown in Figure 5.3.
The FSE pulse sequence, similar to other spin echo sequences, can be sensitised to diffusion by
the addition of two diffusion gradients, of equal polarity, either side of the refocusing pulse.
5.3.3.2 Echo Planar Imaging
Echo planar imaging, developed by Mansfield in the late 1970s (Mansfield 1977; Mansfield et al.
1978) remains one of the fastest, most widely used MRI sequences (Poustchi-Amin et al. 2014).
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Figure 5.3: Fast spin echo pulse sequence diagram with echo train length (ETL) of four. rf
= Radiofrequency pulses, slice/phase/read = spatial encoding gradients. Reproduced from
Pohmann (Spatial Encoding - Basic Imaging Sequences from Schro¨der et al. 2011)
Unlike conventional spin-echo sequences which acquire one line of k-space in one repetition
time, EPI acquires multiple lines of k-space after a single RF excitation. This is achieved by
applying a rapid-oscillation (from positive to negative amplitude) of the frequency encoding
gradient to produce a train of gradient echoes and phase-encoding each echo by the application
of a brief phase-encoded gradient (blip). The oscillation in the frequency-encoding direction
fills one line of k-space and the phase-encoded blip transitions to the next line in k-space; this
results in the sampling of the entirety of k-space during one acquisition. Not all MR scanners
are capable of performing EPI acquisition owing to the hardware configuration required with
gradients necessitating rapid switching, large amplitudes and higher duty cycles (% of time on
during TR cycle) in comparison to conventional spin-echo sequences.
The sampling of k-space in one acquisition is termed single-shot EPI but is limited to coarser
matrix sizes, magnetic field inhomogeneities and image distortion or signal loss owing to suscep-
tibility artefacts. To circumvent these artefacts, k-space can be sampled in multiple acquisitions,
termed multi-shot EPI, which, although takes a longer time to acquire, places less stress on the
gradients and is less sensitive to phase errors. A single shot gradient-echo EPI pulse sequence
is shown in Figure 5.4.
As EPI affects only the readout, it can be sensitised to diffusion in the same manner as a
standard spin-echo or gradient-echo sequence by the placement of diffusion gradients either
side of the refocusing pulse (of equal polarity) in a spin-echo EPI sequence or of opposite
polarity in a gradient-echo EPI sequence (Turner et al. 1991).
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Figure 5.4: Pulse sequence diagram for single shot EPI pulse sequence. rf = Radiofrequency
pulses, slice/phase/read = spatial encoding gradients. Reproduced from Pohmann (Spatial
Encoding - Basic Imaging Sequences from Schro¨der et al. 2011)
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5.4 Diffusion Imaging Techniques
The described diffusion-sensitised sequences are only sensitive to diffusion that occurs along the
single direction applied by the diffusion gradients. Appreciating the three-dimensional nature of
the diffusion distribution profile in biological tissue necessitates the need to measure diffusion in
multiple directions, for which several different imaging techniques exist (Hagmann et al. 2006).
5.4.1 Diffusion Weighted Imaging
The simplest form of diffusion imaging, diffusion weighted imaging (DWI) is the output of a
single acquisition with the application of a diffusion gradient pulse in one direction only. The
resultant image provides a crude overview of the properties of diffusion in the tissue in a single
direction, although large changes in diffusivity, such as those seen in acute ischaemic stroke are
easily visible (Roberts et al. 2003).
Diffusion weighted imaging has the advantages of a fast, well tolerated, acquisition (as only one
direction is sampled) and images require no post-processing.
5.4.2 Apparent Diffusion Coefficient
In the simplest form of three-dimensional diffusion imaging, the diffusion distribution is assumed
to be a free isotropic Gaussian model i.e. equal in all directions. In this model the apparent
diffusion coefficient (ADC) can be calculated by re-arranging the Stejskal-Tanner equation to
yield
ADCd =
1
bd
. ln
(
S0
Sd
)
(5.4)
Where ADCd is the ADC in the diffusion direction d, Sd is the signal intensity in an image
without diffusion sensitisation (the b0, T2-weighted image), Sd is the signal intensity in the
image with diffusion sensitisation applied in direction d and bd is the b-value applied.
By measuring the ADC in three orthogonal directions, the ADC trace can be calculated by
averaging the three to give a value of the degree of (isotropic) diffusion in tissue.
5.4.3 Diffusion Tensor Imaging
The diffusion tensor is a more sophisticated method of displaying the diffusion distribution
profile in three dimensions and importantly, allows for anisotropy, as found in biological tissue.
First described in the early 1990s by the work of Basser (Basser et al. 1994a; Basser et al. 1994b),
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diffusion tensor imaging (DTI) continues to be used in present day clinical and experimental
studies (Mori et al. 2006).
In considering an anisotropic, Gaussian distribution of diffusion, a total of six diffusion di-
rections must be sampled to build the diffusion profile (Shrager et al. 1998), compared to the
three for calculation of the ADC trace. The diffusion coefficient in the Stejskal-Tanner equation
now needs to represented by a tensor D, which is a mathematical construct that defines the
properties of an ellipsoid in 3-D space:
D =
Dx,x Dx,y Dx,zDy,x Dy,y Dy,z
Dz,x Dz,y Dz,z
 (5.5)
D is a symmetric covariance matrix with the diagonal elements (Dxx, Dyy, Dzz) representing the
diffusion variances in the x, y and z directions and the off-diagonal elements (Dxy = Dyx, Dxz
= Dzx,Dzy = Dyz) representing the symmetrical covariances. These six independent elements
of the diffusion tensor can be found using a linear least squares method of fitting the diffusion
co-efficients (ADCd) from each of the six diffusion gradients probed (Basser et al. 1994a).
Diagonalisation of D, generates three eigenvalues (λ1, λ2, λ3)and three eigenvectors (e1, e2, e3)
which allows for visualisation of the 3-D diffusion profile in ellipsoid form with the direction of
the axes defined by the eigenvectors and the radii of the axes defined by the eigenvalues.
The relationship between the eigenvectors describes the characteristics of the tissue. Several dif-
fusion generated metics have been proposed, of which mean diffusivity and fractional anisotropy
are the most commonly used (Le Bihan et al. 2001).
Mean diffusivity (MD) is an invariant (not dependent on orientation) measure of the overall
diffusion within a voxel, principally affected by cellular size and integrity (Pierpaoli et al. 1996).
MD =
λ1 + λ2 + λ3
3
(5.6)
Fractional anisotropy (FA) is a normalised, scalar measure of the degree of anisotropy within
a voxel with a sphere having an FA of 0 and unidirectional tissue having an FA approaching 1
(Basser et al. 1996).
FA =
√
1
2
√
(λ1 − λ2)2 + (λ2 − λ3)2 + (λ3 − λ1)2√
λ21 + λ
2
2 + λ
2
3
(5.7)
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5.5 Cardiac Applications of Diffusion MRI
The initial work in applying clinical diffusion MRI focused on neuroradiology applications,
specifically imaging of ischaemic stroke, demyelination, neoplasia and white matter tractogra-
phy (Alexander et al. 2007).
Early cardiac applications of diffusion MRI focused on validation of the technique and in prob-
ing the three-dimensional laminar structure of myocardium. Detailed histological and imaging
studies of rabbit (Scollan et al. 1998; Holmes et al. 2000) and canine (Hsu et al. 1998) my-
ocardium confirmed the correlation between orientation of the primary eigenvector and fibre
orientation, and provided the basis for the concept of helix and inclination angles to describe
the myocardial architecture (Geerts et al. 2002; Helm et al. 2005).
Remodelling of the infarct region post-MI has been characterised with diffusion MRI (specifi-
cally DTI) in a range of experimental (Chen et al. 2003; Wu et al. 2011) and clinical (Wu et al.
2009; Wu et al. 2006a) studies. The majority have shown FA to decrease (i.e. fibre architecture
becomes more disordered and less anisotropic) in infarcted regions (Chen et al. 2003; Wu et al.
2006b; Wu et al. 2007a) and in regions adjacent to the infarct (Wu et al. 2007a), in contrast
to the findings of Stijkers et al. (Strijkers et al. 2009) that showed an increase in FA post-MI,
attributed to the structured nature of collagen fibres. Mean diffusivity has been shown to in-
crease in infarcted regions (Chen et al. 2003; Wu et al. 2007a; Wu et al. 2009) attributed to
cell necrosis, oedema and loss of cellularity.
In addition to quantifiable measures of fibre orientation and architecture, fibre reconstruction
(tractography) has been developed to provide three dimensional structural information and
visualisation on a whole-heart level in both normal (Schmid et al. 2005; Wu et al. 2007b;
Sosnovik et al. 2009c and pathological (specifically infarction and hypertrophic cardiomyopathy)
states (Sosnovik et al. 2009b; Wang et al. 2010)
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5.6 Pilot DTI Study
5.6.1 Rationale
Prior to the studies described in thesis, no diffusion MRI small-animal cardiac imaging studies
were undertaken at Imperial College. The aim of developing DTI was to allow, as described in
the literature, for non-destructive quantitative measurements of myocardial architecture and
organisation, and, to determine whether any of these can be used as signatories of arrhythmic
risk. In order to achieve this several important sequential steps needed to be performed; a
diffusion sensitising pulse sequence needed to be applied, tested for feasibility and any artefacts
addressed; tissue handling needed to be optimised to maximise SNR and image quality and
the underlying biological processes that were being measured needed to be quantified by a
gold-standard method to allow direct comparison with DTI derived metrics.
5.6.2 Methods
All studies described in this section were performed in collaboration with Dr. Josef Habib at
the Biological Imaging Centre, Hammersmith Hospital, on a 9.4T Varian MR Scanner with
100G/cm gradient coils controlled with VNMRJ 3.2.
5.6.2.1 Feasibility
In assessing the feasibility of performing DTI, an infarcted (see Section 2.3.3) and a non-
infarcted (control) heart were explanted from two male Sprague-Dawley. Hearts were perfused
using a Langendorff apparatus with buffered Krebs-Henseleit solution to flush excess blood from
the capillaries and ventricular cavities before being perfusion fixed with 10% neutral-buffered
formalin solution. Immediately prior to scanning hearts were embedded in low melting point 2%
agarose in a 20cc NMR compatible plastic tube before being placed in the 33mm RF quadrature
coil.
After placing the sample inside the scanner, a pulse frequency and power calibration was per-
formed, the magnetic field shimmed and the coil tuned and matched (see Section 2.7.4). The
slice plan was created and scanning performed using a diffusion sensitised spin-echo sequence
with multi-shot EPI readout with the following parameters: TR = 2500ms, TE = 19.96ms
(minimum), number of shots = 4, NSA = 6, diffusion encoding scheme = Jones 30, b-value
= 1000, |G| = 26.98, ∆ = 9ms, δ = 5ms, data matrix = 128x128, FOV = 25.6x25.6mm, slice
thickness = 0.5mm, slice gap = 0mm. A total of 33-37 slices covered the entire heart with an
effective pixel resolution of 200x200x500µm. Scan time for six averages was 110 minutes, with
all scans performed at room temperature (19oC) with no change in temperature between the
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start and end of the experiment. Following scanning, hearts were removed from agar and un-
derwent histological staining (see Section 2.8). MR Data were visually inspected in real-time to
ensure adequate SNR and application of diffusion-sensitising gradients before being exported,
converted to NifTi format and an attempt made to fit the diffusion tensor and generate FA and
MD maps as described in Section 2.7.5.
5.6.2.2 Sample Preparation
Ensuring adequate image quality and preserving the underlying myocardial architecture were
addressed as part of the initial work in establishing DTI. Several steps were taken to ensure
sufficient penetration of fixative and adequate preservation of the tissue. Immediately after
Langendorff perfusion, hearts were perfusion fixed with 100mls of 10% Neutral Buffered For-
malin (NBF) at a rate of 10mls/minute to ensure that myocytes in the centre of the tissue (i.e.
those in the distribution of the coronary arteries), where fixative penetration would take the
longest by immersion, received an early bolus of fixative. Following this, hearts were placed
in a large volume (minimum 50mls) of 10% NBF to immersion fix for a minimum of 72 hours
(median 108, range 72-144). At a penetration rate for 10% NBF of 0.5mm/hour (Dempster
1960) the immersion time of 72 hours was in excess of the theoretical time required for fixation
and the use of a large immersion volume ensured that adequate fixative molecules remained
as fixation progressed. Following fixation and immediately prior to embedding, hearts were
washed in a large volume (minimum 50mls) of phosphate-buffered saline to remove excess fixa-
tive and rehydrate the tissue (Thelwall et al. 2006). Hearts were then embedded in low-melting
point 2% agarose (to minimise thermal damage) and the effects of the time in agar assessed on
signal quality and tissue degradation. Six normal hearts were fixed with 10% NBF, washed in
PBS, embedded in 2% low-melting point agarose and sub-divided into two equal sized groups.
An early-embedding group were scanned at a median of 5 hours post embedding (range 3-27
hours) whereas a late-embedding group were scanned at a median of 440 hours post embedding
(range 432-456 hours). The values and histograms of FA and MD were compared between the
two groups to determine the effect of prolonged embedding on sample degradation and diffusion
metrics.
5.6.2.3 Histological Validation
To explore the relationship between the primary eigenvector of the diffusion tensor and my-
ocardial fibres the orientation of the two were compared. The primary eigenvector map from
a non-infarcted heart was registered to a histology section as described in Section 2.8.3, using
a total of 20 individual point-sets located using anatomical landmarks (e.g. RV insertion, LV
cavity).
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To explore the relationship between diffusion derived metrics of tissue architecture and biolog-
ical changes that occur post infarction four post-infarction-reperfusion hearts were subject to
diffusion imaging and detailed histology.
The surgical protocol for generating a reperfused infarct has been described in Section 2.3.3.
The four hearts imaged in this study formed part of the larger study to characterise the 60-
minute in vivo model of infarction-reperfusion described in Chapter 4. Hearts were explanted
and prepared for MRI as described previously (Section 2.7.2.2). Diffusion MR imaging was
performed with a multi-shot EPI sequence, with diffusion sensitisation in 30 directions (Jones
30 diffusion scheme), full details of which are provided in Section 2.7.4.3. After imaging, hearts
were removed from agar and underwent detailed histological study and co-registration with MR
images using rigid and non-rigid methods as described in Section 2.8.3. The robustness of the
co-registration method was assessed by calculating the mean Euclidean distance between the
point sets after registration. From this registered map, directionality analysis was performed as
described in Section 2.7.2.3 and the mean fibre directions compared. A total of 20 histological
sections were co-registered (median 5, range 3-7/heart from 4 hearts) with MR images and the
infarct, border zone and remote regions identified from the histological sections. MD and FA
values were then extracted from each region across all slices, tested for normality and compared
on an intra-heart and inter-heart basis.
The method of co-registering histological sections and MRI slices is error prone, owing to factors
affecting the histological quality of the sections and the precision with which sections can be
registered. Destructive histological processing results in non-linear geometric deformation of
the tissue including shrinking and contracture as a result of dehydration and paraffin infiltration
and shearing and distortion as a result of sectioning. These deformations are sufficient to distort
the anatomy of the intact heart to an extent where both rigid and non-rigid transformations
are required to transform the image back to it’s original (pre-histology) state. Furthermore,
attempting to define histological regions of interest (infarct, infarct border zone) and extract
regional data from MRI images has an element of subjectivity in that the size of the ROI is
dependent on the size of the imaging voxel. High resolution histological studies of the healing
border zone in a chronic-MI rat model of infarction measured the IBZ as occupying an area of
1.73mm3 (Rutherford et al. 2012), which, based on a maximum DTI voxel size of 200x200µm
would result in a thickness in the order of 5-7 voxels. Although this suggests that DTI imaging
is of sufficient spatial resolution to detect changes at the IBZ any error in precise co-registration
could lead to bias by inadvertently measuring metrics from adjacent regions (remote or infarct).
No single method of image registration is error-free, and previous DTI studies have instead
applied a segmentation based approach, with post-segmentation histological validation rather
than co-registration. This method reduces the error in co-registration and histology-processing
errors, reduces the time for analysis and possesses greater clinical relevance as direct clinical
histological validation is rarely possible. Significant variation exists between studies in the
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exact methodology regarding segmentation, with most studies dividing the short-axis image
into an arbitrary number of equally sized segments (range 4-12, Chen et al. 2003; Wu et al.
2006b; Strijkers et al. 2009) and allocating a segment to a single region (i.e. remote, adjacent
or infarct) based on the predominant histological findings within each segment. This is prone
to error owing to the presence of an unknown proportion of a mixed population of different
tissues within a single segment. Another method employed is that of prospective segmentation
(Wu et al. 2009; Wu et al. 2011), based on the signal intensity in the b0 image and the change
in wall thickness, when present, to define the infarct, adjacent and remote regions which has
been employed in both animal and human studies of infarction. To determine whether the
prospective segmentation method resulted in data comparable with the histologically-guided
co-registration method, a series of paired-analyses were performed. All (n=20) slices that
had been co-registered with histology were subject to prospective segmentation into infarct,
adjacent and remote regions, as described in Section 2.7.6 (Wu et al. 2009). DTI metrics (FA
and MD) generated from the histology method and the segmentation method were compared
on a slice-by-slice and region-by-region basis by linear correlation and by comparison of the
absolute median values and interquartile ranges.
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5.6.3 Results
5.6.3.1 Feasibility
Initial scan results demonstrated adequate signal in both b0 (predominantly T2-weighted) and
diffusion weighted images with appropriate application of the diffusion gradients in different
directions as evidenced by the alterations in signal intensity along the direction of gradient
application (Figure 5.5).
b0 Image [1,0,0]
[-0.82,-0.39,0.43]
[0.16,0.97,0]
[0.66,0.37,0.66]
[-0.11,0.66,0.74]
[0.58,0.80,0.14] [0.90,0.26,0.35]
[0.90,-0.42,-0.11]
[-0.17,-0.61,0.78]
Figure 5.5: Sample b0 image and nine diffusion directions from mid-LV slice of non-infarcted
heart. Note directional change in signal intensity in diffusion images owing to differing gradient
direction application. Vector beneath each diffusion image represents the b-vector (direction of
gradient application) in scanner co-ordinates.
On review of the data in the z-axis plane, an artefact was noted with alternative slice signal
attenuation, consistent throughout the entire z-stack (see Figure 5.6). Owing to the homoge-
neous nature of the artefact a problem within the pulse sequence was expected, rather than a
magnetic field inhomogeneity. This artefact was explained by the nature of the 180o refocusing
pulse, which, owing to a non-rectangular slice profile, was inadvertently exciting a larger than
expected slice, rather than the intended profile excited by the initial 90o RF pulse. As the time
for longitudinal magnetisation to recover was long the mismatch between excitation bandwidth
and refocusing bandwidth meant reduced magnetisation was available for subsequent acquisi-
tions resulting in signal attenuation. This was initially remedied by altering the pulse shape for
a more rectangular excitation but an error in the Varian code used to calculate the pulse width
resulted in no improvement in attenuation. To address this, the code was manually altered and
the target slice width of the refocusing pulse reduced (set at 85% of excitation pulse width),
which, once applied by the erroneous code, resulted in equal slice thickness for both refocussing
and excitation pulse and loss of attenuation (Figure 5.6).
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Figure 5.6: (A) Alternate slice attenuation owing to poorly designed refocusing pulse and (B)
Correction of attenuation by modification of refocusing pulse and pulse width
Although the diffusion image(s) and histological sections from the hearts used to assess fea-
sibility were not precisely aligned, on preliminary review there was a clear visual relationship
between areas of low fractional anisotropy, high mean diffusivity and areas of collagen (scar)
on Masson’s Trichrome staining (Figure 5.7). This observation was explored further by precise
co-registration and extraction of DWI metrics from multiple histological sections, as reported
in Section 5.6.3.4.
0
1
0
3.0x10
-03
200 micron
A B C
Figure 5.7: Initial appreciation of the spatial relationship between (A) Regions of collagen
deposition on Masson’s Trichrome stained histological section and (B) Areas of low Fractional
Anisotropy and (C) Areas of high Mean Diffusivity from a single section through the mid-LV
of an infacted heart.
5.6.3.2 Sample Preparation
All hearts in the long-duration embedding group demonstrated a FA histogram with two dis-
tinct peaks (Figure 5.8). The first peak (representing epicardium and mid-myocardium voxels)
peaked at ∼0.08, and contained over 50% of voxels compared to the second peak (representing
endocardium) peaked at ∼0.20, containing the remainder. This double-peak histogram was
absent from hearts in the short-duration group, with all containing a single, defined peak, at
a value of ∼0.20 (Figure 5.9). The spatial distribution of the double-peak FA histogram with
lower values in the epicardium and mid-myocardium suggests that tissue anisotropy has been
lost, consistent with tissue decay. Although clear differences were visible between the MD of
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the epicardium and endocardium in the long-duration group, the histogram(s) remained uni-
modal. However, the diffusivity was significantly higher in the long-duration group (median
1.54 x 10−3, IQR 1.36 x 10−3 – 1.69 x 10−3) compared to the short-duration group (median 1.38
x 10−3, IQR 1.24 x 10−3 – 1.51 x 10−3, p<0.05), again supportive of the theory that prolonged
embedding promotes tissue decay and degradation.
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Figure 5.8: Effect of long-duration embedding in agar prior to DWI. (A) Bimodal Fractional
Anisotropy Histogram and (inset) epicardial ring of reduced FA. (B) Unimodal Mean Diffusivity
Histogram and (inset) epicardial ring of increased MD.
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Figure 5.9: Effect of short-duration embedding in agar prior to DWI. (A) Unimodal Fractional
Anisotropy Histogram and (inset) homogeneous FA map. (B) Unimodal Mean Diffusivity
Histogram and (inset) homogeneous MD map.
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5.6.3.3 Myofibre Orientation
The mean Euclidean distance between histology and MRI point-sets post-registration was 1.27
± 0.11 pixels (from n=20 registrations), indicating good co-registration between images using
the methods described. There was agreement between the orientation of myocardium calcu-
lated from histology, compared to the orientation calculated from the two-dimensional primary
eigenvector with a mean error of 9.5 ± 2.3 degrees (Figure 5.10), in keeping with previous
literature values (Scollan et al. 1998).
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Figure 5.10: Orientation of Cardiac Myocytes. (A) Three paired sections of normal myocardium
showing (left) histology and (right) 2-D primary eigenvector. Scalebar (white) = 500µm (B)
Comparison of orientation in normal myocardium between histology and primary eigenvector.
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5.6.3.4 DTI Metrics post-Infarction
Owing to variability in the remote region of FA (range 0.20-0.24) and MD (range 1.24-1.31
x10−03mm2/s) when pooling data from four hearts, regional analysis was performed normalised
to the remote region of each heart. The infarct region demonstrated a significant reduction in
FA (39 ± 10 %, p<0.05, Figure 5.11) and increase in MD (19 ± 5 %, p<0.05, Figure 5.12),
with a similar pattern visible in the IBZ which failed to reach significance (FA; 25 ± 10 %,
MD; 11 ± 4 %).
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Figure 5.11: Pooled DTI fractional aniostropy data (from n=4 hearts) for three regions dis-
played as (A) Raw values (median ± interquartile range) and (B) Normalised (to remote) FA
values (mean ± SEM). Rem = Remote, IBZ = Infarct Border Zone, Inf = Infarct. ∗ p<0.05
using ANOVA.
166
Rem. IBZ. Inf.
0.0
5.0×10-04
1.0×10-03
1.5×10-03
2.0×10-03 *
LV Region of Interest
M
ea
n 
D
if 
fu
siv
ity
Rem. IBZ. Inf.
0.00
0.25
0.50
0.75
1.00
1.25
*
LV Region of Interest
N
or
m
al
ise
d 
M
D
A B
Figure 5.12: Pooled DTI mean diffusivity data (from n=4 hearts) for three regions displayed
as (A) Raw values (median ± interquartile range) and (B) Normalised (to remote) MD values
(mean ± SEM). Rem = Remote, IBZ = Infarct Border Zone, Inf = Infarct. ∗ p<0.05 using
ANOVA.
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On an individual heart basis, the differences between the three regions were more pronounced
with all hearts demonstrating a significant decrease in FA and increase in MD between the
infarct, IBZ and remote regions of sufficient magnitude so as to achieve statistical significant
separation of all three regions (Figure 5.13).
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Figure 5.13: Data from single heart analysis showing significant separation between all three
regions for (A) Fractional Anisotropy and (B) Mean Diffusivity. Rem = Remote, IBZ = Infarct
Border Zone, Inf = Infarct. ∗p<0.05
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5.6.3.5 Histological Method Comparison
Two methods of defining the infarct, infarct border zone and remote myocardium were com-
pared. A histology-based approach, requiring co-registration of histology and DTI images and
identification of histological regions of interest was compared to a prospective segmentation ap-
proach (Section 5.6.2.3). Median FA and MD values for each region (n=3) in each slice (n=20)
were generated (n=60 data points/metric) using both approaches and the values correlated
and the residuals compared. There was good correlation between methods for both FA values
(R2 = 0.80) and MD values (R2 = 0.77) with residual plots from both showing a homogeneous
spread across the range of FA and MD values (Figure 5.14).
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Figure 5.14: (A) Linear correlation between FA values generated by histology-based approach
and segmentation based approach and (B) Residual plot for FA values. (C) Linear correlation
between MD values generated by histology-based approach and segmentation based approach
and (D) Residual plot for MD values. Data from all three regions (infarct, border zone, remote),
for n=20 slices, total n=60 data points.
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Absolute values of FA and MD in the remote, infarct border zone (termed ’adjacent’ in the
segmentation approach) and infarct region were comparable between methods (Table 5.1 &
5.2).
Method
FA
Remote IBZ/Adjacent Infarct
Histology-based 0.22 (0.21-0.24) 0.17 (0.15-0.20) 0.15 (0.10-0.18)∗
Segmentation 0.23 (0.20-0.24) 0.18 (0.16-0.20) 0.15 (0.12-0.17)∗
p value ns ns ns
Table 5.1: Comparison of pooled FA data on a region-by-region basis between histology-based
and segmentation methods of defining regions of interest.. Data displayed as median (IQR).
∗p<0.05 vs. remote.
Method
MD
Remote IBZ/Adjacent Infarct
Histology-based 1.26 (1.20-1.33) 1.40 (1.30-1.51) 1.51 (1.32-1.63)∗
Segmentation 1.29 (1.22-1.34) 1.35 (1.25-1.43) 1.49 (1.39-1.60)∗
p value ns ns ns
Table 5.2: Comparison of pooled MD data on a region-by-region basis between histology-based
and segmentation methods of defining regions of interest. All data x10−03 mm2/s, displayed as
median (IQR). ∗p<0.05 vs. remote.
In addition to the similarity in pooled data analysis between methods, on intra-heart analysis,
the significant separation between the three regions demonstrated using the histology-based
method was preserved using the segmentation method.
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5.6.4 Discussion
The pilot study was successful in demonstrating the feasibility of performing ex vivo cardiac
diffusion tensor imaging at Imperial College with collection of an entire diffusion MRI dataset
taking under two hours. During the early stages of development several technical issues were
addressed, including correction of the refocusing pulse and determining sample preparation
parameters.
In keeping with the findings of the effects on signal quality (and possible tissue degradation)
of a prolonged time in agar, Hales et al. (Hales et al. 2010) demonstrated that the use of
different embedding mediums resulted in changes in T1 and T2 relaxation times. In their
study T1 relaxation decreased most when using Fomblin, compared to agarose or iso-osmotic
agarose, whereas T2 relaxation showed the greatest increase when embedding in agarose. It
is important to recognise the relatively short fixation time (24 hours) and that the study was
designed to assess for temporal changes in relaxation times (up to 48 hours). They found no
differences between any relaxation times when scanned shortly after embedding (<5 hours), and
differences appear to stabilise, as re-scanning one week later revealed no change in relaxation
time compared to those at 48 hours. It is not clear as to whether the samples used in this
study were kept in embedding medium or placed back in fixative, as the data presented would
suggest that remaining in embedding medium for the period of time in the study (over one
week) would lead to changes in FA and MD. The cause of the bimodal FA and increased MD
after a prolonged period in agar could be attributed to several reasons. The samples may not
have been sufficiently fixed, although the fixative period of a minimum of 72 hours is sufficient
based on the penetration rate of 10% NBF and is longer than that used in other studies with
larger tissue (Wu et al. 2007a). The post-mortem interval (time from end of Langendorff
perfusion to start of fixation) was kept to a minimum (less than 1 minute), so as to negate
the effects demonstrated by Eggen et al. (Eggen et al. 2011) in their study of human hearts
who demonstrated that as post-mortem interval increased, diffusion became less restricted
with a significant increase in MD and reduction in FA. Although the size of their sample was
considerably larger than the rat heart, they were still able to reconstruct the diffusion tensor
with a post-mortem interval of three days, suggesting that the small post-mortem interval used
in this chapter would not have an effect on diffusion derived metrics. Commonly used aldehyde
fixative solutions (e.g. 4% Formaldehyde) have been shown to decrease the relaxation times
of non-cardiac tissue (Shepherd et al. 2009a), although the decrease in T2 can be reversed by
washing in buffered solution to remove fixative prior to scanning (Thelwall et al. 2006). Another
putative explanation for the changes in FA and MD, considering the predilection of changes
occurring at the interface between agarose and epicardial surface, is the effect of the agar and
heart having different osmotic properties and being in direct contact.. A possible explanation
is an osmotic effect with heart tissue drawing in water from the agarose gel (which is a 98%
water solution) resulting in increased cell and interstitial space size (and hence increased MD)
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and, if sufficient, osmotic rupture of the cell membrane leading to disruption of normal end-end
myocyte structure and reduced anisotropy. Although care was taken to minimise air in the
LV and RV cavity and reduced artefact on MR scanning, it is not clear as to whether agarose
replaced fixative within the cavities, if not, this offers an explanation for the relative preservation
of FA and MD values in tissue closest to the LV centre. Despite the extent of the FA and MD
changes seen at long (> two weeks) durations of embedding, no changes were demonstrable
when the embedding time was kept as short as possible (< one day), suggesting that myocardial
architecture was best preserved and hence most suitable for scanning by minimising the duration
in embedding medium.
After demonstrating feasibility, addressing technical and sample preparation artefacts, data
were successfully reconstructed and compared against gold-standard histology. The calculated
primary eigenvector represented local myofibre orientation, evidenced as the mean difference in
histological derived fibre orientation and MRI derived fibre orientation being within the ±10o
quoted in previous correlation studies (Scollan et al. 1998). The reduction in anisotropy and
increase in diffusivity in the histologically-defined infarct region is in agreement with the ma-
jority of previous experimental and clinical studies (Chen et al. 2003; Wu et al. 2006b; Wu et al.
2007a; Wu et al. 2009). The biological basis for these changes is attributed to the formation
of loose collagen bundles in the infarct region such that for each voxel the extracellular space
occupies a larger fraction and diffusion is able to occur with less restriction. The disruption in
normal cell laminar structure and end-to-end connectivity owing to the replacement with colla-
gen increases the relative radial diffusivity at the expense of longitudinal diffusivity, resulting in
an overall reduction in anisotropy. Despite standardising sample preparation (fixation, washing,
embedding) for all hearts, there still existed a range of normal values (for FA and MD) so that
on pooling data the sensitivity to detect a difference between regions was reduced, although
between regions with the greatest change (i.e. remote versus infarct) differences persisted.
Two methods of defining regions of interest (i.e. remote, border zone, infarct) were compared,
a histology-based approach and a prospective segmentation approach (based on the b0 signal
intensity and geometry of the infarcted myocardium). Although widely accepted as the gold-
standard validation technique, histological analysis is subject to error, owing to deformations
and distortions introduced to the tissue during processing and the difficulties in accurately
co-registering and extracting data from MR images. Furthermore, histological processing and
analysis is labour and time intensive and isn’t feasible in clinical practice. For this reason,
a prospective segmentation approach, described in the literature, was applied and validated
against the histology-based approach by linear correlation and comparison of absolute values of
extracted DTI metrics on a region-by-region basis. There was good overall agreement between
the two methods, as evidenced by the R2 values of linear lines of best fit for all FA and
MD data points. The absolute values of FA and MD were also comparable between regions
with no difference in statistical significance on analysis of either pooled or individual-heart
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data. These findings suggests that the prospective segmentation method is non-inferior to the
histology-based method and can be used to define and extract regions of interest in infarcted
myocardium. It is prudent however to note that some degree of histological validation is still
necessary to demonstrate that regions defined prospectively as infarct, infarct border zone or
remote, do correlate with gross histological findings.
5.6.4.1 Further Work
Having demonstrated the feasibility of DTI and the relationship between remodelled my-
ocardium post-infarction reperfusion and diffusion-derived metrics of tissue architecture (FA
and MD), DTI was intended to be applied to study the effects of potential structural remodelling
afforded by early gap junction enhancement in the reparative phase post-infarction (Chapter 6).
However, the closure of the Biological Imaging Centre in February 2013 necessitated the need
to seek an alternative scanner and re-test and re-establish the feasibility and reproducibility of
DTI.
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5.7 Diffusion-Sensitised Fast Spin Echo Sequence
5.7.1 Introduction
Following closure of the Biological Imaging Centre in February 2013, further imaging studies
were performed in collaboration with Prof. A. Shah and physicist Dr. Andrea Protti at Kings
College London.
The Pre-Clinical Imaging unit at Kings College London has a 7T Varian MR scanner with
100G/cm gradients, running VNMRJ 3.2 software which allowed for the transfer of the EPI
sequence previously used at Imperial College. On scanning with the exact same diffusion
parameters as used previously, a marked loss of signal, correlating with areas of infarction was
demonstrated consistently across multiple hearts (Figure 5.15).
b0 Image
Single Diﬀusion
Image
Original EPI KCL - EPI
Figure 5.15: Comparison of b0 image (top row) and single direction diffusion weighted image
(bottom row) for EPI sequence scanned originally (far left) showing infarct location (red arrow)
and no signal void on b0 or diffusion weighted image, compared to EPI sequence scanned at
Kings College London (KCL), showing infarct locations (red arrows) with extensive signal voids
in both b0 and diffusion weighted images.
EPI is exquisitely sensitive to magnetic field inhomogeneities with artefacts including signal loss,
blurring and geometric distortion (Basser et al. 2002; Le Bihan et al. 2006). To understand the
nature of such artefacts, it is important to consider the effects of T2 and T2∗ relaxation times
on transverse magnetisation (Chavhan et al. 2009). After application of the radiofrequency
(RF) pulse and tilting the longitudinal magnetisation onto the transverse plane, spins begin to
dephase as a result of spin-spin interaction, resulting in an exponential reduction of transverse
magnetism. This decay is individual to each tissue and the time at which it reaches 37% of
initial value is termed the T2-relaxation time. In addition, spins also undergo dephasing as
a result of magnetic field inhomogeneities and susceptibility effects generated by the interface
between tissues with different magnetic properties (e.g. tissue-air, ferrous material). This
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dephasing occurs quicker than T2 relaxation and is termed T2∗. Unlike T2, T2∗ dephasing can
be mitigated (reversed) by the use of a 180o refocusing pulse, as used in spin-echo sequences.
This results in reduced signal loss, blurring and distortion due to magnetic field inhomogeneities
and susceptibility effects when compared to gradient-echo sequences which lack a refocusing
pulse or gradient-echo readouts (such as EPI) which are sensitive to the effects of T2∗ (Abduljalil
et al. 1999).
The signal loss demonstrated in the infarct region is characteristic of a susceptibility effect owing
to the close proximity of tissues with different magnetic properties. The likely culprits being
the presence of trapped ferrous-rich red blood cells in regions of intra-myocardial haemorrhage
adjacent to regions of collagen and normal myocardium. Similar intra-myocardial haemorrhage
has been demonstrated in post-reperfusion in both animal (Ye et al. 2013) and human (Bekkers
et al. 2010) MRI studies.
In order to address this signal loss, a spin-echo sequence and readout, which is less sensitive to
T2∗ effects was sought. A diffusion-sensitising fast-spin echo sequence was made available by
Varian (VNMRJ 4.0), which reduced the T2∗ effect substantially (Figure 5.16).
A B
Figure 5.16: Comparison of b0 image from EPI sequence (A) and FSE sequence (B) from the
same slice demonstrating markedly reduced signal void on FSE sequence compared to EPI in
infarct region.
This diffusion-FSE sequence was a standard FSE sequence as described (Section 5.3.3.1), with
a pair of diffusion gradients either side of the refocusing pulse and an echo train length of two.
The time of acquisition of a single average scan in 30 directions (Jones 30) was 80 minutes,
compared to 15 minutes using the spin-echo EPI readout. As a result, the diffusion scheme was
reduced from 30 to 6 directions (Jones 6), which reduced the single average scan time to 20
minutes. As the diffusion-FSE sequence had not been used in the department before, a series
of validation steps were performed, first to test the application of diffusion sensitisation and
then to determine the optimal diffusion parameters and number of spatial averages.
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5.7.2 Methods
A water phantom was scanned at room temperature (19oC) to systematically test the applica-
tion of diffusion sensitisation as described in Section 2.7.3. Use of an isotropic water phantom
is a well-established method of validating diffusion-sensitisation sequences by comparing calcu-
lated ADC values with those in the literature (Simpson et al. 1958; Mills 1973). The formula
for ADC calculation is as follows:
ADC =
(log S0
S
)
b
(5.8)
Where ADC equals apparent diffusion coefficient in mm2/s, S0 is the voxel signal intensity in
the b0 image, S is the voxel signal intensity after application of the diffusion gradient and b is
the b-value used for acquisition of the diffusion weighted image (Burdette et al. 1998). For each
test, data from the resulting ADC map were extracted from 15 separate regions-of-interest,
with each ROI containing a minimum of 400 voxels, and the mean and SEM reported.
The first test applied diffusion sensitising gradients along each of the three orthogonal directions
defined in scanner co-ordinates as the x-axis (1,0,0), y-axis (0,1,0) and z-axis (0,0,1). Correct
application of the gradients in each isolated direction should result in equal ADC in each
direction at a value comparable to the ADC value of water at 19oC.
The second test applied diffusion sensitising gradients as defined in the Jones 6 direction scheme
(Jones et al. 1999, Table 5.3). This test was to ensure that the three orthogonal gradients could
be combined and applied successfully, and was tested by comparing ADC in each direction and
with the literature reported ADC value.
Gx Gy Gz
1 0 0
0.446 0.895 0
0.447 0.275 0.851
0.448 -0.723 -0.525
0.447 -0.724 0.526
-0.449 -0.277 0.849
Table 5.3: Jones 6 Diffusion Direction Scheme
The third test applied diffusion sensitising gradients along the Jones 6 direction scheme but
also with random offset and random rotation of the slice-plan so as to mimic the geometry that
would be used when scanning a sample. Again, comparison was made between each (rotated)
direction and with the literature reported ADC-value.
The fourth test applied diffusion sensitising gradients along the Jones 6 direction scheme with
random offset and rotation at different gradient strengths (|G|), separation time (∆) and du-
rations (δ). The b-value was kept constant (at 600 mm/s2). These scans tested the in-built
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b-value calculation, and, if correct, would expect the ADC to be equal between scans with
different diffusion parameters provided the b-value was kept constant.
After completion of testing with the water phantom, a non-infarcted, normal heart was placed
in the scanner to complete the validation process. Scans performed on this heart addressed
two specific questions; firstly, what parameters result in the optimal detection of diffusion and
secondly, what number of spatial averages (NSA) are needed for adequate signal quality. Small
changes in either |G|, ∆ or δ (with the same b-value) alter the sensitivity to detect diffusion
and alter the calculated FA or MD. Ideally, in normal myocardium, the SD/SEM of calculated
metrics would be small, reflecting minimal variation. This was determined by scanning five
different sets of diffusion parameters (Table 5.4), and calculating FA and MD in a random
selection of 1000 pixels distributed throughout the myocardium. A b-value of 1000 was used
for all experiments in-keeping with that used in previous EPI experiments.
Set |G| ∆ δ b-value
1 43 12 2.5 1000
2 54 8 2.5 1000
3 22 12 5 1000
4 37 15.7 2.5 1000
5 28 8.38 5 1000
Table 5.4: Five diffusion parameter sets used for optimisation of FSE sequence. Units of |G| =
mT/m, ∆ & δ = ms, b-value = mm2/s.
In determining the NSA, a trade-off between scan time (approximately 20 minutes for 1 NSA),
signal-to noise ratio (SNR) and data quality must be reached. This was assessed by performing
a total of six NSA and analysing data with increasing number of NSA. SNR was defined as the
ratio between average signal intensity in the tissue (S) to the standard deviation of the noise
(σ) in the b0 image. Data quality was assessed by calculating FA and MD maps at increasing
number of NSA and comparing standard deviation of measurements.
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5.7.3 Results
The application of the diffusion sensitising gradients was tested and compared with the litera-
ture value of the ADC of water at room temperature of 0.002mm2/s and the literature reported
scanner variability of ±10% (Kivrak et al. 2013).
Application of three gradients in orthogonal directions based on scanner co-ordinates revealed
equal ADC values in all directions, within range of literature reported values (Figure 5.17)
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Figure 5.17: Application of diffusion sensitising gradients in three orthogonal directions. Data
from n=10,000 voxels (spatially identical between gradient directions)
Application of six gradients, in the direction of the Jones 6 scheme, with or without random
geometry (Figure 5.18) reassuringly demonstrated equal and appropriate ADC values in all
directions.
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Figure 5.18: (Top) Application of diffusion sensitising gradients in six directions (Jones 6), with
no offset or rotation. (Bottom) Application of diffusion sensitising gradients in six directions
with random offset and rotation to simulate slice-plan geometry. Data from n=5,000 voxels
(spatially identical between gradient directions)
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The final water phantom test, the application of diffusion gradients in the Jones 6 scheme
with random geometry at a fixed b-value (600), but varying the individual diffusion parameters
(gradient strength, separation time, duration time), also demonstrated equal and appropriate
ADC values (Figure 5.19).
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Figure 5.19: Application of diffusion-sensitisation with varying diffusion parameters but con-
stant b-value. Data from n=5,000 voxels (spatially identical between gradient directions). Units
of |G| = mT/m, ∆ & δ = ms, b-value = mm2/s.
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Following water phantom experiments, a normal, non-infarcted heart underwent a series of
scans to test the effect of varying diffusion parameters and to measure signal-to-noise ratio.
Different diffusion parameters (with constant b-value) reassuringly had no significant effect on
mean FA or MD values, with both sets of data following a normal distribution. To assess the
variability in how sensitive a set of parameters was to diffusion, the standard deviations of
FA and MD were compared. As shown in Table 5.5, although no significant difference existed
between sets, parameter set 5 (|G| 28 mT/m, ∆ 8.35ms, δ 5.00ms) showed the smallest variation
in both FA and MD.
Parameter FA MD
Set Mean SD Mean SD
1 0.31 0.053 9.4 x 10−3 6.5 x 10−5
2 0.29 0.052 9.7 x 10−3 6.2 x 10−5
3 0.31 0.052 9.4 x 10−3 6.3 x 10−5
4 0.31 0.054 9.3 x 10−3 6.2 x 10−5
5 0.29 0.051 9.5 x 10−3 6.1 x 10−5
p-value ns ns ns ns
Table 5.5: Effect on mean and SD of FA & MD using five diffusion parameter sets to optimise
FSE sequence. FA is a scalar value between 0 and 1. Units of MD = mm2/s. Data from
n=1000 randomly selected pixels.
Using the parameters obtained from Table 5.5, the effects of the number of spatial averages
was probed by plotting SNR (actual and predicted) and mean and SD of FA against NSA. As
expected, SNR increased as a function of the square root of the number of averages (i.e. four
averages has double the SNR of one average, Figure 5.20). In addition, increasing NSA led to a
reduction in both the mean and the SD of FA; presumably due to the reduced noise component
in images with greater NSA. Beyond four averages (shaded area, Figure 5.20) increasing the
number of averages did not result in any further statistical difference in either mean nor SD of
FA.
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Figure 5.20: Effects of number of spatial averages on (A) Actual and Predicted SNR in b0
Image. Data from n=10 paired regions (tissue and background) and (B) FA Mean and Standard
Deviation. Shaded area - beyond four averages there were no further significant difference in
either mean or SD of FA. Data from n = 1000 randomly distributed voxels
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5.7.4 Discussion
The presence of significant signal loss in the infarcted region, rendering diffusion MR images
uninterpretable, was unexpected, based on the previous work performed with the identical spin-
echo EPI sequence at Imperial College. From a non-MRI perspective, the surgical preparation
(reperfused-infarction) and tissue handling (fixation in formalin, rehydration in PBS, embed-
ding in agar) were identical to previous. Previous histological examination had not revealed
trapped red blood cells although the presence of a local magnetic field inhomogeneity due to
the presence of tissue with different magnetic properties remains the most likely explanation.
The reduction of the signal void by the change of sequence to a diffusion-sensitised fast-spin
echo sequence further supports the explanation of local magnetic field inhomogeneity due to a
T2∗ effect, mitigated by the presence (in a spin-echo sequence) of the 180o refocusing pulse and
a readout which is not based on gradient-echoes (as in EPI).
The diffusion sensitisation module of the new FSE sequence was systematically tested and
shown to apply diffusion sensitisation equally and appropriately in three orthogonal directions,
the six directions of the Jones 6 scheme and in the six directions with added geometry. Fur-
thermore, the inbuilt calculation of the b-value, based on gradient strength, separation and
duration time was shown to be correct by demonstrating equivalent ADC values after minor
parameter modifications.
The most significant difference between the two acquisitions (FSE and EPI) is the time required
for scanning; a single average sampling 30 diffusion directions using EPI took 15 minutes
compared to 50 minutes using FSE. Owing to the need to maximise SNR by repeating more
averages, the time constraints on sampling a high number of directions with FSE meant that
a compromise in the form of reducing the number of sampled directions was employed. The
choice of initial diffusion sampling scheme (Jones 30) was informed by the work of Jones (Jones
et al. 1999; Jones 2004) who showed using Monte Carlo simulations that a minimum of 30
unique gradient sampling directions were required to provide a robust estimation of the mean
diffusivity and tensor orientation. Other theoretical analyses support the view that increasing
the number of sampled gradient directions leads to more robust and error free tensor sampling
(Papadakis et al. 2000; Skare et al. 2000). However, this standpoint is not shared consistently
across the literature. Hasan et al (Hasan et al. 2001) demonstrated that using an optimised
gradient scheme with six directions (optimised defined as maximising electrostatic repulsion
between directions, resulting in each direction pointing towards the vertices of an icosahedron)
resulted in tensor estimation equivalent to that generated using up to 30 directions. In an in
vivo human brain DTI study, Ni et al. (Ni et al. 2006) demonstrated that when measured
on a ROI basis, there were no differences in either FA or MD between 6, 21 or 30 gradient
sampling directions although fewer directions resulted in higher values for λ1 and λ2 and when
analysed on a voxel-by-voxel basis, differences in FA and MD existed between all sampled
directions. Owing to the increased acquisition time of the FSE sequence, using the Jones 30
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diffusion scheme (as for EPI) was not feasible and as such the optimised Jones 6 scheme was
used instead (Jones 2004).
To assess the effects of increasing the number of spatial averages the signal to noise ratio was
measured (in the b0 image), and the variability of FA assessed. Measuring SNR in the diffusion
MR image is prone to errors owing to the intrinsic directionality of the image and SNR in FA and
MD maps are biased by error introduced during tensor fitting and mathematical transforms.
The SNR, as expected, increased as a factor of the square root of the number of averages.
Likewise, the reduction in mean and SD of FA was found to reduce with increasing averages,
although there was no statistical difference in values when increasing above four averages. On
balance, the increased SNR afforded by performing more averages was felt to offset the marginal
increase in scan time and for future FSE studies six averages were performed. Performing six
averages sampling 6 diffusion directions using FSE took 110 minutes, compared to six averages
sampling 30 diffusion directions using EPI which took 90 minutes.
In assessing the effects of altering diffusion scan parameters, the optimal b-value is defined
as that which minimises the variance in ADC and is approximated by 1.1/ADC. Taking the
range of reported ADC values for healthy myocardium from the literature (ranging from 0.7-
1.1 mm2/s) gives a b-value range of ∼1000-1600. A trade-off then exists between increasing
gradient time to achieve the b-value and increasing TE; Jones (Jones et al. 1999) showed that
for brain white matter this trade-off was optimal at a factor of 0.77 of the initial b-value; which;
for the work described would give a new b-value range of ∼770-1232. Considering this range
of b-values; a value of 1000 was chosen to represent the best compromise between variance of
ADC and prolonging TE. The effect of altering the constituents of the b-value was probed by
altering the diffusion time (defined as ∆ - (δ/3)). The diffusion signal measured is proportional
to the duration of the diffusion-sensitising gradients applied to the sample. If the diffusion time
is short then molecules will not have had time to encounter obstacles and diffusion will appear
isotropic in contrast to long diffusion times where molecules will have had chance to interact
with fixed structures (hence will appear more anisotropic) but the overall signal intensity will be
reduced as a result of T2 relaxation. Assuming the diffusivity of water at scanning temperature
(19oC) to be 0.002mm2/s (Mills 1973), a diffusion time of 6.5ms results in a displacement of
8.85µm. The shortest diffusion time (6.5ms) used gave MD and FA values comparable to longer
diffusion times (maximum 14.8ms) and demonstrated the smallest variance, suggesting that this
diffusion time was sufficient to probe the microstructure of the heart and minimise TE.
Although only one (normal, non-infarcted) heart was used in the optimisation of the FSE se-
quence, the diffusivity was noted to be lower and anisotropy higher, compared with the median
values from the remote region of the four (infarcted) hearts used in the EPI sequence. Multiple
potential confounding factors exist which may explain this difference and can be divided into
sample or sequence effects. From a sample perspective the four hearts scanned using EPI had
all undergone infarction-reperfusion surgery and had obvious histological remodelling which,
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although most obviously confined to the infarct region, may extend to the remote region. In
addition, these hearts had undergone optical mapping and prolonged (up to two hours) ex vivo
Langendorff perfusion prior to fixation, compared with the single FSE heart that was explanted,
briefly perfused and fixed (total time < 20 minutes). It is possible that the ex vivo Langendorff
perfusion, necessary to quantify the arrhythmia susceptibility and electrophysiological remod-
elling, results in greater interstital oedema owing to increased vascular perfusion pressure and
thus larger diffusivity and reduced anisotropy. From a scanner and sequence perspective, the
two scans (FSE and EPI) were performed on different field strength magnets (7 vs. 9.4T)
although the gradient strengths and coils were identical. Diffusion sensitising parameters (|G|,
∆, δ), TE, TR and voxel size were also identical, with the principal difference being the reduced
sampling of the tensor from 30 directions (EPI) to 6 directions (FSE). Whilst the reduction in
the number of sampling directions has an established effect on the variability of anisotropy mea-
surements (Jones 2004), the effect on absolute FA and MD values is inconsistent, although Lebel
(Lebel et al. 2012) demonstrated an increased FA and reduced MD when using 6 directions,
compared to either 30 or 60 directions in their study of brain white matter. Further comparison
between DTI metrics will be performed in Chapter 6 where the experimental preparation and
sample handling is comparable and more samples have been subject to the FSE acquisition.
5.8 Summary
Diffusion tensor imaging was successfully developed in collaboration, first at Imperial College
with Dr, Josef Habib on a 9T system and a diffusion sensitised spin-echo sequence with multi-
shot EPI readout and later at Kings College with Dr. Andrea Protti on a 7T system and a
diffusion sensitised fast spin-echo sequence.
The preliminary work at Imperial College demonstrated the feasibility in performing DTI with
generation of diffusion-sensitised images with sufficient SNR to allow fitting of the diffusion
tensor and generation of diffusion tensor metrics representing tissue architecture. These metrics
were then compared against histology, which acts as the gold-standard, with reproduction of
results as detailed in the literature for normal and infarcted myocardium.
Validation of the diffusion-sensitised fast spin echo sequence was performed by testing the
application of diffusion sensitisation by a series of water phantom scans and the diffusion scan
parameters and number of averages tested to ensure optimal SNR and minimal variance.
Having validated the DTI sequence, further DTI studies formed part of the assessment of
structural remodelling afforded by enhanced gap junction coupling in the early phase post-
reperfused infarction (Chapter 6).
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Chapter 6
In Vivo Enhancement of GJ Coupling
in Reperfused Myocardium
The studies in this chapter describe the changes in electrophysiological and structural remod-
elling that occur as a result of pharmacological enhancement of gap junction coupling in the
early phase post-infarction in an in vivo rat model of infarction-reperfusion.
6.1 Introduction
6.1.1 Gap Junctions in Healed Infarction
Alterations in gap junction (GJ) spatial distribution and functional state have been extensively
studied in a variety of clinical conditions (heart failure, ischaemia, infarction) in human and
animal models of disease (Peters et al. 2000; Severs et al. 2004; Severs et al. 2008).
The relationship between alterations in GJ coupling and arrhythmogenesis in the early, repar-
ative phase post-infarction were first demonstrated by Peters et al. (Peters et al. 1997). In
a four-day old canine infarct, Cx43 immunolabelling of myocytes at the IBZ underwent redis-
tribution to the lateral aspect of the cell surface and correlated with the anatomical central
common pathway (CCP) of figure-of-8 re-entrant VT circuits inducible on programmed stim-
ulation. Furthermore, Cabo et al (Cabo et al. 2006), in the same model, demonstrated that
GJ conductance and distribution occurred in a heterogeneous manner within the inducible VT
circuit, with preservation of transverse cell-cell conduction in the CCP colocalising to later-
alised Cx43. Remodelling of gap junctions occurs in a time-dependent fashion. The electron
microscopy study of Luke et al. (Luke et al. 1991), performed 3-10 weeks post-MI demon-
strated a 50% reduction in interconnected myocytes at the IBZ with a preferential reduction
in side-to-side coupling. Similar findings were demonstrated in healed human infarction in the
study of Smith et al. (Smith et al. 1991), who showed GJ redistribution to the lateral cell
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membrane at the IBZ, away from the intercalated disk, in addition to the presence of strands
of surviving, coupled myocytes traversing the infarct zone. Alterations in GJ conduction due
to lateralisation, resulting in functional conduction block, and the presence of conduction path-
ways through scar, combine to render healed myocardium susceptible to re-entry arrhythmias
(Wit et al. 2011).
In addition to their effect on the electrophysiological properties of the tissue, alterations in
GJ coupling also determine the extent of structural remodelling that occurs in reperfused
myocardium (Garc´ıa-Dorado 2004). This suggestion was originally formulated by detailed
examination of the histology and geometry of porcine infarcts which could be replicated by
computer stimulation with a contiguity condition, implying a necessary degree of coupling
between viable and non-viable myocardium (Garc´ıa-Dorado et al. 1989). Further support was
offered from experimental paired cell studies which demonstrated the spread of reperfusion-
induced hypercontracture from cell-to-cell (Garc´ıa-Dorado et al. 2000). Whilst GJ channels
allow the passage of small ions (e.g. Na+, Ca2+), it is possible that mediators of cell death or
promoters of cell survival may also pass from cell to cell via open GJ channels (Decrock et al.
2009). This passage of apoptotic factors may affect the spread of the ischaemia or reperfusion-
induced injury wavefront, so as to result in a ‘kiss-of-life’ or ‘kiss-of-death’ effect (Wygoda et al.
1997; Andrade-Rozental et al. 2000) on adjoining myocytes to determine the extent of injury.
6.1.2 Modulating Gap Junction Coupling
Considering the alterations in GJ spatial distribution and functional state in the pathogenesis
of arrhythmias during healed infarction and the contribution of GJ coupling to the extent of
cellular injury post-infarction, it is reasonable to suggest that attempting to maintain cell-cell
coupling during infarction-reperfusion may be an effective anti-arrhythmic strategy (Wit et al.
2011) by ameliorating adverse structural remodelling and limiting infarct size and heterogeneity,
two key determinants of late arrhythmogenicity.
In the study of Hennan et al. (Hennan et al. 2006), Rotigaptide treatment pre-reperfusion in a
canine model of infarction-reperfusion reduced the incidence of acute reperfusion arrhythmias
and afforded a 46% relative reduction in infarct size, measured at four hours post-reperfusion.
Danegaptide, a second generation stable analog of Rotigaptide, reduced infarct size (at four
hours) and the incidence of reperfusion-induced arrhythmias in a canine model (Hennan et al.
2009) and reduced infarct size (at three hours) in a porcine model of infarction-reperfusion
(Skyschally et al. 2013). Studies assessing the longer term (greater than four hours) effects
of early Rotigaptide administration on infarct size, infarct heterogeneity and arrhythmogen-
esis in clinically relevant infarction-reperfusion models are lacking. The study by Haugan et
al. (Haugan et al. 2006), using a chronic MI rat model and pre-treatment with Rotigaptide,
demonstrated a mean relative reduction in infarct size of 21% when studied at three-weeks
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post-infarction but did not assess the effects of Rotigaptide on arrhythmogenesis. The work
by Ng et al. (Ng et al. 2011) using a rat chronic MI model demonstrated no reduction in
infarct size at four weeks after administration of Rotigaptide in the early phase (for one week)
post-MI but did demonstrate a reduction in both arrhythmia susceptibility on PES and infarct
heterogeneity at the infarct border zone.
Although enhancement of GJ coupling appears to have a beneficial effect on infarct size, there
exists a body of evidence that conflicts this with studies suggesting that maintaining gap
junction coupling at ischaemia may increase, rather than decrease infarct size and that reducing
gap junction coupling may in fact reduce infarct size. The study by Kanno et al. (Kanno et al.
2003) using the Cx43 knock-out mouse showed a 50% reduction in infarct size compared to wild-
type mice when measured at 10 weeks post-chronic LAD ligation. In the study by Maass et al.
(Maass et al. 2009), the regulatory domain of Cx43 was modified by the addition of a K258stop
allele which rendered gap junction channels insensitive to changes in pH and hence remained
open during acute ischaemia and resulted in a significantly increased infarct size after ex vivo
myocardial infarction in comparison to Cx43 knock-out mice. Prestia et al. (Prestia et al. 2011)
enhanced gap junction coupling by using an adenoviral-Cx32 injected (Cx32inj) murine model
of chronic MI which resulted in enhanced expression of the voltage and pH-insensitive Cx32
channel. At four days post-MI they demonstrated no difference in arrhythmia susceptibility
on PES between Cx32inj and wild-type mice although did demonstrate a significant increase
in infarct size in Cx32inj mice on tetrazolium red staining. Owing to the reduced conductance
of the Cx32 channel in comparison to Cx43, Prestia was unable to explain the findings with
respect to transfer of apoptotic signals and instead hypothesised that calcium overload and
resultant calcium-mediated cell death was the predominant mechanism.
6.1.3 Hypothesis & Aims
A sufficient body of theoretical and experimental data exist (De Vuyst et al. 2011) to suggest
that pharmacological enhancement of gap junction coupling at the time of infarction-reperfusion
may attenuate the spread of necrosis, limit infarct size and reduce structural heterogeneities
resulting in a healed substrate less prone to late arrhythmogenesis.
The primary hypothesis addressed in this chapter is that enhancement of GJ coupling, in the
early phase post infarction-reperfusion results in a healed substrate with reduced susceptibility
to late arrhythmogenesis owing to reduced infarct size and infarct heterogeneity.
The primary aim of this chapter is to pharmacologically enhance GJ coupling, using Rotigap-
tide, in a rat model of infarction-reperfusion (fully described in Chapter 4) and to compare the
subsequent electrophysiological and structural remodelling against untreated controls.
To address the primary hypothesis and aim, the specific aims of the chapter were as follows:
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1. To assess the effects of Rotigaptide therapy on the in vivo arrhythmia phenotype, specif-
ically the incidence of ventricular arrhythmias and ECG parameters in the healed phase
of infarction
2. To assess the effects of Rotigaptide therapy on the ex vivo arrhythmia phenotype, specifi-
cally the susceptibility to arrhythmia provocation protocols in the healed phase of infarc-
tion
3. To explore the differences in electrophysiological remodelling of the action potential and
calcium transient at the remote, infarct border zone and infarct region as a result of
Rotigaptide therapy
4. To assess the effects of Rotigaptide therapy on infarct size and infarct morphology
5. To explore the alterations in diffusion tensor (DTI) derived metrics of myocardial archi-
tecture (fractional anisotropy, mean diffusivity) that occur in reperfused myocardium and
the effects of Rotigaptide therapy
6. To explore the alterations in DTI derived descriptors of 3-D myocardial architecture
(helix angle and transverse angle) that occur in reperfused infarction and the effects of
Rotigaptide therapy
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6.2 Methods
6.2.1 Infarction-Reperfusion Surgery
Male Sprague-Dawley rats (250-300g) underwent myocardial infarction surgery, with 60 minutes
of infarction, followed by reperfusion, as described in Section 2.3.3. The duration of 60 minutes
of infarction was chosen based on the results of studies described in Chapter 4. Following
recovery from surgery animals were singly housed until four weeks post-infarction
6.2.2 Administration of Pharmacological Therapy
Animals were divided into two equal groups (Control and Rotigaptide) and treated with either
phosphate-buffered saline (PBS) or the pharmacological GJ enhancer, Rotigaptide. A bolus
of drug was given 15 minutes post-ligation by an intraperitoneal (IP) injection of either 1.0ml
of PBS or 2.5nmol/kg Rotigaptide (made up to 1.0ml). To allow for drug administration
during the early phase post-infarction all animals underwent osmotic minipump implantation
at the time of MI surgery as described in Section 2.3.3.3. Control animals were administered
PBS at a rate of 10µl/hr for seven days (total 2ml), whereas Rotigaptide treated animals
were administered Rotigaptide at a dose of 0.11nmol/kg/day for seven days, dissolved in a
total volume of 2ml of isotonic saline. Rotigaptide dosing was based on previously reported
therapeutic steady state plasma concentrations in the rat (Haugan et al. 2006).
6.2.3 In Vivo Electrophysiological Studies
A measure of the spontaneous incidence of ventricular arrhythmias following infarction-reperfusion
was made by performing in vivo telemetry recordings at four weeks post-infarction, when the
healing process was complete, before the onset of heart failure, by implanting wireless ECG
telemetry transmitter as described in Section 2.4.1, between 7-10 days post-MI surgery. At
four-weeks post-infarction a 72 hour recording was taken from which a 24 hour block of data
was analysed and the total number of VPB, VT and VF episodes quantified and a composite
arrhythmia score calculated (Curtis et al. 1988, Equation 2.1). All analysis was performed
blinded to treatment group.
A recording of the rat 6-lead ECG was performed to assess for changes in basic ECG parameters
(RR interval, PR interval, QRS duration, QTc interval)as described in Section 2.4.2, between
days 26-30 post-MI surgery. Data were collected for five minutes following anaesthetic stabil-
isation and analysed oﬄine using LabScribe v2.0 with the average ECG intervals (PR, QRS,
RR, QTc) reported for 10 consecutive beats. All analysis was performed blinded to treatment
group by assigning a unique identifier to each heart and randomising the order of analysis using
a random number generator paired to the unique identifier.
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6.2.4 Ex Vivo Electrophysiological Studies
The effect of Rotigaptide on the electrophysiological remodelling of the action potential and
calcium transient at four-weeks post infarction-reperfusion was assessed by performing dual
voltage and Calcium optical mapping with RH237 and Rhod-2/AM as described in Section 2.6.
Baseline optical mapping data were collected by pacing at a CL of 150ms at twice diastolic
threshold before to allow calculation of local conduction velocity, dispersion of CV (standard
deviation of CV measurements), action potential and calcicum transient duration (at 50%, 75%
and 90% repolarisation), action potential and calcium transient dispersion (standard deviation
of APD and CaTD measurements) and action potential upstroke kinetics (dFdTmax, rise time).
All analysis was performed blinded to treatment group.
Following optical mapping the susceptibility to arrhythmias induced by programmed stimu-
lation was tested using an extrastimulus pacing protocol as described in Section 2.5.5 with
calculation of an arrhythmia score for each heart (Section 2.5.5.3).
Following optical mapping and PES studies, hearts were removed from the Langendorff appa-
ratus and perfusion-fixed with 100mls of 10% NBF for 10 minutes prior to storage in 10% NBF
before either diffusion tensor imaging and/or histological analysis.
6.2.5 Infarct Size Quantification
Histological analysis was performed on formalin-fixed, wax embedded sections as described in
Section 2.8. Each heart was sectioned at 1mm intervals from apex to base with between 12-16
sections covering the entire heart.
A total of 29 hearts (15 control, 14 Rotigaptide treated) underwent infarct size quantification
using the area-based method described in 2.8.2. A comparison between groups was also made
by categorising infarcts into those with transmural extension (defined as full thickness infarction
on >3 consecutive slices) and those with infarct thinning (defined as a reduction in thickness
in the infarct region resulting in thickness <50% of remote myocardium)
6.2.6 Diffusion Tensor Imaging
All imaging took place at the Pre-Clinical Imaging Facility, Kings College London, in collabora-
tion with Prof. Ajay Shah and Dr. Andrea Protti on a 7T Varian MR scanner, using 100G/cm
gradients running VNMRJ 3.2 with a 33mm quadrature RF coil.
Hearts were prepared for imaging as described in Section 2.7.2.2 prior to the scanner being set
up (2.7.4) and the scan geometry being planed (2.7.4.2).
Diffusion weighted data were obtained using a validated diffusion-sensitised fast spin echo se-
quence (for details of validation see Section 5.7) with the following parameters: TR = 2500ms,
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effective TE = 26ms, ETL = 2, Diffusion Encoding Scheme = Jones 6, b-value = 1000, |G|
= 28 mT/m, ∆ = 8.35ms, δ = 5.00ms, data matrix = 128x128, FOV = 25.6x25.6mm, slice
thickness = 0.5mm, slice gap = 0mm, giving a voxel size of 200µm x 200µm x 500µm. A total
of six spatial averages were performed with a total scan time of 110 minutes. All scans were
performed at room temperature (19oC) with no change in temperature between the start and
end of scanning.
MRI data were processed as described in Section 2.7.5 with analysis performed on nine consec-
utive LV slices, all containing infarcted myocardium, and segmented into remote, adjacent and
infarct regions as described in Section 2.7.6.
Fractional anisotropy and mean diffusivity maps for each region were generated as described in
Section 2.7.5.2, tested for normality and compared. Helix and transverse angles were calculated
for the remote and adjacent regions as described in Section 2.7.5.3 with the LV wall divided
into deciles and the mean angle reported for each decile at each region. Mean helix angle values
were plotted as a function of decile position through the myocardial wall and a linear line fit
through the points to generate a slope and y-intercept for comparison between groups.
To determine the optimal data points for linear line fitting, a comparison was made between
fitting a linear line through all data points, data points >30% from the endocardium and data
points occupying 20% either side of the point of transition (i.e. helix angle = 0o) and reporting
the slope and y-intercept for each line for a normal, non-infarcted heart. To determine whether
a significant apex-base difference existed, the linear line of best fit was performed for the entire
z-stack (9 slices) and compared against the line fit generated by fitting data to three separate
regions (basal, equatorial and apical (three slices per region).
For transverse angle data the mean transverse angle at each decile was compared between
groups and for both helix and transverse angle data, the angular deviation, defined as the
standard deviation of the respective angle in each region were compared between groups.
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6.3 Results
6.3.1 Study Numbers & Operative Mortality
A total of 37 animals underwent in vivo infarction-reperfusion surgery with an overall survival
rate of 81%, resulting in a total of 15 animals studied in each group (Control (CON) versus.
Rotigaptide (ROT)). Operative mortality, weight pre-surgery, weight at four-weeks post surgery
and weight gain over four weeks were similar between groups (Table 6.1)
MI + CON MI + ROT p value
Number Studied (Operated) 15 (19) 15 (18) -
Survival Rate 79% 83% ns
Pre-Op Weight (g) 263 ± 9 263 ± 10 ns
4 Week Weight (g) 414 ± 4 421 ± 8 ns
Weight Gain (g) 151 ± 8 158 ± 8 ns
Table 6.1: Total number of animals studied, survival rate and weights (in gram (g), prior
to surgery, at four-weeks post-operatively and net weight gain) in Control (MI + CON) and
Rotigaptide (MI + ROT) groups.
Of the seven animals that died, four were due to ischaemia-induced VF (before drug bolus), one
was due to uncontrollable bleeding (before drug bolus) and the remaining two occurred within
24 hours post-operatively, presumed late-arrhythmic, both in the control (PBS) treatment arm.
6.3.2 6-Lead ECG Parameters
ECG data were recorded from all surviving animals (n=30, 15 in each group) at four weeks post-
infarction reperfusion, summarised in Table 6.2, with data from sham-operated animals (n=5,
see Chapter 4) provided for comparison. There were no differences in either ECG parameters
between groups.
ECG Interval (ms) Sham MI + CON MI + ROT p value
PR 47 ± 3 49 ± 4 48 ± 4 ns
QRS 26 ± 1 28 ± 3 29 ± 4 ns
QTc 74 ± 5 76 ± 7 75 ± 8 ns
RR 168 ± 5 164 ± 10 167 ± 9 ns
Table 6.2: Surface 6-lead ECG intervals at 4 weeks post-infarction reperfusion surgery. Sham
= sham-operated (n=5). Control (MI + CON)& Rotigaptide (MI + ROT) n=15/group.
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6.3.3 Incidence of Spontaneous Arrhythmias
Telemetry data were recorded from all surviving animals (n=30, 15 in each group) at four-weeks
post-infarction reperfusion, summarised in Figure 6.1, with data from sham-operated animals
provided for comparison.
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Figure 6.1: (A) Scatter dot plot of incidence of VPB (log-transformed) and (B) Scatter dot
plot of composite arrhythmia score for a 24 hour period. Dots represent data from individuals
animals during a 24 hour period recorded 4 weeks post-infarction reperfusion, line at median
± IQR. Sham = Sham operated n=5, MI + Control (PBS) & MI + Rotigaptide n=15/group.
60’ I/R = 60 minutes infarction-reperfusion. ∗ p<0.05 vs. Sham-operated
Rotigaptide treatment did not reduce the incidence of spontaneous VPB (mean 1736 ± 630)
compared to control (1866 ± 1513 p=ns), with both groups demonstrating significantly greater
VPB compared to sham-operated (4 ± 1, p<0.05 vs. control and Rotigaptide arms). Likewise,
composite arrhythmia scores were similar between Rotigaptide and control groups (2.6 ± 0.3
vs. 2.0 ± 0.2, p=ns) and significantly higher than sham-operated (0.6 ± 0.1, p<0.05 vs. control
and Rotigaptide arms.).
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6.3.4 Action Potential & Calcium Transient Remodelling
Dual optical mapping was successfully performed in 25 (83%) of reperfused hearts (n=12 Con-
trol, n=13 Rotigaptide treated). Fewer hearts in the Rotigaptide treatment group demonstrated
transmural extension of the infarct and visible epicardial scar, compared to control (38% vs.
75%, χ2 = 0.11).
Conduction velocity (in cm/s, see Figure 6.2A) of the remote myocardium of control hearts
was significantly lower compared to sham-operated (62.5 ± 2.6 vs. 80.0 ± 5.0, p<0.05) but
similar to the remote region of Rotigaptide treated (65.7 ± 3.6, p=ns). The IBZ conduction
velocity was similar between control and Rotigaptide treatment groups (54.1 ± 3.0 vs. 50.9 ±
2.7, p=ns), as was the percentage reduction in CV from remote (10.8 ± 5.5 vs. 29.5 ± 7.5,
p=ns). CV dispersion (cm/s) was increased in the IBZ, compared to remote, with no difference
between treatment groups (sham, remote: 3.2 ± 0.5; control (remote) 3.5 ± 0.6 vs. (IBZ) 9.9
± 1.8, p<0.05; Rotigaptide (remote) 3.4 ± 0.4 vs. (IBZ) 11.5 ± 1.6, p<0.05; Figure 6.2B)
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Figure 6.2: (A) Reduction in CV at IBZ, comparable between treatment groups, (B) Increased
dispersion of CV at IBZ, comparable between treatment groups. Sham = Sham-operated, CON
= Control, ROT = Rotigpatide treated. Rem = Remote region, IBZ = Infarct Border Zone.
∗p<0.05
Action potential upstroke kinetics were remodelled in a similar fashion between control and
Rotigaptide groups, with findings in keeping with those demonstrated in early studies (Chapter
4). Rise time (in ms) was significantly prolonged in the infarct region when compared to remote
(control: 11 ± 2 vs. 5 ± 1, p<0.05, Rotigaptide: 12 ± 4 vs. 6 ± 1 p<0.05) with no difference
between treatment groups. Rise time in the remote region was similar to that of sham-operated
hearts (5 ± 1, p=ns, Figure 6.3A). dFdTmax (in AU/s) was significantly reduced in the infarct
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region when compared to remote (control: 0.13 ± 0.01 vs. 0.16 ± 0.01, p<0.05, Rotigaptide
0.13 ± 0.01 vs. 0.16 ± 0.01, p<0.05) with no difference between treatment groups. dFdTmax
in the remote region was similar to that of sham-operated hearts (0.17 ± 0.01, p=ns, Figure
6.3B)
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Figure 6.3: (A) Prolongation of Rise Time in the Infarct region, comparable between treatment
groups. (B) Reduction in dFdTmax at the infarct region, comparable between treatment groups.
Sham = Sham-operated, CON = Control, ROT = Rotigpatide treated. Rem = Remote region,
IBZ = Infarct Border Zone. ∗p<0.05
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Remodelling of AP duration was similar to that previously shown in Chapter 4, with a signifi-
cant prolongation in APD50 only in the infarct region (compared to remote), with no difference
between treatment groups. There were no differences in AP duration or dispersion in the re-
mote regions of sham-operated and control or Rotigaptide-treated hearts and absolute values
of AP duration and dispersion in the IBZ and infarct regions were similar between groups. AP
duration and dispersion data is summarised in Table 6.3
Remote Region
APD Duration (ms) APD Dispersion (ms)
APD50 APD75 APD90 APD50 APD75 APD90
Sham 26 ± 2 53 ± 4 72 ± 6 2 ± 1 3 ± 1 4 ± 1
Control 27 ± 2 51 ± 4 70 ± 3 1 ± 1 1 ± 1 2 ± 1
Rotigaptide 26 ± 1 48 ± 3 66 ± 3 1 ± 1 1 ± 1 1 ± 1
ANOVA (p value) ns ns ns ns ns ns
IBZ Region
APD Duration (ms) APD Dispersion (ms)
APD50 APD75 APD90 APD50 APD75 APD90
Control 29 ± 2 51 ± 4 71 ± 4 1 ± 1 2 ± 1 2 ± 1
Rotigaptide 33 ± 3 55 ± 4 73 ± 4 1 ± 1 1 ± 1 3 ± 1
t-test (p value) ns ns ns ns ns ns
Infarct Region
APD Duration (ms) APD Dispersion (ms)
APD50 APD75 APD90 APD50 APD75 APD90
Control 38 ± 4 ∗ 58 ± 4 74 ± 3 1 ± 1 2 ± 1 3 ± 1
Rotigaptide 34 ± 6 # 57 ± 5 76 ± 3 1 ± 1 2 ± 1 2 ± 1
t-test (p value) ns ns ns ns ns ns
Table 6.3: Effect of Rotigaptide treatment on Action Potential Duration and Dispersion, com-
pared to control-treated and sham-operated in the remote, infarct border zone and infarct
regions. ∗ p<0.05 vs. APD50 in remote region of control, # p<0.05 vs. APD50 in remote region
of Rotigaptide-treated
Examining the relative changes in APD (the % change in AP duration compared to remote
region) revealed a greater relative increase in AP duration in Rotigaptide treated hearts, com-
pared to control, reaching statistical significance at repolarisation of 75% (18 ± 9 % vs. -1 ±
3, p<0.05) and 90% (13 ± 8 % vs. 0 ± 2, p<0.05) in the IBZ region only (Figure 6.4)
The duration and dispersion of the Ca2+ transient in remote, IBZ and infarct regions was
similar, in keeping with the findings of Chapter 4, with no differences in absolute or relative
values between treatment groups (Table 6.4).
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Figure 6.4: Relative change in AP duration (50%, 75% and 90%) at (A) Infarct Border Zone
and (B) Infarct Region, with significant relative increase in APD75 and APD90 in Rotigaptide
treated group compared to control. CON = Control, ROT = Rotigpatide treated. ∗p<0.05
Remote Region
CaTD Duration (ms) CaTD Dispersion (ms)
CaTD50 CaTD75 CaTD90 CaTD50 CaTD75 CaTD90
Sham 51 ± 4 70 ± 4 79 ± 6 1 ± 1 2 ± 1 1 ± 1
Control 44 ± 2 65 ± 2 78 ± 2 2 ± 1 2 ± 1 3 ± 1
Rotigaptide 46 ± 2 66 ± 2 78 ± 2 1 ± 1 2 ± 1 2 ± 1
ANOVA (p value) ns ns ns ns ns ns
IBZ Region
CaTD Duration (ms) CaTD Dispersion (ms)
CaTD50 CaTD75 CaTD90 CaTD50 CaTD75 CaTD90
Control 48 ± 3 66 ± 3 77 ± 3 3 ± 1 3 ± 1 3 ± 1
Rotigaptide 52 ± 4 69 ± 5 80 ± 5 3 ± 1 3 ± 1 4 ± 1
t-test (p value) ns ns ns ns ns ns
Infarct Region
CaTD Duration (ms) CaTD Dispersion (ms)
CaTD50 CaTD75 CaTD90 CaTD50 CaTD75 CaTD90
Control 49 ± 3 65 ± 3 76 ± 2 3 ± 1 3 ± 1 4 ± 1
Rotigaptide 47 ± 3 64 ± 3 74 ± 3 3 ± 1 3 ± 1 3 ± 1
t-test (p value) ns ns ns ns ns ns
Table 6.4: Effect of Rotigaptide treatment on Calcium Transient Duration and Dispersion,
compared to control-treated and sham-operated in the remote, infarct border zone and infarct
regions.
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6.3.5 Susceptibility to Inducible Arrhythmias
Ex vivo PES, to test the susceptibility of reperfused myocardium to inducible arrhythmias
was performed in all surviving animals (n=30, 15 in each group) at four-weeks post-infarction
reperfusion, summarised in Figure 6.5.
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Figure 6.5: (A) Inducibility (expressed as %) of all VT episodes (non-sustained VT (NSVT) or
Sustained VT (SusVT)) and Sustained VT alone on PES for control and Rotigaptide treated
hearts and (B) Scatter dot plot of arrhythmia score (range 0-8) on PES. Dots represent data
from individuals animals, line at mean ± SEM. CON = Control (PBS), ROT = Rotigaptide
treated. n=15/group. ∗ p<0.05 vs. Control
Rotigaptide treatment resulted in a significant reduction in PES-arrhythmia score compared
to control (1.4 ± 0.4 vs. 3.2 ± 0.6, p<0.05), driven predominantly by a reduction in the
inducibility of sustained VT (20% vs. 53%, p=0.06).
6.3.6 Mechanisms of Arrhythmogenesis
To investigate the mechanisms of arrhythmogenesis in reperfused infarcted myocardium, optical
mapping data were collected at the time of arrhythmia provocation studies. A total of 8 datasets
were collected during episodes of VF (2/8), non-sustained VT (2/8) and sustained VT (4/8).
Activation maps were drawn to map the sequential activation pattern and identify regions of
slowed conduction and/or lines of functional block (defined as areas of crowding of>3 isochrones
and calculated conduction velocities in excess of 250cm/s (non-physiological)). Representative
optical action potential recordings during VT are shown in Figure 6.6.
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Of the sustained VT arrhythmias, 75% (3/4) of hearts demonstrated the presence of a visible
epicardial border zone. This border zone displayed slowed conduction on baseline pacing, but
no fixed block, and was the site for the development of functional block and re-entry during
sustained VT (see Figure 6.7 and Figure 6.8) in all hearts.
In non-sustained VT and VF arrhythmias, optical mapping data revealed areas of focal epi-
cardial breakthrough, without correlation to the infarct border zone (visible in 50% of cases),
with, in the case of VF, transient lines of functional block and rotational activity (maximum
duration <200ms, Figure 6.9).
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Figure 6.6: Representative optical action potential recordings during PES-induced VT. Three
examples (A-C) of sustained VT recorded during programmed electrical stimulation. Black
and white CMOS image represents visible epicardial optical mapping surface with three ac-
tion potential transients showing rapid (CL<100ms) tachyarrhythmia voltage recordings from
normal (blue), infarct border zone (black) and infarct (red) myocardium.
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Figure 6.7: Optical Mapping of Sustained VT post-infarction. (A) CMOS image with grey
dashed line indicating optical mapping field of view, red dashed line indicating visible epi-
cardial border zone. (B) Representative Action Potential traces from three regions during
monomorphic VT (CL = 90ms). (C) Activation map during sustained VT demonstrating line
of functional block (black line), corresponding to superior edge of infarct border zone. White
arrows indicate direction of wavefront propagation. (D) Activation map during paced rhythm
(CL 150ms) demonstrating absence of fixed conduction block
203
A50ms
t = 0ms
0 ms
20ms
10ms
t = +10ms t = +20ms t = +30ms
t = +40ms t = +50ms t = +60ms
B
C
Figure 6.8: Activation Map of VT post-infarction. (A) Representative optical mapping action
potentials demonstrating monomorphic VT at cycle length ∼60ms. (B) Activation map at t
= 0ms demonstrating line of (functional) block at infarct border zone. (C) Activation maps at
10ms intervals demonstrating activation sequence and delayed conduction manifest at infarct
border zone during VT.
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Figure 6.9: Optical Mapping of VF post-infarction. (A) CMOS image with no visible epicardial
border zone. (B) Representative Action Potential traces from four regions during VF. (C)
Activation map for five action potentials (1-5) during VF demonstrating areas of epicardial
focal breakthrough (white stars), areas of transient conduction block (solid black lines) with
short-lived rotational activity (map 2) and direction of wavefront propagation (white arrows)
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6.3.7 Infarct Size Quantification
Infarct size, measured by the area-based planimetry method was comparable between control
(17.3 ± 2.9 %) and Rotigaptide treated groups (12.2 ± 1.7 %, p=0.16, Figure 6.10A). As pre-
viously demonstrated in Chapter 4, infarct morphology varied from full-thickness (transmural)
infarction with or without infarct wall thinning to more patchy, discrete fibrosis, limited to the
mid-myocardial wall (Figure 6.10B, 6.11, 6.12).
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Figure 6.10: (A) Infarct size at four-weeks following infarction-reperfusion quantified by the
area-based method. CON = control hearts n=15, ROT = Rotigaptide-treated hearts n=14.
p=0.16. (B) Representative apex-base serial histology sections (at 2mm intervals) for (Left)
Control treated heart demonstrating thinned, transmural infarction and (Right) Rotigaptide
treated heart demonstrating patchy, mid-myocardial infarction
Rotigaptide did not significantly alter infarct morphology although fewer Rotigaptide treated
hearts demonstrated transmural extension (29%) compared to control (60%, χ2=0.09, Table
6.5), in keeping with visual observations during optical mapping experiments. The total number
of hearts demonstrating thinned wall infarcts (< 50% thickness of remote region) was similar
between groups (control 27% vs. Rotigaptide 14%, χ2=0.41, Table 6.6)
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Figure 6.11: Representative Massons Trichrome histological sections from (top) apex to (bot-
tom) base at 2mm intervals for two (A, B) infarcted hearts demonstrating partial thickness
infarction extending from sub-endocardium to mid-myocardium. Red asterisks highlight areas
of blue (collagen) staining representative of scarred myocardium post-infarction.
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Figure 6.12: Representative Massons Trichrome histological sections from (top) apex to (bot-
tom) base at 2mm intervals for two (A, B) infarcted hearts demonstrating full thickness in-
farction extending from endocardium to epicardium resulting in thin walled, infarcted scar.
Red asterisks highlight areas of blue (collagen) staining representative of scarred myocardium
post-infarction.
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Treatment Group Transmural Extension No Transmural Extension
Control (n=15) 9 (60%) 6 (40%)
Rotigaptide (n=14) 4 (29%) 10 (71%)
χ2 = 0.09
Table 6.5: Effect of Rotigaptide on transmural extension at four-weeks post-MI.
Treatment Group Thinned Infarct No Thinned Infarct
Control (n=15) 4 (27%) 11 (73%)
Rotigaptide (n=14) 2 (15%) 12 (85%)
χ2 = 0.41
Table 6.6: Effect of Rotigaptide on infarct thinning at four-weeks post-MI.
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6.3.8 DTI Derived Indices of Tissue Architecture
A total of 12 sequential hearts (7 Control, 5 Rotigaptide-treated) underwent diffusion tensor
imaging at Kings College London, as detailed in Section 6.2.6. Segmentation was not possible
in three hearts owing to lack of wall thinning and lack of contrast in the b=0 image. The mean
FA of the remote (posterior LV wall) region of these hearts ± 2SD was used as the basis of
inclusion criteria for the analysis of the remaining nine hearts; hearts with FA in the remote
region outside of this range were excluded from analysis (n=2).
Fractional anisotropy (FA) and mean diffusivity (MD) were compared for a total of 7 hearts
(4 Control, 3 Rotigaptide-treated) on a region-by-region (remote, adjacent, infarct) basis. In
support of the findings in Chapter 5, six out of seven hearts demonstrated a significant reduction
in FA in the infarct area compared to remote, with no difference between treatment groups.
Likewise, the adjacent region demonstrated significant separation from the remote region in
five out of seven and the infarct region in four out of seven of hearts. Comparing normalised
pooled data from the control group further supported the findings of Chapter 5 with only
the reduction in FA in the infarct region, compared to remote, reaching statistical significance
(15 ± 6 % reduction vs. remote, p<0.05) . However, this reduction was not present in the
Rotigaptide-treated group, with a relative reduction of only 5 ± 3 % which failed to reach
significance (p=0.23, Figure 6.13). FA in the remote, adjacent and infarct regions for both
treatment groups was significantly greater than FA of the embedding medium (0.13 ± 0.01,
p<0.05), indicating significant diffusion anisotropy.
Mean diffusivity demonstrated a significant increase in the infarct region compared to remote in
only three out of seven hearts, all from the control treatment group. Diffusivity of the adjacent
region demonstrated significant separation from the remote region in four out of seven hearts
and the infarct region in four out of seven hearts. Comparing normalised pooled data supported
the findings of Chapter 5, with only the increase in MD in the infarct region, compared to
remote, reaching statistical significane (6 ± 2 % increase vs. remote, p<0.05). However, this
increase was not present in the Rotigaptide-treated group, with a relative reduction of only 2
± 1 %, which failed to reach signifcance (p=0.12, Figure 6.14)
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Figure 6.13: Effect of Rotigaptide treatment on fractional anisotropy post-infarction. CON =
Control (n=4), ROT = Rotigaptide-treated (n=3). Rem. = Remote region, Adj. = Adjacent
region, Inf = Infarct region. ∗p<0.05
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Figure 6.14: Effect of Rotigaptide treatment on mean diffusivity post-infarction. CON =
Control (n=4), ROT = Rotigaptide-treated (n=3). Rem. = Remote region, Adj. = Adjacent
region, Inf = Infarct region.
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6.3.9 DTI Derived Three-Dimensional Myocardial Structure
Helix and transverse angles were compared for a total of 8 hearts (5 Control, 3 Rotigaptide-
treated) on a region-by-region (remote versus adjacent) basis.
6.3.9.1 Determining Analysis Parameters
The optimal data points to be fitted with a linear line were determined by fitting three lines to
helix angle data from an anterior LV wall segment from a normal heart. Lines were fitted to a)
all data points through the myocardial wall, b) data points greater than >30% of the transmural
distance through the myocardial wall from the endocardium and c) data points ±20% either
side of the x-intercept (i.e. where the helix angle transitions from positive to negative) and the
R2 values compared to assess goodness-of-fit. Fitting a linear line to data points greater than
30% of the transmural distance through the myocardial wall resulted in the highest R2 value
of 0.985, compared to 0.971 (all data points) and 0.979 (±20%, Figure 6.15). For the remote
region of control and Rotigaptide-treated infarcted hearts (n=8), a similar result was seen with
mean R2 0.974 ± 0.02 (>30% from endocardium) compared to 0.964 ± 0.02 (all data points)
and 0.968 ± 0.02 (±20%).
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Figure 6.15: Comparison of three linear lines fitted through helix angle data points
To determine the extent of an apex-base difference in helix angles, the nine slice z-stack from
a normal heart was equally divided into three regions; termed apex, equatorial and base. The
slope and intercepts from the linear line fits to the three regions were compared against each
212
other, and against the entire nine slice z-stack. The x-intercept represents the distance through
the LV wall at which fibre orientation is equal to zero degrees, i.e. in plane with the slice profile
and is the point at which the transition from left-handed helix to right-handed helix occurs.
The slope of the line represents the rate of change of the smooth helix angle transition from
left to right-handed helix through the LV wall with a greater slope representing a larger rate
of change from decile to decile. No differences existed in any linear line fit parameters between
the apex, equatorial or basal regions with no difference in comparison to data from all nine
consecutive slices (Table 6.7, Figure 6.16).
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Figure 6.16: Comparison of linear line and helix angle data points generated from analysis of
all (n=9) slices in z-stack or apex, basal and equatorial regions (n=3 slices in each)
Best-Fit Apex Equatorial Basal All p value
Slope -177 ± 7 -171 ± 12 -151 ± 10 -164 ± 9 ns
y-Intercept 117 ± 5 118 ± 8 100 ± 10 110 ± 6 ns
x-Intercept 0.66 0.69 0.66 0.67 ns
Table 6.7: Best fit parameters from linear line fitting through three regions (apex, equatorial,
base, n=3 slices/region) and from entire 9 slice LV-stack.
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6.3.9.2 Effects of Infarction on 3-D Myocardial Structure
Changes in the three-dimensional laminar structure of reperfused myocardium were examined
by analysing helix angle and transverse angle data from the remote and adjacent regions of
control-treated hearts (n=5), segmented as defined in Section 2.7.6. For helix angle data, a
best-fit linear line was fitted (R2 0.995 in remote, 0.997 in adjacent) through data points at a
distance >30% through the myocardial wall from the endocardium and the slope, y-intercept
and x-intercept compared between regions. The slope of the fitted line (i.e. the rate of change
of helix angle through the myocardial wall) was equal between the two regions (-157 ± 5 vs.
-158 ± 4, p=0.88), although the intercepts (the position the helix angle transition through 0
degrees occurs) were significantly different (y-intercept: 110 ± 3 vs. 103 ± 3; x-intercept: 70%
transmural distance vs. 65% transmural distance, p<0.01, Figure 6.17).
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Figure 6.17: Comparison of helix angle (in degrees) and best-fit linear lines from control-treated
hearts in remote and adjacent regions.
Helix angle deviation (expressed as the standard deviation of helix angle measurements at each
decile) taken as a whole-wall measure (averaged across all deciles) was higher in adjacent regions
compared to remote (16 ± 1 degrees vs. 14 ± 1, p<0.01). On a decile-by-decile comparison,
the greatest variation in helix angle occurred in the mid-myocardial region, between 50-70%
transmural distance (Figure 6.18).
Whole-wall mean transverse angle (averaged across all deciles) was significantly higher in the
adjacent regions, compared to remote (19 ± 1 degrees vs. 14 ± 1, p<0.05), with the greatest
difference visible from towards the epicardial wall. Transverse angle deviation (expressed as
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Figure 6.18: Comparison of helix angle deviation (in degrees) from endocardium to epicardium
(in ten equally spaced deciles) from control-treated hearts in remote and adjacent regions. ∗
p<0.05
the standard deviation of helix angle measurements at each decile) was significantly greater in
the adjacent region, compared to remote (12 ± 1 degrees vs. 9 ± 1, p<0.05).
6.3.9.3 Effects of Rotigaptide Treatment on 3-D Myocardial Structure
Changes in the three-dimensional laminar structure of reperfused myocardium afforded by
Rotigaptide treatment in the early reparative phase post-infarction were examined in remote
and adjacent regions from Rotigaptide-treated hearts (n=3), segmented as defined in Section
2.7.6, and compared to the changes noted in non-drug treated hearts.
The remodelling in helix angle between the remote and adjacent regions were similar in Rotigaptide-
treated hearts, compared to control, with the linear lines of best fit (R2 0.977 and 0.992 re-
spectively) demonstrating similar slopes (rate of change of helix angle, remote -151 ± 10 vs.
adjacent -167 ± 7, p=0.22), but significantly different y-intercepts (98 ± 7 vs. 102 ± 5) and
x-intercepts (65% vs. 61%, p<0.01, Figure 6.19).
Helix angle deviation in Rotigaptide-treated hearts was similar in remote and adjacent regions
(14 ± 1 degrees vs. 15 ± 1, p=0.46), with values in the remote region comparable to the same
region of control-hearts (14 ± 1 degees, p=0.71).
Mean transverse angle in Rotigaptide-treated hearts was greater in adjacent regions, compared
to remote (16 ± 1 degrees vs. 13 ± 1, p<0.01), with values in the remote region comparable
between treatment groups (vs. control 14± 1 degrees, p=0.61). In comparison, mean transverse
angle in the adjacent region of Rotigaptide treated hearts was significant lower compared to
control (16 ± 1 vs. 19 ± 1 degrees, p<0.05).
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Figure 6.19: Comparison of helix angle (in degrees) and best-fit linear lines from Rotigaptide-
treated hearts in remote and adjacent regions.
Transverse angle deviation in Rotigaptide-treated hearts was similar in remote and adjacent
regions (9 ± 1 degrees vs. 10 ± 1, p=0.22). On comparison with control hearts, the remote
regions demonstrated similar values (control 9 ± 1, p=0.55), whereas the adjacent regions in
Rotigatide-treated hearts had significantly reduced transverse angle deviation (control 12 ±,
p<0.05, Figure 6.20)
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Figure 6.20: Comparison of transverse angle deviation (in degrees) in remote and adjacent
regions of control and Rotigaptide-treated groups. Rem = remote region, Adj = Adjacent
region, CON = Control, ROT = Rotigaptide-treated. ∗ p<0.05
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6.4 Discussion
6.4.1 Effect of Rotigaptide on Late Arrhythmogenesis
The arrhythmia phenotype resulting from early Rotigaptide treatment in infarcted-reperfused
myocardium was assessed using a range of in vivo and ex vivo modalities. ECG parameters
in the healed phase of infarction (four-weeks post-infarction) were similar between groups, in
keeping with expectations considering the specific effect of Rotigaptide only on gap junction
conductance, not on the electrical properties of the plasma membrane (Xing et al. 2003). The
incidence of spontaneous arrhythmias in the healed phase were similar between groups, with no
difference in either the incidence of VPB or in composite arrhythmia score. Rotigaptide treat-
ment afforded a >50% reduction in arrhythmia score on PES, driven primarily by a reduction in
inducibility of sustained VT from 53% to 20% when subject to ex vivo arrhythmia susceptibility
testing. Re-entry is the primary mechanism of PES induced arrhythmias (Wellens 1978) and
requires formation of a circuit with unidirectional block, slow conduction and critical timing in
order for re-entry to initiate and sustain. The reduction in arrhythmias induced by PES in the
Rotigaptide treatment group suggests that Rotigaptide attenuatess the negative electrophysio-
logical or structural sequela of infarction resulting in hearts unable to sustain arrhythmogenesis.
Optical mapping of induced sustained arrhythmias confirmed the importance of the epicardial
border zone in the development of an area of functional conduction block around which a macro
re-entrant circuit could sustain. This was in agreement with the findings of Ding et al. (Ding
et al. 2010), although no fixed block, only conduction slowing, could be demonstrated at the
IBZ. The magnitude of the reduction in conduction slowing at the IBZ was similar between
groups, as was the degree of conduction dispersion, suggesting that the anti-arrhythmic effect
of Rotigaptide was not mediated by a change in the conduction properties of myocytes at the
border zone. Upstroke kinetics of the cardiac action potential were similar between groups,
lending further support to the GJ conductance specific effect of Rotigaptide. Absolute changes
in action potential duration were in agreement with the findings of Chapter 4 and were similar
between groups with only a significant prolongation in APD50 at the infarct zone. Rotigat-
pide treatment resulted in a greater relative change in action potential duration (APD75 and
APD90), only at the infarct border zone, although this alone, without any significant change in
dispersion is unlikely to fully explain the reduction in arrhythmia inducibility.
In considering the mechanism of re-entrant ventricular arrhythmias Allessie (Allessie et al.
1976) showed that re-entry could arise owing to differences in the recovery of excitability of
tissue within the re-entrant circuit. The effective refractory period of tissue, defined as the
time from depolarisation to the recovery of excitability maintains a close relationship with
the APD, which, when measured at 50%, 75%, or 90% of repolarisation provides a surrogate
measurement of the repolarisation time (Burton et al. 2001). Although some debate exists as
to whether there is a true transmural repolarisation gradient in the intact heart (Opthof et al.
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2009) there is a wealth of experimental data that suggests that APD gradients exist in models
of disease and are contributory towards arrhythmogenesis in models of infarction (Wong et al.
1982) and heart failure (Akar et al. 2003).
The demonstration in the studies in this chapter of an APD50 gradient between the infarct
region and remote region offers a putative mechanistic explanation for the development of ven-
tricular arrhythmias as the increased dispersion provides the conditions necessary for re-entry
arrhythmias to initiate and sustain and is in agreement with previous experimental models of
infarction. Thollon first showed APD prolongation (at 25%, 50%, 75%, and 90%) in hyper-
trophied rat myocytes four weeks post-MI (Thollon et al. 1989). This was corroborated by
Qin (Qin et al. 1996), also in isolated rat myocytes at four weeks post-MI with prolongation
of APD 50%, 75% and 90% who performed elegant patch-clamp studies that attributed APD
remodelling to a significant decrease in density in both Itof and Itos currents with no alteration
in calcium handling kinetics. The presence of APD prolongation and a repolarisation gradi-
ent between infarcted and remote myocardium were associated with a significant increase in
arrhythmia vulnerability, in agreement with the results demonstrated in studies in this chapter.
It is prudent to note a limitation of the method of optical action potential and calcium transient
analysis in examining the mechanisms of arrhythmogenesis. The visible epicardial surface was
divided into three regions (infarct, infarct border zone and normal) based on the CMOS image
appearance and data presented are representative of averaged data from each region. It is con-
ceivable however that within each region (specifically the infarct border zone and infarct) there
may exist significant inter-regional variability, particularly in APD, which, owing to the spatial
resolution of analysis may not be appreciated. This inter-regional variability may unmask areas
of local heterogeneity which may offer a mechanistic explanation of arrhythmogenicity whereas
averaged, large, regional-based analysis would appear to show little heterogeneity. In order to
explore this, the method of analysis could be refined by sub-dividing each of the three larger
regions into a number of smaller (20 by 20 voxel) regions and extracting and comparing optical
action potential and calcium transient data between these sub-divided regions.
6.4.2 Effect of Rotigaptide on Infarct Size
Infarct size is a well recognised determinant of VT inducibility in animal and human survivors
of infarction (Kaplinsky et al. 1978; Bello et al. 2005). As the area of infarction increases
the likelihood of meeting the conditions required for re-entry also increases with the distance
the wavefront travels before meeting non-refractory tissue a key determinant in allowing the
re-entrant circuit to establish. Although Rotigaptide treatment showed a trend towards reduc-
ing the number of hearts demonstrating transmural infarct extension there was no significant
reduction in infarct size measured by planimetry. This is in agreement with the work from Ng
(Ng et al. 2011) using the chronic-MI model of infarction although infarct sizes were smaller
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in the reperfusion model used in this thesis (untreated controls: 17 ± 3 %) compared to the
chronic MI model used by Ng (untreated controls: 21 ± 5 %) likely owing to the differing
biological effects of each model and methodological differences in quantifying infarct size. The
lack of effect on infarct size is in contrast to the work by Haugan (Haugan et al. 2006) who
demonstrated a significant relative reduction in infarct size in a rat model of chronic MI with
a comparable dose of Rotigaptide used in these studies. It is important to note the significant
differences between the model used by Haugan and that used in these studies. The chronic
MI model produces a consistent, thinned, transmural infarct across all treatment groups in
contrast to the infarction-reperfusion model which produces a broader spectrum of infarct mor-
phology ranging from patchy, discrete fibrosis to transmural, thinned infarction. The mortality
from the chronic MI model in Haugan’s study was significantly higher than mortality in these
studies (44% vs. 29%), with most (>30%) occurring during the MI surgery, presumably ow-
ing to the larger area-at-risk without reperfusion salvage. Another important difference is the
pre-treatment with Rotigaptide, justified to give a therapeutic concentration of Rotigaptide
at the time of LAD occlusion is in contrast to the more clinically relevant administration of
Rotigaptide after LAD ligation in these studies. Large animal studies using either Rotigaptide
(Hennan et al. 2009) or Danegaptide (Skyschally et al. 2013) in the acute setting of myocardial
infarction-reperfusion have demonstrated reductions in infarct size when measured early (up
to four hours), but these must be treated with caution as the measurement of infarct size at
this early time point represents area-at-risk, not healed scar, as the necrotic phase is yet to
complete and the reparative and healing phases have yet to start.
6.4.3 Analysis of DTI Metrics of Structural Remodelling
In applying diffusion tensor imaging to study the remodelling of myocardium post-reperfusion,
careful consideration was taken in the methodology of analysis, informed by the findings of
Chapter 5 and the current literature. Previous studies of regional changes in DTI derived
metrics (i.e. FA, MD) have commonly divided the short-axis slice into an arbitrary number of
equally sized segments (range 4-12, Chen et al. 2003; Wu et al. 2006b; Strijkers et al. 2009)
and allocated each segment to a single region (i.e. remote, adjacent or infarct) based on the
predominant histological findings within each segment. This method however is prone to error
owing to the presence of an unknown proportion of a mixed population of different tissues
within a single segment. To ameliorate this potential source of error, the work in this thesis
adopted the method of prospective segmentation (Wu et al. 2009; Wu et al. 2011), based on
the signal intensity in the b=0 image and the change in wall thickness, when present, to define
the infarct, adjacent and remote regions. This method is not without its limitations however as
although wedge shaped regions of interest in hearts with transmural infarction contain a single
population of tissue types, the nature of patchy infarction means that some wedge shaped
regions inevitably contain a mixed population of tissue types. Alternative methods, such as
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the co-registration method outlined and applied in Chapter 5 are also prone to errors, from a
registration perspective owing to deformation and distortion of the tissue and a segmentation
perspective as applying a histological definition of infarct border zone to individual voxels is a
partly subjective process.
Considerable variation exists in methodologies reported in the literature to analyse transmural
changes in helix and transverse angles. The commonest, adopted in these studies, was the
division of the LV wall into ten equally spaced deciles, (Walker et al. 2005; Schmitt et al. 2009;
Li et al. 2009) in comparison to the five divisions of Wu et al. (Wu et al. 2011) and 33 divisions
of Healy et al. (Healy et al. 2011). Only the remote and adjacent regions were analysed, owing
to the variable degree of wall thinning demonstrated in the infarct region and the potential
partial volume effect in attempting to divide the infarct region into deciles. In determining
how to quantitatively assess changes in helix angle, a series of linear lines were fitted (for each
region) through either all data points (Healy et al. 2011), data points greater than 30% from the
endocardial wall (Geerts et al. 2002) or data points either side of the transition (zero degrees)
point and the goodness-of-fit (R2) compared. In agreement with visual inspection, fitting a
linear line to points >30% from the endocardial wall resulted in the most robust fit (mean R2
value 0.974).
6.4.4 DTI Derived Indices Remodelled by Rotigaptide
Changes in infarct heterogeneity, independent of infarct size is a potential mechanistic expla-
nation for the reduction in PES inducible arrhythmias in the Rotigaptide treatment group (Ng
et al. 2011). Rotigaptide treatment reversed the relative reduction in FA and increase in MD
in the infarct region of control hearts resulting in FA and MD values comparable to those of
remote myocardium. There were no differences between groups with respect to infarct thinning
(χ2=0.43) or transmural extension (χ2=0.49). A reduction in FA and increase in MD in the
infarct region of the healed rat myocardium has been previously demonstrated by Chen et al.
(Chen et al. 2003), attributed to the replacement of viable myocytes by loose strands of collagen
which allow greater transverse diffusion (λ2 and λ3) and infiltration of inflammatory cells in
the infarct region which possess a more spherical cell shape, compared to the rod-like shape
of normal myocytes. These findings are in contrast to those reported in the mouse model of
infarction of Strijkers et al. (Strijkers et al. 2009), who demonstrated an increase in FA in the
infarct region, and no alteration in apparent diffusion coefficient (ADC) when studied at four-
weeks. These findings were attributed to the development of tightly packed collagen fibres with
a large increase in λ1 and small λ3, rendering water diffusivity anisotropic with restored ADC.
It is possible that Rotigaptide therapy has an intermediate effect on collagen deposition, with
an increase in collagen density of sufficient magnitude to render diffusion as equal in magnitude
and anisotropy as remote myocardium, but of insufficient magnitude to replicate the findings
of Strijkers. An alternative explanation is the presence in Rotigaptide treated hearts of greater
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surviving strands or islands of myocytes within the infarct region, so as to result in a partial
volume effect whereby the measured FA and MD is a reflection of both reduced anisotropy
and increased diffusivity in areas of collagen deposition, offset against preserved anisotropy and
normal diffusivity in areas with surviving myocytes.
The transmural course and mean values of helix and transverse angles are in agreement with
those reported in the literature (Chen et al. 2003) although care needs to be exercised in com-
paring with other experimental work considering the large variability in fibre structure between
different species (Healy et al. 2011) and changes afforded by different states of contracture
(Hales et al. 2012). In normal rat myocardium, helix angle values and transmural course is
similar in anterior, lateral, septal and inferior regions, and, as demonstrated, does not show a
significant base-to-apex gradient (Chen et al. 2003), unlike other species (Geerts et al. 2002;
Schmitt et al. 2009). In the four-week chronic MI model of Chen et al. (Chen et al. 2003)
the infarct region exhibited a greater change in helix angle per millimetre through the LV wall,
owing to its thinned nature, but when plotted as a function of transmural distance showed
no significant change from remote. In the studies described in this thesis, the adjacent region
did not demonstrate significant thinning, and showed a rate of change (i.e. slope of linear
fitted line) comparable to the remote region. However, the point of transition of the helix
angle (through zero degrees) appeared to occur ∼5% (of total LV wall thickness) closer to
the endocardium, with similar findings in both control and Rotigaptide-treated groups. This
shift in transition point is in keeping with the study of Rutherford (Rutherford et al. 2012),
who, in a high resolution histological study of the infarct border zone demonstrated that the
normal pattern of transmural myofibre rotation was disrupted across the IBZ with a shift in
transition point towards the endocardium. Helix angle deviation, a marker of fibre orientation
coherence was similar in remote and adjacent regions in both treatment groups, with sporadic
differences between remote and adjacent regions only present in the mid-myocardium (45-65%
of transmural distance) of control-treated hearts. The mean helix angle deviation of 14o in the
remote region is higher than the 10o reported by Chen et al (Chen et al. 2003), with the 16o in
the adjacent region lower than the 20o reported in the infarct region although discrepancies in
values likely reflect differences in the segmentation of myocardium between studies.
Transverse angle, the component of the myofibre orientation in the x-y plane, was similar in
remote regions of control and Rotigaptide treated hearts and was significantly higher in the
adjacent regions of both when compared to respective remote regions. However, the mean trans-
verse angle in the adjacent region was significantly reduced in the Rotigaptide-treated group,
compared to the adjacent region of control hearts, suggesting a more ordered and tightly packed
orientation of myofibres. Transverse angle deviation, another marker of fibre orientation co-
herence was significantly higher in adjacent regions of control hearts in comparison to remote
regions, a finding that wasn’t replicated in the Rotigaptide treated group which instead demon-
strated restoration of transverse angle deviation in the adjacent region to values seen in remote
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myocardium. The reduced mean transverse angle and reduced deviation of myofibres in the
x-y plane in the adjacent region of Rotigaptide treated hearts may reflect a more ordered heal-
ing process and offers a putative mechanistic explanation for the reduced arrhythmogenesis by
creating a more homogeneous, less arrhythmia prone border zone.
Owing to the number of hearts undergoing diffusion tensor imaging it was not possible to
perform subgroup analyses of arrhythmic versus non-arrhythmic hearts to determine whether
diffusion imaging could identify hearts with high arrhythmic risk. Although Rotigaptide treat-
ment appeared to confer significant remodelling benefit in the form of restoring FA and MD
in the infarct region to values of the remote region and in reducing the variation in fibre ori-
entation in the adjacent region, it is not possible to comment whether these changes rendered
individual hearts less or more susceptible to arrhythmogenesis.
6.4.5 Summary
The studies in this chapter describe the effects of early Rotigaptide therapy in a rat model
of infarction-reperfusion on the electrophysiological and structural remodelling post-MI. Roti-
gaptide was found to confer a protective effect against arrhythmias induced by programmed
stimulation at four-weeks post-MI with no alteration in resting ECG parameters, the incidence
of spontaneous arrhythmias in vivo or overall mortality. Infarct size, hypothesised to be re-
duced by Rotigaptide owing to a limited spread of mediators of cell death, was not reduced at
four-weeks although the number of hearts with transmural infarct extension was reduced. In
seeking potential explanations for the reduced inducibility of VT in Rotigaptide treated hearts,
diffusion tensor imaging revealed that Rotigaptide partially reversed indices of adverse struc-
tural remodelling with restoration of anisotropy and diffusivity in the infarct region, relative to
remote. In addition, examining the three-dimensional structure of infarcted myocardium with
DTI revealed a reduction in angular deviation in the adjacent region, shown in optical mapping
studies to be important in re-entrant arrhythmogenesis due to the development of functional
block and slowed conduction. The reduction in structural inhomogeneities in the infarct border
zone offers a potential mechanistic explanation for the reduced inducibility of arrhythmias in
Rotigaptide treated hearts.
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Chapter 7
Conclusions
This chapter provides a summary of the key findings from the studies described in this thesis
and the potential translation of these findings into clinical practice. A review of the major
limitations and considerations that arose during the studies are described before a series of new
hypotheses are presented based on the key findings of this thesis.
7.1 Summary of Key Findings
7.1.1 Antiarrhythmic Effects of Rotigaptide
The arrhythmia phenotype and temporal nature of arrhythmogenesis during ischaemia and
reperfusion in an ex vivo model of ischaemia-reperfusion were characterised in a series of studies
using the isolated rat heart. In agreement with previous work using similar small rodent models,
the time course of arrhythmogenesis is monomodal with a single peak between 12-15 minutes
post-ligation (Curtis 1998). Although different from the well described bimodal distribution of
Phase 1 arrhythmias characterised by Kaplinsky (Kaplinsky et al. 1979) in the canine heart, the
onset of arrhythmias at 12-15 minutes post-insult coincides with the increase in intracellular
tissue resistance representing gap junction uncoupling (Beardslee et al. 2000). Enhancing GJ
coupling by administration of Rotigaptide at, or prior to this vulnerable arrhythmic period
was hypothesised to reduce the incidence of ischaemia or reperfusion-induced arrhythmias.
The studies described in Chapter 3 showed that Rotigaptide was only effective in reducing
ischaemia-induced arrhythmias when administered prior to ligation, administration at the time
of ligation or on reperfusion had no effect on the incidence of either ischaemia-induced or
reperfusion-induced arrhythmias.
The beneficial effects of Rotigaptide therapy administered prior to a specific insult (i.e. pre-
treatment) have been well described in the literature. In the global low-flow isolated rat heart
model of cardiac ischaemia, pre-treatment with Rotigaptide prevented dephosphorylation of
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serine residues 297 and 368 and reduced the proportion of hearts in asystole after 30 minutes
ischaemia and prolonged the mean time to asystole (Axelsen et al. 2006). In the isolated guinea-
pig model of acidosis, pre-treatment with Rotigaptide partially reversed conduction slowing
seen with acidosis and reduced APD dispersion, both postulated as mechanisms to explain the
antiarrhythmic effects of Rotigaptide. Both of these studies administered Rotigaptide prior to
the insult, and would suggest that either a sufficient level of Rotigaptide needs to be present in
myocardium before a specific insult or that the effect of Rotigaptide (enhanced coupling) has
occurred to a sufficient degree prior to the insult.
In the ex vivo model used in this thesis, Rotigaptide administration at the time of ischaemia was
instantaneous (<5 seconds), however the time for it to be incorporated into the myocardium
and take effect (i.e. enhance coupling) is unknown. During ischaemia, Cx43 dephosphorylation
occurs with a similar time course to gap junction uncoupling (Beardslee et al. 2000) although
the extent to which dephosphorlyation contributes to uncoupling, alongside well-established
mechanisms of uncoupling during ischaemia such as calcium overload and acidosis (White et al.
1990), remains undetermined. Although the mechanism of action of Rotigaptide is not fully
understood, it is postulated to prevent dephosphorylation of Cx43 and hence act to prevent
uncoupling (Axelsen et al. 2006). It follows that the extent of GJ coupling preserved (or uncou-
pling prevented) by Rotigaptide is therefore offset against the degree of irreversible uncoupling
determined by either the magnitude of the cellular response to ischaemia or the time course of
ischaemia. If administration of Rotigaptide is delayed it is likely that Cx43 dephosphorylation
and subsequent uncoupling has already occurred to render the effect of Rotigaptide minimal or
that the cell-cell coupling preserved by Rotigaptide is of insufficient extent such that any effect
on reducing the arrhythmogenicity of the substrate is lost.
In the in vivo studies described in this thesis Rotigaptide was administered 15 minutes after
temporary LAD occlusion, 45 minutes prior to reperfusion. This time point was chosen by con-
sidering the pharmacokinetics of Rotigaptide to ensure adequate therapeutic circulating levels
at the time of reperfusion, akin to the pre-treatment model of Haugan (Haugan et al. 2006).
Owing to animal licensing limitations, no in vivo ECG recordings were possible and hence the
incidence of ischaemia-induced and reperfusion mediated ventricular arrhythmias in vivo are un-
known. The incidence of early (< 1 hr post-ischaemia, presumed arrhythmic) death did not dif-
fer between Rotigaptide and non-treated groups suggesting that no large early anti-arrhythmic
effect existed. However, prior studies in larger animal models of in vivo ischaemia-reperfusion
have demonstrated a consistent early anti-arrhythmic benefit of Rotigpatide treatment with a
reduction in the inducibility of VT in the early (<1hr) stages of ischaemia in the canine heart
(Xing et al. 2003) and a reduction in the incidence of reperfusion VPB and VT and a reduction
in infarct size in an open-chested canine model (Hennan et al. 2006). Care needs to be applied
in comparing the findings of this thesis with the aforementioned studies owing to substantial
differences in choice of animal model and methodology as the principle hypothesis addressed
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in this thesis addressed the potential reduction in late arrhythmogenesis occurring during the
healed phase of infarction.
The most striking, novel finding of this thesis, was the significant reduction in the inducibility
of ventricular arrhythmias in the Rotigaptide treated group when studied with PES four-weeks
post infarction-reperfusion surgery. Rotigaptide administration prior to reperfusion and as a
continuous infusion during the early necrotic and reparative phase (between 7-10 days post-
MI) conferred a significant benefit in reducing arrhythmia susceptibility on PES although did
not alter the incidence of spontaneous arrhythmias, resting ECG parameters (PR, QRS, QTc,
RR intervals) nor reduce overall survival. The lack of effect in Rotigaptide treated hearts on
resting ECG intervals and on upstroke kinetics of the cardiac action potential measured by op-
tical mapping suggests that, in agreement with the literature, Rotigaptide does not mediate its
effects via alterations in cardiac ion channel expression or conductance. In seeking mechanistic
explanations for the reduction in arrhythmias induced by PES, high resolution optical mapping
of the cardiac action potential and calcium transients was performed in the remote, infarct and
infarct border zone regions of control and Rotigaptide treated hearts. Owing to the re-entrant
nature of arrhythmias induced by PES and the dependence therefore on the development of
areas of slow conduction and conduction block to initiate and sustain such arrhythmias, the
preservation of conduction velocity in the remote region compared to control, and a similar
reduction in conduction velocity across the infarct border zone, shown to be critical in the
development of re-entrant arrhythmias, was unexpected. Optical mapping of action potential
and calcium transient duration and dispersion (as a measure of heterogeneity) also failed to
demonstrate significant differences between control and Rotigaptide treated hearts. Although
unable to provide an electrophysiological-based mechanism to explain the reduction in ventric-
ular arrhythmias induced by PES, studies in this thesis also considered other determinants of
late ventricular arrhythmogenesis post-MI, specifically novel indices of structural remodelling
which may offer tentative explanations for the observed reduction in arrhythmia inducibility.
7.1.2 Determinants of Arrhythmogenicity In Vivo
An in vivo model of infarction-reperfusion was characterised to mimic the current gold-standard
clinical management of acute MI with target vessel primary percutaneous coronary intervention
to restore vessel patency and distal flow. The well-established rodent chronic MI model pro-
duces a consistent, thin walled, transmural infarct with a high incidence of spontaneous arrhyth-
mias prior to the development of heart failure as adverse remodelling progresses. The rodent
reperfused infarction model described in this thesis, in agreement with previous infarction-
reperfusion rodent studies produces a more heterogeneous pattern of infarction with patchy,
mid-myocardial infarction evident in half of all hearts and thinned transmural infarction evident
in the remaining half. This heterogenous pattern of infarction mimics the diversity of infarction
in humans and gives rise to a phenotype that is more prone to spontaneous arrhythmias com-
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pared to sham-operated but less prone compared to the chronic MI model (Lyon et al. 2011).
Also in agreement with studies in the literature, a duration of only 30 minutes of infarction,
prior to reperfusion, although rendering the heart susceptible to arrhythmogenesis compared to
sham-operated, was not sufficient to provoke sufficient cellular apoptosis and subsequent scar
formation, demonstrated by the lack of collagen deposition on histology. An increase in the
infarction time to 60 minutes rendered the heart pro-arrhythmic but also led to scar formation,
owing to the greater duration and magnitude of the cellular insult. Importantly, this 60 minute
duration of infarction produces a phenotype which remains separate from the total, permanent
occlusion model, which, in previous rat infarction-reperfusion studies has been shown to occur
at durations beyond 90 minutes of infarction characterised by almost universal wall-thinning
and transmural infarct extension on histology and a highly pro-arrhythmic phenotype.
In agreement with previous experimental and clinical studies, hearts with larger infarcts were
more susceptible to both spontaneous arrhythmias and arrhythmias inducible by PES. In de-
termining infarct size, absolute values were found to be highly sensitive to the method of quan-
tification, in agreement with the study of Takagawa (Takagawa et al. 2007). The area-based
method was found to under-estimate infarct size by 2.5 times compared to the length-based
method with a compression of the range of values of 0.3 fold. Owing to the patchy nature of
infarction the area-based method was chosen as the sole method for reporting infarct size for
the studies during this thesis and as such, care must be taken in direct comparison with cited
values for infarct size in the literature owing to differing methodology.
Whole heart dual optical mapping with voltage and calcium sensitive dyes was performed to
examine the changes in cardiac action potential and calcium handling in the remote, infarct
and infarct border zone post-MI and to determine whether these changes play a causal role
in arrhythmogenesis. Owing to the small infarct size after 30 minutes of infarction no hearts
in this group displayed visible epicardial infarct border zone. The action potential and cal-
cium transient characteristics from this group were similar to that demonstrated in the sham
operated group suggesting that the area of myocardium imaged had not undergone significant
electrophysiological remodelling. As some (50%) of the hearts in the 30 minute group did have
evidence of mid-myocardial fibrosis the lack of remodelling on optical mapping suggests that
the volume imaged was limited to the epicardial surface and did not extend to a significant
depth. In contrast, 60 minutes of infarction yielded an epicardial border zone visible to the
naked eye and on optical mapping in a substantial (80%) proportion of hearts with transmural
infarct extension confirmed on histology. The infarct border zone demonstrated a reduction in
local conduction velocity of similar magnitude to reported values (59% reduction vs. remote)
with increased conduction velocity dispersion and prolongation of rise time and blunting of the
steepness of the upstroke of the optical action potential. Although no fixed conduction block
was visible on baseline pacing, the infarct border zone was shown to be critical to the mech-
anism of ventricular arrhythmogenesis with the development of functional conduction block
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providing one of the necessary conditions for re-entrant arrhythmias to sustain, demonstrated
by optical mapping during PES.
7.1.3 Examining Tissue Architecture with Diffusion MRI
A specific aim of the work in this thesis was to development, validate and apply diffusion MR
imaging, specifically diffusion tensor MRI to the study of myocardial architecture. Initially
performed using a diffusion-sensitised EPI sequence at Imperial College, feasibility and sample
preparation were optimised prior to acquisition of a pilot dataset of normal, non-infarcted
hearts. Detailed dual histological and diffusion MRI confirmed, in keeping with the literature,
an agreement between the direction of fibre orientation and the primary eigenvector of the
diffusion tensor. Two methods of segmenting MRI data for the study of regional (remote,
border zone, infarct) changes in diffusion-derived metrics were compared; a labour intensive
co-registration approach requiring precise histological sectioning and a series of linear and
non-linear transforms to map histological images to the same two-dimensional space as MRI
images and an approach whereby the characteristics of the B=0 image (no diffusion weighting)
were used to define regions of interest ahead of prospective segmentation. There was excellent
regional agreement in values of each diffusion-derived metric when comparing methods with no
statistically significant differences in absolute values.
Significant variation exists between the diffusion-sensitised MRI sequences used in this thesis
(an EPI-readout at Imperial College compared to an FSE sequence at Kings College), necessi-
tating a degree of caution in considering the reproducibility of diffusion-derived MRI metrics
(Fractional anisotropy (FA) and mean diffusivity (MD)). Pooled data from all complete diffu-
sion MRI datasets described in this thesis (n=11 hearts) results in FA of 0.24 ± 0.02 and MD
of 1.18 ± 0.02 x 10−3 mm2/s in the remote region, both significantly different than FA (0.14 ±
0.01, p<0.05) and MD (1.78 ± 0.02 x 10−3 mm2/s, p<0.05) of surrounding isotropic embedding
medium, with sufficiently small standard deviations to suggest a good degree of reproducibility.
There is a paucity of published literature reporting normal FA and MD values for ex vivo rat
myocardium; the study by Hales (Hales et al. 2012) assessing the change in helix and sheet
angle afforded by contraction state reported FA values of 0.34 ± 0.04 and MD of 1.01 ± 0.07 x
10−3 mm2/s (with no change afforded by contraction state), whereas Chen (Chen et al. 2003),
in assessing the effects of chronic infarction reported a FA in the remote region of 0.27 ± 0.03.
Substantial variation also exists across species with in vivo human DTI reproducibility studies
reporting FA of 0.41 ± 0.04 and MD of 1.10 ± 0.06 x 10−3 mm2/s (Tunnicliffe et al. 2014)
in contrast to ex vivo large animal studies reporting FA of 0.32 ± 0.01 and significantly lower
MD of 0.67 ± 0.10 x 10−3 mm2/s. In addition, unlike the study by Hales (Hales et al. 2012)
who found no difference in FA or MD dependent on contraction state, Tunnicliffe (Tunnicliffe
et al. 2014) demonstrated a significant increase in FA in diastole (0.54 ± 0.03) compared to
systole (0.41 ± 0.04, p<0.05). Explanations for the wide variability of reported values are wide-
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ranging and include differences in sample handling (specifically fixative agent used, embedding
agent used, post-mortem interval and time in fixative), data acquisition (specifically the MRI
sequence, variation in b-value, number of gradient directions sampled and number of averages)
and differences in data handling (specifically the software used to reconstruct and fit the diffu-
sion tensor, generating diffusion-derived metrics and methods of segmenting the myocardium
into regions of interest.)
7.1.4 Effects of Rotigaptide on the Structural Phenotype in Reper-
fused Infarction
Reported reductions in infarct size by modulating GJ coupling are conflicting. Both enhancing
(Haugan et al. 2006) and reducing (Kanno et al. 2003) GJ coupling peri-infarction have been
shown to reduce infarct size although substantial differences exist between studies in both
experimental design, specifically animal model used and duration of insult and in method and
timing of infarct size quantification. Recent studies using pharmacological agents to enhance GJ
coupling have focused on early (within hours) assessment of infarct size and reported significant
reductions in area-at-risk although the eventual true infarct size remains unknown and findings
reflect the outcome of GJ modulation on the necrotic and early apoptotic phase post-MI rather
than on the fully healed substrate which has greater clinical relevance. The work in this
thesis demonstrated no reduction in infarct size measured at four-weeks post-MI, in agreement
with previous GJ modulation studies in a chronic MI model reported by our group (Ng et al.
2011). Putative explanations for the discrepancy in the findings of this thesis with infarct size
reductions described in the literature include the use of a small, rather than large animal model,
the administration of Rotigaptide post-LAD occlusion, rather than pre, and the difference in
timing of infarct size measurement. It is possible that Rotigaptide exerts a reduction in the area-
at-risk measured early (within hours) but as the cellular insult from infarction and reperfusion
resolves over a longer period of time the final, resultant infarct area is not significantly reduced.
Infarct size is not the sole determinant of arrhythmogenesis post-MI with infarct heterogeneity,
among other factors, having an important role. Diffusion tensor MRI was developed and
applied to study subtle infarct remodelling characteristics which may help explain the observed
reduction in arrhythmia susceptibility afforded by Rotigaptide treatment. The results from
these preliminary studies, although with small numbers, suggest that significant differences in
myocardial tissue architecture exists between control and Rotigaptide treated hearts. Relative
to remote, infarcted myocardium has been consistently reported to have lower FA and higher
MD values as the anisotropic structure of normal myocardium is replaced by the disorganised,
looser collagen structure of scar. This relationship was reproduced in this thesis in both post-
MI (no drug) validation studies and in the control arm (PBS treated) of the enhancing GJ
coupling studies with significance demonstrated between remote and infarct regions for both
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FA and MD values. Rotigaptide treatment resulted in a loss of statistical significance for both
FA and MD with a restoration of values in the infarct region to those in remote. In describing
the three-dimensional structure of myocardium, two angles, the helix and transverse angle can
be calculated to provide quantifiable measures of the laminar structure of the myocardium
(Streeter et al. 1973a; Streeter et al. 1973b), both of which can be measured with DTI (Geerts
et al. 2002). In agreement with widely reported values, the helix angle demonstrated a smooth
transition from a right-handed helix (i.e. a positive helix angle) in the endocardial fibres to
a left-handed helix (i.e. a negative helix angle) in the epicardial fibres. The linearity of this
transition through the entire LV wall thickness (i.e. the rate of change through the 10 deciles of
the LV wall), represented by the slope of the linear line fitted through the helix angle plot was
similar between control and Rotigaptide treated hearts, suggesting that no gross alteration in
the helix angle occurs. The mean transverse angle, which describes the orientation of myofibres
in the x-y direction on the short-axis plane of each slice of the heart was found to be significantly
reduced in the adjacent, or border zone region, of Rotigaptide treated hearts. Whereas the
transverse angle was significantly higher in the adjacent region compared to the remote region
of control treated hearts, representing disorganised tissue architecture in the adjacent region,
this difference was abolished in Rotigaptide treated hearts in addition to a reduction in the
angular dispersion of transverse angle.
The preliminary findings of the DTI studies of this thesis demonstrate a reduction in structural
heterogeneity in Rotigaptide treated hearts with a preservation of FA and MD in the infarct
region and a reduction in the myofibre transverse angle and reduced angular dispersion in the
region adjacent to the infarct. This reduction in structural heterogeneity offers a putative
explanation for the reduction in arrhythmia susceptibility demonstrated on PES.
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7.2 Translation to Clinical Practice
7.2.1 Enhancing GJ Coupling peri-Infarction
Results from ex vivo studies described in this thesis suggest that administration of Rotigaptide
at the time of ischaemia-reperfusion would have no effect in reducing the incidence of acute
arrhythmias of ischaemia or reperfusion and importantly does not result in a pro-arrhythmic
effect. Pre-treatment with Rotigaptide did afford a reduction in the incidence of acute arrhyth-
mias and has a potential application in patients with high-risk, but not emergent acute coro-
nary syndromes, prior to reperfusion. In these patients the pathogenesis of unstable coronary
artery plaque with a modest degree of distal flow differs from the pathophysiology of STEMI
with vessel occlusion and systemic administration of Rotigaptide prior to planned reperfusion
may ameliorate the negative electrophysiological and structural consequences in non-STEMI
patients.
Current clinical trials are ongoing with administration of Danegaptide, a 3rd generation agent
to enhance GJ coupling (Clinical Trial ID: NCT01977755) in STEMI patients at the time of
primary PCI. Owing to the beneficial effect of Danegaptide on infarct size in pre-clinical large
animal models, this trial is designed with myocardial salvage index (defined as difference be-
tween MRI derived volume at risk and final infarct volume) at 3 months as the primary endpoint
with secondary endpoints of relative infarct size, extent of ST segment resolution and compos-
ite major clinical adverse events. Unfortunately, no arrhythmia endpoints are specified, either
spontaneous incidence (i.e. 24 hour Holter monitoring) or arrhythmia testing (i.e. invasive PES
studies) in the study protocol. Future study design would benefit from arrhythmia assessment
as although increased myocardial salvage and a reduction in infarct size is likely to reduce the
likelihood of progression to heart failure it is also likely to afford a reduction in the incidence
of potentially fatal ventricular arrhythmias, an important endpoint that pharmacological gap
junction modulator studies need to demonstrate ahead of gaining accepted clinical use.
7.2.2 Clinical Diffusion MR Imaging
Clinical diffusion MRI, despite being a quantitative, novel modality to image diseased my-
ocardium, is technically challenging owing to bulk cardiac motion with the majority of recent
publications concerned with firstly addressing technical improvements in sequence and navi-
gator design to ameliorate movement artefact (Baete et al. 2013; Nguyen et al. 2013; Nielles-
Vallespin et al. 2013) and secondly ensuring reproducibility (Tunnicliffe et al. 2014)
The first in vivo human cardiac diffusion imaging studies were pioneered by the group of Van
Weeden in the late 1990s, performed in healthy volunteers, primarily addressing the issue of
measuring diffusion in the presence of cardiac strain (Tseng et al. 1999; Tseng et al. 2000).
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The first study to apply diffusion imaging to study remodelling post-infarction was performed
in 2006 by Wu et al. (Wu et al. 2006a) who enrolled 37 patients at a median of 26 days post-
infarction and performed whole heart delayed-enhanced MRI and cine MRI alongside diffusion
MRI in three mid-LV slices. With delayed-enhanced MRI providing a reference for the infarct
region, Wu demonstrated, in agreement with previous animal models and the findings of this
thesis, that FA decreased and MD increased in the infarct region relative to the remote region.
This work was expanded in the 2009 study by Wu (Wu et al. 2009) who followed up the original
cohort of 37 patients with a further diffusion MR scan in the chronic phase of MI with a mean
interval between scans of 191 days. This demonstrated a recovery in MD and FA in infarct and
adjacent regions from recent to chronic MI, correlating with an improvement in wall-thickening
in the infarct-adjacent region and functional recovery.
The utility of diffusion MRI in identifying acute and subacute myocardial infarction was ad-
dressed in the study by Laissy et al. (Laissy et al. 2013), akin to widespread use of clinical
diffusion MRI in the diagnosis of hyperacute stroke. Laissy used a fast (six minute) acquisition
sequence to calculate the trace ADC at a range of b-values in patients with acute, subacute
and chronic MI, and compared to delayed-enhanced MRI as gold-standard. Across all patients,
diffusion imaging showed a sensitivity of 80% and specificity of 100% in identifying infarction,
with the greatest sensitivity in acute infarction (mean 3 days, sensitivity 97%), followed by
subacute infarction (mean 40 days, sensitivity 86%) and chronic infarction (mean 230 days,
sensitivity 36%). Owing to the rapid acquisition sequence possible with diffusion imaging and
the lack of contrast agent, the authors conclude that diffusion may offer an imaging modality
to aid the diagnosis of patients with recent or acute NSTEMI although acknowledge the limited
spatial resolution and discrepancy in ADC values with previous literature values
In addition to studies of myocardial infarction, diffusion imaging has been applied to the study
of a range of other cardiac diseases. In the case of hypertrophic cardiomyopathy (HCM),
diffusion MRI derived measures of fibre disarray have been proposed as a method to identify
patients at risk of sudden early cardiac death (Tseng et al. 2006). The largest diffusion imaging
study of HCM patients to date, by Mcgill (McGill et al. 2012), demonstrated the interstudy
reproducibility of diffusion MRI derived metrics (FA and MD) in 10 HCM patients. In the case
of acute myocarditis, low b-value diffusion imaging was able to detect global myocardial oedema
in 13 patients and co-localised with regions of hyper-enhanced signal on delayed-enhanced MRI
(Potet et al. 2013). In Takotsubo cardiomyopathy, a case report from Driss (Ben Driss et al.
2010), showed that despite no abnormalities on either early or late delayed-enhanced MRI,
diffusion imaging demonstrated an area of hyperintense signal with decreased ADC in the
akinetic segment which had resolved, along with clinical symptoms when scanned 6 weeks later
As demonstrated in the studies in this thesis, significant differences can be detected using
diffusion MRI between the remote, infarct border zone and infarct regions in the healed, in-
farcted heart. Considering the importance of IBZ remodelling in arrhythmogenesis and the
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co-localisation of re-entry VT circuits to the anatomical IBZ, it follows that descriptive indices
of tissue architecture at the IBZ or infarct may allow for finer risk stratification and have a role
in predicting future arrhythmic events. In addition, cardiac diffusion MRI may be useful in
evaluating the efficacy of treatments or invasive therapies designed to modulate the arrhythmic
substrate, by providing quantitative measures of tissue integrity and anisotropy.
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7.3 Limitations
7.3.1 Choice of Reperfusion Model
The well-established rat model of infarction-reperfusion was used for all ex vivo and in vivo
studies owing to it’s reproducibility, ease of handling, consitent cardiac anatomy, cost and abil-
ity to power studies sufficiently. However, several limitations exist with regards to translating
findings from the rat model to humans, principally owing to the species difference in rat elec-
trophysiology compared to other mammalian species. First noted by Weidmann (Weidmann
1957), the rat ventricular AP is more akin to the atrial AP found in other species with a lack
of a high plateau, and a slow final repolarisation phase resulting in a triangular-like AP shape.
These differences between rat and other mammalian APs have been attributed to altered inward
current generated by the Na+-Ca2+ exchanger (Schouten et al. 1985) and by the K+ currents
I t0 and IK (Apkon et al. 1991). Unlike cardiac ion channels, gap junction channel expression
(Cx43, Cx40, Cx45) appear preserved between species with similar expression in ventricular
myocytes in both rodent and human hearts (Gros et al. 1996b). As the studies in this thesis
were concerned only with enhancing gap junction function, and not modulating ionic currents,
the negative effect of the species difference in ion channel expression were offset against the
benefits of using a small animal model of infarction-reperfusion which allowed for longitudinal
study of the arrhythmia and structural phenotype using a variety of methods, not possible in
clinical or larger animal models.
In comparison with larger animal models, a technical limitation of small animal models concerns
the ability to co-localise electrical activity (i.e. optical mapping data) and structural indices (i.e.
histology and MRI images) owing to the small (<2cm) size of the rat heart. This limitation
is realised further when considering the combined functional and modelling work of Pop et
al. (Pop et al. 2012) who, using a porcine model of infarction combined 3-D structural MRI
data with optical epicardial activation maps to allow for development and testing of a realistic
3-D computer model of cardiac conduction. In addition to providing mechanistic insight into
arrhythmogenesis post-infarction, patient-specific computer models of disease have the potential
to offer a personalised approach to treatment by allowing substrate-targeted ablation procedures
and optimising implantable lead position for ICD and resynchronisation devices. Despite the
studies described in this thesis having all component parts required to construct a 3-D computer
model of infarction with optical mapping data describing epicardial activation and histology
and diffusion MR data providing fibre orientation and detailed infarct geometry, this was not
possible owing to the small physical size and difficulty in precisely translating and co-localising
a curvilinear 2-D epicardial plane onto a 3-D geometry without introducing an unacceptably
large degree of error.
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7.3.2 Isolated Heart Studies
The isolated perfused heart, described by Langendorff (Langendorff 1898), was used for the
study of ex vivo arrhythmogenesis in ischaemia-reperfusion, and in ex vivo arrhythmia vulner-
ability and high-resolution dual optical mapping studies of the healed, reperfused heart. The
Langendorff system is well-established and offers numerous advantages for studying the intact
organ with relative ease-of-setup in a non time-consuming, controllable environment which is
not feasible in vivo (Bell et al. 2011). However, there remain limitations with the Langen-
dorff method of perfusion and with the experimental set-up required to obtain robust and
reproducible data. The preparation itself requires a degree of skill to minimise the effect of
pre-conditioning or inadvertent ischaemic injury upon handling of the heart. Perfusion must
be carefully controlled both in terms of initial set-up to ensure competence of the aortic valve
and sufficient coronary flow but also to minimise the risk of excessive flow rates or pressure
resulting in tissue oedema, especially with crystalloid based perfusates. Although intact and
spontaneously beating, the heart is isolated from it’s normal neurohumoral input and is free
from control by the central and autonomic nervous system. Although failing to truly mimic in
vivo physiology, this can be viewed as an advantage as it allows finer control of external factors
(temperature, pressure, buffer composition) to modulate heart function and allow, as described
in this thesis, for the effects of cardio-active drugs to be measured in a consistent and precise
manner.
The use of Blebbistatin as an excitation-contraction uncoupler in dual optical mapping studies
was necessary to minimise motion artefact and allow collection of cardiac AP and calcium
transient data. Conflicting reports exist as to the deleterious effects of Blebbistatin on the
electrophysiological properties of intact myocardium. Fedorov (Fedorov et al. 2007), in isolated
rabbit hearts, right ventricles, right atria and single rat ventricular myocytes demonstrated
that Blebbistatin had no effect on ECG parameters, atrial or ventricular activation maps or
effective refractory periods. Despite duplicating the experimental protocol of Fedorov, Brack
et al. (Brack et al. 2013) demonstrated that Blebbistatin had a series of profound effects
on cardiac electrophysiology. In isolated rabbit hearts Blebbistatin prolonged LV apical and
basal monophasic APD, prolonged the effective refractory period and increased the steepness
of the restitution curve. The reason for the discrepancies between these two studies remains
unclear. In addition to potential effects on electrophysiology, Swift et al. (Swift et al. 2012)
showed that without meticulous preparation Blebbistatin could precipitate in the coronary
vasculature, and, in low-flow global ischaemia studies, delayed the onset of ischaemia owing
to the reduction in energy consumption afforded by eliminating cardiac motion. The optical
mapping studies described in this thesis were performed in hearts with healed infarction with
no superimposed ischaemic insult with the principal aim of studying the electrophysiological
properties of the myocardium, rather than cardiac function or energy kinetics.
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7.3.3 Diffusion MR Imaging
The FSE sequence was the first sequence sensitised to diffusion and is well-established in the
literature although due to the significantly long acquisition times has been superseded in the
majority of experimental and clinical applications of diffusion by multi-shot or 3-D EPI based
sequences. For the same scan time the EPI sequence used at Imperial College was able to provide
6 spatial averages for a total of 30 diffusion-sensitising directions compared to the FSE sequence
used at Kings College which provided 6 spatial averages for only 6 directions. To reconstruct the
diffusion tensor a minimum of 6 directions are required, although the accuracy of describing
the diffusion profile increases with using an optimised scheme (Hasan et al. 2001) and with
increasing the number of gradient directions sampled (Papadakis et al. 2000). Owing to the time
interval between scanning at Imperial College and KCL and the need to perform histological
analysis on samples scanned at Imperial College, no comparison was possible between sequences
by scanning samples on both systems.
A further limitation concerns the methods used to co-localise and register diffusion MR and
histological images. The first method, which required time and labour intensive destructive
histology before a series of rigid and non-rigid transformations based on point-sets gave a good
registration result with a minimal mean-squared error. The utility of point-sets to transform
images relies on accurate placement of each point-set in the initial registration which in these
studies was based on obvious anatomical landmarks (LV cavity, papillary muscle). However,
owing to distortion, shrinking and warping introduced by dehydration, wax embedding and
sectioning of the histological samples it was not always possible to reliably identify such land-
marks which rendered a number of sections unable to be registered with MRI images and
increased the potential error in those that were registered successfully. The second method,
a prospective method of identifying the infarct and ‘adjacent’ regions based on the charac-
teristics of the un-weighted (B=0) image was chosen based on its application in clinical (Wu
et al. 2009) and experimental (Wu et al. 2011) studies. All infarcts were clearly identifiable on
un-weighted images although patchy infarction would, by definition, include an area of non-
infarcted myocardium within the region of infarct, based on the method used. In addition, the
‘adjacent’ zone owing to its size, does not represent the true structural infarct border zone, but
instead represents the transition zone from infarcted to remote myocardium. All methods of
co-registering and identifying regions of infarct, IBZ and remote myocardium are prone to error
although reassuringly, direct comparison of the two methods showed good correlation between
absolute values of FA and MD in all three regions and no differences when data were analysed
on method-by-method comparative basis.
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7.4 Future Research Topics
7.4.1 Study Design of GJM Clinical Trials
The studies in this thesis have provided preliminary evidence that modulating GJ coupling
by pharmacological administration of agents with already proven clinical safety in humans
can render the healed substrate post-MI less prone to arrhythmogenesis. Within the body
of literature on pharmacological gap junction enhancement this thesis provides novel insight
by utilising a clinically relevant reperfusion model of MI and demonstrating a reduction in
arrhythmia susceptibility in the late, healed phase, rather than in the very early, necrotic
phase post-MI. The translational potential of gap junction modulation with agents such as
Rotigaptide or Danegaptide is clear with a clinical trial underway in STEMI patients with
acute administration of Danegaptide with outcome measures focused on infarct size. Current
administration of agents to modulate GJ coupling is limited to intravenous preparations and
hence is restricted to 24 hours in duration. It is not known whether prolonged dosing over the
course of several days or weeks confers an additional benefit in humans although the findings
of this study suggest that it will. However, in order to administer GJ modulators for greater
than 24 hours oral formulations will need to be developed with sufficient pharmacodynamics
to provide stable steady state plasma concentrations.
Infarct size is an attractive endpoint and can be quantified alongside heterogeneity with current
cardiac MRI techniques. However, future trial design will also need to address the potential
anti-arrhythmic effects of both a potential reduction in infarct size or infarct heterogeneity which
may impact the incidence of both early and late arrhythmias post-MI. Early arrhythmias peri-
MI are common and those occuring in hospital and during PCI carry a lower mortality compared
to those occuring out of hospital. Although it is important to examine the effects of modulating
GJ coupling at the time of reperfusion on early arrhythmogenesis, the greater clinical relevance
and reduction in mortality and morbidity occurs by reducing the incidence of late arrhythmias.
Assessing the incidence of late arrhythmias, both spontaneous and programmed, is more difficult
and trial design will need to utilise ambulatory measures of arrhythmia incidence either in the
form of recorded data from ICD leads which are able to sense and store data or in the form
of minimally invasive implantable devices (e.g. implantable loop recorders) which can be used
alongside survival data to assess for any effect of GJ modulation.
7.4.2 Correlating in vivo Electrophysiology and DTI
The studies in this thesis have provided preliminary evidence that DTI derived metrics can
be used to assess the complexity and heterogeneity of the infarct and infarct border zone
and applied as an outcome measure to compare the efficacy of pharmacological agents that
may modify the pattern of infarct healing. As DTI was performed in a small animal model
238
in this thesis the co-registration with electrophysiology data (specifically conduction velocity
and activation pattern), and an in-depth study of the effect of disrupted fibre architecture
on conduction in intact myocardium was not possible. Performing clinical EP studies with
subsequent DTI in either a large animal model or, if technically feasible, in humans, would
provide the basic means necessary to dissect the relationship between fibre orientation and
conduction in vivo. Extending these studies to patients with pathology (i.e. post-MI) adds
an additional layer of complexity owing to the thinned nature of the infarct and thus reduced
spatial resolution and in addition the tolerance required for prolonged supine scanning, but,
if feasible, would allow for the relationship between disrupted architecture of the infarct and
border zone to be studied alongside in vivo EP data. This may provide mechanistic insights into
the role of complex infarct border zone structure and geometry and the effect on conduction and
arrhythmogenesis in vivo and potentially allow for refinement of ablation treatment stratgies.
7.4.3 Combining deMRI and DTI to probe tissue architecture
Delayed-enhanced MRI (deMRI) with Gadolinium-based contrast agents is the current mainstay
of clinical cardiac MR post-MI imaging and provides quantifiable indices of area at risk, infarct
size, infarct heterogeneity and has been used in combination with real-time EP studies to guide
catheter ablation (Bello et al. 2005; Crawford et al. 2010). However, deMRI is not without its
drawbacks owing to the necessary use of exogeneous contrast agents which are poorly tolerated
in some patients and the limitations in our understanding of the pharmacokinetics of such
agents which are pivotal to accurately identify regions of abnormal myocardium. Although
DTI will not supersede or replace clinical deMRI imaging, it offers a wide array of quantitative
metrics without the need for external contrast agents which can compliment the information
from deMRI and provides a more in-depth description of myocardial remodelling. In addition
to the need to develop in vivo DTI, which is challenging, detailed comparative studies, which
can be performed ex vivo are needed to compare the findings from deMRI and DTI data. Key
questions to be determined include the magnitude and extent of change in FA and MD that
occur in the deMRI defined infarct region and similiarly in the ”grey zone” infarct border zone.
Whether DTI-derived metrics display significant departure from remote regions through the
entire extent of the grey zone is an important question as identifying and understanding the
alterations in tissue architecture within the border zone may allow more accurate arrhythmia
prediction and may have a role in guiding ventricular ablation.
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7.5 Conclusion
In conclusion, the studies in this thesis have successfully demonstrated the beneficial effects
of acutely enhancing gap junction in both ex vivo and in vivo reperfused myocardium. Roti-
gaptide treatment at the time of, and immediately post-MI in vivo, significantly reduced the
susceptibiity to PES induced arrhythmias during the healed phase without reducing infarct size.
A tentative mechanistic explanation is provided by preliminary diffusion MRI data showing a
significant beneficial remodelling effect in both the infarct and border zone regions with reduced
fibre disruption and restoration of metrics reflecting normal myofibre architecture. These stud-
ies provide further evidence that enhancing GJ coupling in patients with myocardial infarction
may reduce late arrhythmia risk and lends support to the potential application of DTI as a
clinical tool to probe structural remodelling and allow finer risk stratification post-MI.
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